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Abnormalities of the lipid profile are one of the major risk factors for the 
development of atherosclerosis. The menopause is associated with increases in 
the concentrations oftotal cholesterol (TC), low density lipoprotein cholesterol 
(LDL-C) and triglycerides (TG), as well as a reduction in concentrations of 
high density lipoprotein cholesterol (HDL-C). Changes also occur in the 
concentrations of other indicators of coronary risk, including the HDL-C 
subfi:actions HDL2-C and HDL3_C, and the apoproteins apo A-I and B. These 
changes in the basic lipid profile are thought to contribute to the higher 
incidence of coronary artery disease (CAD) found in postmenopausal women. 
Another more recently recognized independent marker of CAD is lipoprotein 
(a) [Lp(a)]. Concentrations of this lipoprotein also increase after the 
menopause, and this may account for some of the rise in CAD risk which can 
only partially be explained by changes in the other lipids and lipoproteins. 
Studies conducted primarily among postmenopausal Caucasian women have 
shown that the use of hormone replacement therapy (HRT) is associated with 
favourable changes in the basic lipid profile. Most ofthe commonly prescribed 
lipid lowering drugs except nicotinic acid have no effect on Lp(a), but 
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preliminary evidence suggests that the administration of HRT may reduce 
concentrations ofLp(a) in postmenopausal women. 
Hypothesis 
The hypothesis to be tested in this thesis is that the administration of hormone 
replacement therapy reduces concentrations of Lp(a) and improves the basic 
lipid profile of postmenopausal Chinese women. HRT includes treatment with 
unopposed oestrogen or oestrogen in combination with a progestogen. 
Oestrogen can be administered using a number of different methods, and a 
progestogen as well as oestrogen are usually given to those women who have 
not had a hysterectomy. 
Four studies were plamied to test the hypothesis. The objectives of these 
studies were to examine the short term and sustained effects of oral oestrogen 
on lipids and lipoproteins, to determine whether these effects were similar with 
percutaneous oestrogen and to investigate the significance of adding a 
progestogen to oestrogen replacement therapy. 
Research Model 
(1) The first study examined the short term effects of oral oestrogen on lipids 
and lipoproteins. 
The study group consisted of 100 women who had undergone a total abdominal 
hysterectomy and bilateral salpingo-oophorectomy for benign gynaecological 
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conditions. This was a double-blind, placebo-controlled crossover study of 12 
months' duration. Subjects were randomized into one of two groups. Group 1 
received oral oestradiol (Estrofem) 2 mg daily for the first 6 months of the 
study, and placebo for the second 6 months. Group 2 received the same drugs 
in reverse order. Blood samples for lipid and lipoprotein assay were taken at 
the commencement ofthe study and at 6 and 12 month intervals. 
(2) The second study examined the sustained effects of oral oestrogen on 
lipids and lipoproteins. 
This was an open longitudinal study which commenced at the completion of 
the 12 month crossover study. Fifty-four women who had participated in the 
first study were asked to take the same dose of oestradiol (Estrofem) for 
another 12 months before final blood sampling. 
(3) The third study examined the effects of combined cyclical hormone 
replacement therapy on lipids and lipoproteins. 
The study group consisted of 42 women, all of whom had undergone a 
spontaneous menopause. This was an open longitudinal study, and all subjects 
received 2 mg oral oestradiol (Estrofem) each day as well as 5 mg 
medroxyprogesterone acetate (Provera) for the first 12 calendar days of each 
month. This study was of 12 months duration, with samples collected before 
the start oftreatment and at 6 and 12 month intervals. 
(4) The fourth study examined the effects of percutaneous oestrogen on lipids 
and lipoproteins. 
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The study group comprised 35 women who had undergone total abdominal 
hysterectomy and bilateral salpingo-oophorectomy for similar indications to 
those patients in (1). This was also an open longitudinal study of 12 months' 
duration using 1.5 mg of percutaneous oestradiol (Oestrogel) (equivalent to 2 
mg oral oestradiol) each day. Blood samples were also taken at the 
commencement ofthe study and at 6 and 12 month intervals. 
Results 
Baseline values of Lp(a) in all of the treatment groups were comparable with 
those of other Asian as well as Caucasian populations and showed a similarly 
skewed distribution. 
(1) Short term effects of oral oestrogen 
At the commencement of the crossover study, there were no significant 
differences between the 2 groups in the baseline values of Lp(a) nor in any 
other study variables. In the first 6 months, the median Lp(a) concentration in 
Group 1 (oestradiol) decreased significantly compared with Group 2 (placebo). 
Crossover analysis at the end of 12 months showed a 9.6% reduction in the 
value of Lp(a) with oestradiol compared with placebo (p<0.001). There were 
also significant reductions in TC，LDL-C and apo B concentrations and 
significant increases in the concentrations of HDL-C，the HDL2-C subfraction 
and apo A-I with oestradiol compared with placebo. TG concentrations also 
increased significantly with oestradiol treatment. 
(2) Effects of sustained administration of oral oestrogen 
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The median concentration of Lp(a) in those who had been in Group 1 of the 
crossover study decreased by a further 32.7% with prolonged treatment 
(p<0.001). There was also a significant reduction in the concentration ofLDL_ 
C, a reduction in TC of borderline significance and significant increases in 
mean HDL2-C, apo A-I and TG concentrations. For those who had been in 
Group 2, there was a decrease of 8.8% in the median level of Lp(a) which was 
not significant (p=0.628). There were also significant increases in mean apo A-
I and apo B concentrations. 
(3) Effects oftreatment with combined cyclical hormone replacement therapy. 
After 6 months of treatment there was a reduction of 18.5% in the median 
concentration ofLp(a) (p<0.01). At the completion of 12 months of treatment, 
the median concentration had decreased by 24.5% (p<0.001, 0-12 months). 
There were also significant reductions in the mean concentrations of apo B and 
LDL-C, and a lowering of TC values of borderline significance. Apo A-I 
concentrations increased, but there were no significant changes in either HDL-
C nor the HDL-C subfractions. 
(4) Effects ofpercutaneous oestrogen 
The administration of percutaneous oestradiol resulted in a reduction of21.7% 
in the median concentration of Lp(a) during the first 6 months of treatment 
(p<0.01). This decrease was not maintained, and during the second 6 months, 
the median level increased to a value which did not differ significantly from the 
baseline (p=0.545, 0-12 months). As was the case for Lp(a), there were no 
significant differences between the baseline and 12 month concentrations of 
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any of the other lipids and lipoproteins, although some changes had been 
observed after 6 months. This occurred despite the apparent compliance with 
treatment throughout the study period. 
Conclusion 
The results ofthese studies supported the hypothesis that the administration of 
hormone replacement therapy reduces concentrations of Lp(a) and improves 
the basic lipid profile of postmenopausal Chinese women. The administration 
of oral oestradiol, whether prescribed alone or in combination with a 
progestogen, significantly lowered concentrations of Lp(a) and also had a 
beneficial effect on most other lipids and lipoproteins. The reduction in Lp(a) 
values was maintained with the continued administration of oestradiol after the 
completion of the crossover study, but the effect of percutaneous oestrogen 
differed from that of oral treatment. With the percutaneous gel, there was a 
significant reduction in the median concentration of Lp(a) during the first 6 
months, but there was no significant difference between the baseline and 12 
month values. The discrepancy between the results obtained with oral and 
percutaneous treatment suggests that the hepatic "first pass" effect may be 
important in maintaining reduced concentrations of Lp(a). The magnitude and 
duration of the reduction in Lp(a) concentrations appears to be greater with 
orally administered oestrogen. Li addition, combined cyclical hormone 
replacement therapy may be more effective in reducing concentrations ofLp(a) 
than the use of unopposed oestrogen, but the results of these studies were not 
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directly comparable because the methodology for examining the effects of the 
treatments differed. Further studies are required to determine whether 
oestrogen/progestogen combinations have a greater effect on Lp(a) than 
oestrogen alone. 
These findings provide confirmatory evidence ofthe ability of HRT to produce 
a sustained reduction in concentrations of Lp(a) and improve the basic lipid 
profile of postmenopausal Chinese women. This reduction in Lp(a) values is 
another mechanism to explain the cardioprotective effect of hormone 
replacement therapy. 
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1. PROBLEMS RELATED TO THE MENOPAUSE 
The perimenopause or climacteric is the phase in the ageing process in which a 
women passes from the reproductive to the non-reproductive stage. During this 
time she reaches the menopause, a term which originates from the Greek words 
men and pauo which mean "month" and "stop". The menopause has been 
defined as the permanent cessation of menstruation resulting from loss of 
ovarian follicular activity (Report of a WHO Scientific Group, 1981). The terni 
menopause is also commonly used to describe amenorrhoea secondary to 
surgical removal ofthe ovaries as well as that which occurs after irradiation of 
the ovaries or the administration of chemotherapy. Ovarian failure may cause a 
variety of problems which affect not only quality of life but also subsequent 
health and longevity. The nature of menopausal symptoms is related to the 
duration of oestrogen deficiency. 
(1) Acute Effects 
Acute symptoms usually occur within weeks to months of the menopause, 
although they may develop before the last menstrual period if the deterioration 
in ovarian steroid production is more gradual. The most common acute 
symptoms are hot flushes and sweating，and these have been reported in 70% 
and 84% respectively of Caucasian women after a surgical menopause and in 
60% and 74% following a spontaneous menopause (Hagstad and Janson, 
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1986). Hot flushes are an uncomfortable feeling ofwarmth, usually beginning 
in the upper chest and radiating to the neck and face. They may be associated 
with perspiration, are often worse at night, and vary in frequency from a few 
times each day to a number every hour. Li some women they are triggered by 
stress or by other stimuli such as the ingestion of fluids containing caffeine. 
Hot flushes tend to decline in frequency and severity in the years following the 
menopause, although they can continue to be troublesome for many years. 
Some cross-cultural differences in the reporting of symptoms have been 
observed, and acute menopausal symptoms are relatively uncommon in 
Chinese women in Hong Kong (Haines et al, 1994). Vasomotor symptoms are 
more closely associated with oestrogen deficiency than some of the other acute 
symptoms such as irritability, disturbances of mood and memory, difficulty 
with concentration and insomnia (Haas and Schiff, 1988). 
(2) Intermediate Effects 
Intermediate symptoms are due to atrophic changes in the genitourinary tract 
secondary to oestrogen deficiency. They usually occur within months to years 
of the menopause, and includedyspareunia caused by atrophic vaginitis and 
also urinary frequency and urgency. These symptoms respond well to local 
treatment, but they can also be treated with systemic oestrogen. 
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(3) Long Term Effects 
h the long term, postmenopausal women are exposed to a greater risk of 
developing both osteoporosis and cardiovascular disease (Harlan, 1994). 
Unlike the acute and intermediate effects of the menopause, these conditions 
usually remain asymptomatic until they reach an advanced stage, and each is 
associated with considerable morbidity and mortality. Prevention of these 
diseases is of key importance in improving the quality of life and the life 
expectancy of postmenopausal women. 
(i) Osteoporosis 
Chronic oestrogen deficiency is associated with an acceleration of bone loss 
which particularly affects the lumbar spine, the femoral neck and the distal 
forearm. Reduction in bone density is most rapid in the first few years after the 
menopause, and bone loss may lead to osteoporosis, a condition in which there 
is a reduction per unit volume ofbone mass (Stevenson, 1990). This change in 
bone structure increases the risk of fractures, and these may occur after 
episodes ofrelatively minor trauma. Vertebral fractures cause chronic pain and 
limitation of movement, and fractures of the femoral neck give rise to 
morbidity and mortality secondary to pneumonia, puhnonary emboli and other 
complications. Osteoporosis risk factors include a premature menopause, a 
relatively light build, cigarette smoking, a high intake of caffeine and a family 
history ofthe disease (Stevenson et al, 1989). 
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Not all postmenopausal women develop significant osteoporosis, and screening 
methods using dual x-ray absorptiometry, magnetic resonance imaging or other 
techniques are available which can identify those at greatest risk (Johnston et 
al, 1989). Oestrogens have been shown to prevent bone loss in the majority of 
postmenopausal women (Lindsay et al, 1976), and certain combinations of 
oestrogens and progestogens can replace bone (Christiansen and Riis, 1990), 
although the amount which can be replaced is unlikely to reduce the fracture 
risk of those with advanced disease. The ability of oestrogens to prevent 
osteoporosis is one ofthe strongest arguments in favour oftheir use. 
(ii) Coronary artery disease 
The most important consequence of chronic oestrogen deficiency is the effect 
on the cardiovascular system. The incidence of coronary artery disease (CAD) 
is higher in postmenopausal than in premenopausal women irrespective of the 
age at which the menopause occurs, but women with a premature menopause 
are particularly at risk (Kannel et al, 1976). 
Coronary artery disease (angina pectoris, myocardial infarction, acute cardiac 
death), cerebrovascular insufficiency and peripheral vascular disease are the 
clinical manifestations of atherosclerotic vascular stenosis. Modifiable risk 
factors for CAD include dyslipidaemia, cigarette smoking, hypertension, 
diabetes mellitus, hyperuricaemia and obesity (Kafrissen, 1990). The term 
dyslipidaemia relates to elevated concentrations of total cholesterol (TC), low 
density lipoprotein cholesterol (LDL-C) and triglycerides (TG) as well as 
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reduced concentrations ofhigh density lipoprotein cholesterol (HDL-C). Other 
lipids and lipoproteins thought to be important in the atherogenic process 
include the apoproteins A-I and B，and the HDL-C subfractions HDL2-C and 
HDL3-C. These lipids and lipoproteins will henceforth be referred to 
collectively as the components ofthe basic lipid profile. 
A more recently recognized independent marker of cardiovascular disease is 
lipoprotein (a) [Lp(a)], which is also an independent risk factor for 
cerebrovascular disease and peripheral vascular disease (Woo et al, 1991; 
Widmann and Sumpio, 1993; Lupatteli et al，1994). Lp(a) differs from most 
lipids and lipoproteins in that concentrations are largely genetically determined 
and are basically unaffected by lifestyle and diet. In addition，most of the 
commonly prescribed lipid lowering drugs are ineffective in reducing Lp(a) 
concentrations (Scanu and Fless, 1990). Although at most ages there is no 
gender difference in Lp(a) concentrations, increases in concentrations have 
been observed after the menopause (Meilahn et al, 1991), and preliminary 
studies suggest that users of hormone replacement therapy have lower 
concentrations ofLp(a). 
(4) Coronary Artery Disease in Women 
CAD is the leading cause of death in most developed countries in both women 
and men, but the chance of developing this disease is overall 2.5 to 4.5 times 
higher in men (Kalin and Zumoff, 1990). Although the rates of CAD in men 
exceed those for women at any given age, there is little remaining gender 
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difference after the age of 75 years (Stampfer et al, 1990^). This is due in part 
to an acceleration in risk resulting from the menopause. 
Risk factors for CAD are similar in women as in men, but women tend to be 
more obese and have a greater incidence of diabetes and hypertension as well 
as higher concentrations of TC and fibrinogen. On the other hand, women 
have less central obesity, higher HDL-C concentrations and lower TG 
concentrations (Barrett-Connor, 1994). As far as lipid concentrations are 
concerned, elevated concentrations of TC and LDL-C are directly related to 
CAD morbidity and mortality in women as well as in men (Bush et al，1988)， 
but in women it has been suggested that concentrations ofHDL-C and TG may 
be the more powerful predictors of risk (Gordon et al, 1978; Castelli, 1986). 
The higher incidence of CAD in males despite the similarity in risk factors 
suggests that the difference may be influenced by sex hormones. Although 
CAD prevention is of critical importance in both sexes, in women the first 
cardiac event occurs more often in the absence of a cardiac history and is 
associated with a worse outcome. It has been estimated that 40% of all 
coronary events in women are fatal, and that 67% of sudden deaths occur in 
those without any history of CAD (Eaker et al, 1993). Since CAD is more 
common in men, there have been few studies in which only female subjects 
have been investigated. 






1 The Annual Report of the Department of Health for the financial year 1993-
1994 (Department of Health, Hong Kong, 1993/94) showed that the average 
life expectancy in Hong Kong had risen steadily over the preceding three 
decades from 68.5 to 75.2 years in males and from 75.9 to 80.7 years in 
females. Deaths due to CAD were more common with advancing age, and 
statistics from 1992 showed CAD death rates of 13.9/100,000 for males in their 
forties, 67.9/100,000 for males in their fifties and 205.8/100,000 for males in 
their sixties (Public Health Report No. 1, 1994). Heart diseases were 
responsible for 15.6% of all deaths, second only to cancer with 31.1%. Over 
the last 20 years the crude death rate due to CAD in Hong Kong almost 
doubled, from 28.4/100,000 population in 1972 to 54.7/100,000 in 1992 
(Public Health Report No. 1，1994). This occurred in association with a longer 
life expectancy as well as the development ofamore atherogenic lipid profile. 
The menopause has a similar effect on the incidence of CAD in 
postmenopausal Chinese women in Hong Kong as in most other populations. 
The sex ratio (M:F) is 5.1 in the 30-49 year old age group but decreases to 1.2 
in those aged 65 years or more. However at all ages the gender difference in 
the incidence of cardiovascular diseases in Hong Kong is not as great as in 
most Westem countries. In the 40-69 year old age group, for example, the 
ratio is 2.8 in the United States and 3.3 in England and Wales, but in Hong 
Kong it is only 2.4 (Beaglehole, 1990). Women in Hong Kong therefore 
appear to be at relatively greater risk of developing CAD at a younger age. 
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Despite the increasing incidence of CAD in Hong Kong and in other Chinese 
.i . 
i communities in Asia, the prevalence ofthis disease remains considerably lower 
！ 
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than in the majority of urbanized westem societies (approximately 200-
350/100,000 population). In the 1950's it was estimated that CAD mortality in 
mainland China was 15-20 years behind that ofthe developed countries (Wang 
and Hu, 1957), and in the mid-1980's, crude death rates due to CAD of 
36.9/100,000 and 15.6/100,000 were reported in urban and rural mainland 
Chinese populations respectively (Tao et al, 1989). At that time the number of 
deaths from CAD in Hong Kong and in Taiwan was also relatively low 
(44.4/100,000 and 30/100,000 population respectively) (Woo and Donnan, 
1989)，but it was acknowledged that this number was increasing in all of these 
predominantly Chinese communities. In China, the increase was recognized in 
the late 1950's (Huang, 1957), and subsequent studies have confirmed a 
progressive rise in CAD deaths throughout the country (Wu et al, 1983). This 
has taken place when the trend in most developed countries has been in the 
reverse direction. Li Taiwan, coronary mortality increased from 5.7/100,000 to 
in 1971 to 30/100,000 in 1978 (Chiang, 1978)，but these figures may have been 
influenced by the under-reporting of deaths due to CAD prior to this time. An 
increase was also documented in Singapore, where the standardized death rate 
rose from 40/100,000 population in 1970 to 62/100,000 in 1988 (Emmanuel, 
1989). Heart disease therefore remains a significant problem in Chinese 
populations, and there is no evidence at present to suggest that the number of 
CAD deaths in Hong Kong is likely to decrease in the immediate future. 
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2. RESEARCH PLAN 
(1) Formulation ofResearch Hypothesis 
Recognition ofthe rising number of CAD deaths in the Chinese population of 
Hong Kong and in other Asian communities stimulated the development of a 
research hypothesis related to the prevention ofthis disease in postmenopausal 
women. The risk of CAD increases substantially after the menopause, and 
numerous studies in Caucasians have confirmed an association between the 
menopause and abnormalities in the basic lipid profile (Jensen et al, 1990). 
Lp(a) is a more recently recognized independent marker of cardiovascular risk, 
and concentrations ofthis lipoprotein also increase in postmenopausal women. 
Although there is convincing evidence to show that the use of HRT has a 
favourable effect on the basic lipid profile, there are fewer data concerning the 
response ofLp(a) to HRT. 
The hypothesis to be tested in this thesis is that the administration of hormone 
replacement therapy reduces concentrations of lipoprotein (a) and improves the 
basic lipid profile of postmenopausal Chinese women. This thesis will only 
address the problem of dyslipidaemia and its modification using hormone 
replacement therapy. Other risk factors for CAD will be mentioned but will not 
be investigated in the studies which contribute to this thesis. A summary of 
interventions commonly used in the treatment of lipid abnormalities will be 
provided so that their effects on lipids an lipoproteins can be compared with 
those ofHRT. 
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Dyslipidaemia is an important risk factor in Chinese populations as well as in 
Caucasians, and it can be anticipated that the response to treatment with HRT 
( 
will be similar in the two groups. The ability to show that this treatment 
) 
I 
reduces concentrations of Lp(a) in postmenopausal Chinese women would 
i 
provide additional information to explain the cardioprotective effect of 
hormone replacement therapy. 
(2) Objectives of the research 
Oestrogens oppose the atherogenic changes in the basic lipid profile in 
postmenopausal women, and the type ofoestrogen does not appear to affect the 
response as long as equivalent doses are used (Riis et al，1987). The method of 
administration of HRT may be more important, and although the oral route is 
still most commonly used, percutaneous, transdermal and subcutaneous 
preparations are also widely available. 
Oestrogens are usually prescribed alone to those women who have had a 
hysterectomy, but are otherwise given in combination with a progestogen to 
counteract the adverse effect of oestrogen on the endometrium. The more 
androgenic progestogens oppose the favourable changes in the basic lipid 
profile which occur with oestrogen treatment (Farish et al, 1986), but this does 
not appear to be the case for Lp(a). There have been no published studies in 
Chinese populations ofthe effect ofHRT on concentrations ofthis lipoprotein, 
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nor any which have investigated the response to percutaneous oestrogen 
administration. 
Four studies will be conducted which will test the research hypothesis by 
examining the effects of the method and duration of treatment with hormone 
replacement therapy. 
The first objective ofthese studies is to show that the short term administration 
of oral oestrogen produces a significant reduction in concentrations of Lp(a) 
and favourable changes in the other atherogenic lipids and lipoproteins. Since 
most HRT users continue treatment for prolonged periods of time, the second 
objective is to determine whether the short term effects of oestrogen are 
sustained with prolonged treatment. No long term studies on Lp(a) have been 
performed, and it is not known whether the short term effects of oestrogen will 
be maintained over a longer treatment period. 
The third objective ofthese studies is to determine whether combined treatment 
with oestrogen and a progestogen dso reduces concentrations of Lp(a) and 
improves the basic lipid profile, and the fmal objective is to examine the 
response to percutaneous oestrogen, which is one of the newer methods of 
delivery ofoestrogen which avoids the hepatic "first pass" effect. 
Apart from these major objectives, the relationship between the metabolism of 
Lp(a) and that ofLDL-C will also be investigated. The metabolism ofLp(a) is 
incompletely understood, and if a correlation between changes in Lp(a) and 
LDL-C can be demonstrated, it would support the existence of a shared 
metabolic pathway. 
12 
In addition, an examination ofthe effect ofthe timing ofblood sampling during 
combined oestrogen/progestogen treatment will also be made, as similar studies 
have ignored this potentially important factor. The effect of unopposed 
oestrogen may differ from that of oestrogen combined with a progestogen, and 
ifthe timing of sampling is not controlled for，this may result in the failure to 
measure a true difference in values. 
By confirming that the distribution ofLp(a) concentrations and the response to 
treatment ofLp(a) and the other atherogenic lipids and lipoproteins is similar to 
that which has been found in Caucasians, the results ofthis work could then be 
extrapolated to include Caucasians and other races with similar Lp(a) 
distributions. 
(3) Plan of studies 
As previously stated, four studies will be used to test the research hypothesis. 
The short term effect of oral oestrogen on Lp(a) will be assessed in a double-
blind, placebo-controlled crossover study of 12 months duration in women who 
have become menopausal following a total abdominal hysterectomy and 
bilateral salpingo-oophorectomy. The sustained effect of oestrogen will be 
investigated by recruiting subjects from the crossover study and continuing 
their oestrogen treatment for an additional 12 months. The effect of combining 
a progestogen with orally administered oestrogen will be examined in an open 
longitudinal study of 12 months duration in postmenopausal women with a 
spontaneous menopause who will be treated with combined cyclical HRT. An 
13 
open longitudinal design will also be used in the final study, where an 
alternative method of delivery of oestrogen will be examined using a 
percutaneous gel. 
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1. INTRODUCTION 
This overview is divided into four sections and will provide a background to 
the studies which will be conducted in this thesis. The first section describes 
the process of atherosclerosis and summarizes the biochemistry of lipids and 
lipoproteins and their role as risk factors for CAD. It also discusses the lipid 
profile of the Hong Kong and other Chinese populations, and compares these 
with Caucasians. It concludes by outlining common methods of treating lipid 
abnormalities. The second section focuses on the effects of endogenous and 
exogenous sex hormones in females，which includes the influence ofhormonal 
changes during the menstrual cycle, in pregnancy and after the menopause. A 
discussion on the lipid effects of oral contraceptives is also provided, as these 
are often confused with those of hormone replacement therapy. The third 
section describes the mechanisms of action of oestrogens and progestogens on 
lipids and lipoproteins and summarizes the available evidence for the 
cardioprotective effect of HRT. The final section discusses lipoprotein (a) in 
detail, which includes its relationship with cardiovascular disease, the effect of 
the menopause on Lp(a) and methods of treating individuals with raised 
concentrations ofLp(a). 
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2. ATHEROSCLEROSIS AND THE LIPID PROFILE 
. 
I Atherosclerosis may be defined as a combination of changes in the intima of 
� 
,j • • 
I the arterial wall which promote the focal accumulation of lipids, complex 
carbohydrates and some constituents of blood. Atherogenesis involves a 
number of processes which include increased permeability of the endothelium 
j to LDL-C and other macromolecules, platelet adherence to the damaged 
• 
endothelial surface, the entry ofmonocytes, macrophages and lymphocytes into 
the subintimal space, and the secretion of growth factors by platelets, the 
endothelium and macrophages (Blankenhom and Hodis, 1993). These 
processes may be enhanced by the production of vasoactive agents and by � 
smooth muscle migration from the media into the subintima with subsequent 
proliferation. In addition to these changes, fibrous tissue formation and 
calcification also contribute to atherogenesis. The formation of atheromatous 
plaques predisposes to thrombosis, and the narrowing of the vessel wall 
eventually causes ischaemia. 
The accumulation of atherogenic lipids and lipoproteins in the vascular wall is 
influenced by their rates of transfer and by the degree of arterial degradation 
and retention of intact lipoproteins within the intima. The rate of influx is in 
tum determined by blood pressure, plasma lipoprotein concentrations and by 
vascular permeability OSTordestgaard and Nielsen, 1994). There is a linear 
relationship between the rate of influx of VLDL, IDL and LDL particles and 
their plasma concentrations, but particle size is also important, as LDL and 
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HDL particles cross the wall more easily than VLDL or IDL O^ordestgaard et 
al，1992; Stender and Zilversmit, 1981). Any increase in the arterial 
degradation ofLDL also contributes to the development of atherosclerosis as it 
promotes the retention of lipoproteins in the intima (Schwenke and Carew, 
1988). Oxidation of LDL and its related compounds is another event thought 
to be of critical importance in lipid accumulation. Both LDL and HDL have 
been found in the intima ofhuman arteries (Smith and Staples, 1980) and LDL 
accumulation has been shown to precede the formation of fatty streak lesions 
(Schwenke and Carew, 1989). Lp(a) also appears to accumulate in the vessel 
wall, and has been found in atherosclerotic coronary arteries (Hajjar et al, 
1989). 
A risk factor is a clinical or biochemical marker which is associated with a 
statistically increased likelihood of having or developing a particular disease 
process. There is convincing evidence to show that abnormal concentrations of 
TC，LDL-C, HDL-C and its subfractions，apoproteins A-I and B and TG are 
important risk factors for atherosclerosis. 
The following section provides a summary of the biochemistry of the basic 
lipids and lipoproteins and this will be followed by a discussion of their 
individual associations with CAD risk. The relationship between elevated 
concentrations of Lp(a) and the risk of CAD will be described later in this 
chapter. 
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(1) Biochemistry ofLipids and Lipoproteins 
The plasma lipoproteins are a diverse group of water-soluble complexes of 
high molecular weight composed of lipids (cholesterol, triglyceride and 
phospholipids) and one or more specific proteins called apolipoproteins 
(apoproteins). All of the plasma lipoproteins originate in either the liver, the 
intestine, or both. There are 5 major classes oflipoproteins which are classified 
according to density, and within these major classes there are a number of sub-
classes. 
(i) Lipoprotein classes 
(a) Chylomicrons [d = 0.95 g/ml] • These are lipoprotein particles which are 
formed in the intestine and which transport exogenous triglycerides. The 
degradation of chylomicrons is under the control oflipoprotein lipase which is 
located mainly in muscle and adipose tissue. Chylomicron remnants are 
absorbed in the liver, and they should not be present in plasma in the fasting 
state. 
(b) Very low density lipoprotein (VLDL) [d < 1.006 g/ml] - More than 90% of 
the TG in fasting blood is synthesized in the liver and secreted as a component 
ofVLDL. This group ofmacromolecules is also degraded by lipoprotein lipase 
into intermediate density lipoprotein (IDL) and further to low density 
lipoprotein (LDL). 
19 
(c) Intermediate density lipoprotein [d 二 1.006-1.019 g/ml] - IDL is converted 
to LDL through an incompletely understood process, but hepatic lipase is 
known to be involved in this pathway. 
(d) Low density lipoprotein [d = 1.019 薩 1.063] - 60-70% of total semm 
cholesterol is transported in LDL, the principal apoprotein component ofwhich 
is apo B. LDL cholesterol ester molecules are hydrolyzed intracellularly to 
release cholesterol, and this occurs primarily in fibroblasts, the smooth muscle 
cells of arteries and in lymphocytes. 
(e) High density lipoprotein [d = 1.063 - 1.21 g/ml] - HDL consists of an 
heterogeneous group of macromolecules which are responsible for 20-30% of 
cholesterol transport. HDL is formed in plasma in association with the 
lipolysis of chylomicrons and is metabolized principally in the liver. 
(ii) Apoproteins and lipid transport 
Apoproteins are the surface proteins of lipoproteins which act as an interface 
between lipid and aqueous environments. They are important in the regulation 
oflipid transport and also in lipoprotein metabolism. The characteristics ofthe 
major apoproteins are shown in Table 1. 
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Table 1. Characteristics of the major apoproteins. (Modified from Ginsberg, 
1990). 
APOPROTEIN MOLECULAR LIPOPROTEINS METABOLIC~ 
WEIGHT FUNCTIONS 
Aoo A-I 28 016 HDL, chylomicrons Component of 
^ ‘ HDL，LCAT* 
activator 
Apo A-II 17,414 HDL, chylomicrons Unknown 
Apo A-IV 46,465 HDL, chylomicrons Unknown 
Apo (a) 400-800,000 Lipoprotein (a) Structural protein 
for lipoprotein (a); 
Plasminogen 
inhibitor 
Apo B-48 264,000 Chylomicrons Assembly and 
secretion of 
chylomicrons 






Ligand for LDL 
receptor 
Apo C-I 6 ^ All major Unknown 
lipoproteins 
Apo C-II 8,900 All major Activator of 
lipoproteins lipoprotein lipase 
Apo C-III 8,800 All major Inhibitor of 
lipoproteins lipoprotein lipase 




ApoE 34,145 All major Ligand for 
lipoproteins binding several 
lipoproteins to 
LDL receptor 
* = Lecithin cholesterol acyl transferase 
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The lipid transport system can be divided into two pathways, one being the apo 
A-I (HDL) system and the other related to apo B-lOO (VLDL, IDL and LDL). 
Apo A-I is the major protein on HDL and contributes 70-80% of the protein 
mass. It is synthesized in the liver and small intestine, and facilitates the 
transformation ofthe HDL subfraction HDL3 to HDL2. It may also play a role 
in determining the length oftime HDL remains in the circulation. Apo A-II is 
also present in HDL, but its in vivo function is unknown, and apo A-IV is only 
a minor component ofHDL, as is Apo D (McIntyre and Hany, 1991). Apo (a) 
is a component ofLp(a), and the structure ofLp(a) will be described in detail 
later in this chapter. 
Apo B-lOO is the major apoprotein of VLDL, IDL and LDL and is the largest 
of the apoproteins. It is also synthesized in the liver, and apart from its 
function as a binding protein for LDL receptors, it is essential for the formation 
and secretion ofVLDL (McIntyre and Harry, 1991). As there is no apo B-48 
in human VLDL，IDL nor LDL, the term apo B will be used interchangeably 
with apo B-lOO. 
Having established the relationship between the lipoproteins and apoproteins, 
the following section will discuss the individual associations of lipids and 
lipoproteins with CAD risk. 
(2) Lipid and Lipoprotein Risk Factors for Coronary Artery Disease 
Various risk factors for coronary heart disease were considered by each of the 
Adult Treatment Panels (ATP) ofthe National Cholesterol Education Program 
22 
(NCEP) of the National ^stitutes of Health 0^IH) in 1988 and again in 1993 
^TCEP, 1988; NCEP, 1993). The list of risk factors agreed upon by each of 
these panels is summarized in Table 2. 
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Table 2. Recommendations for the diagnosis and treatment of lipid 
abnormalities. (Adapted from Schaefer, 1993). 
NCEP ATP I，1988 NCEP ATP II，1993 
LDL-C > 160 mg/dl (4.1 mmol/l) LDL-C > 160 mgAU (4.1 mmol/l) 
HDL-C < 35 mg/dl (0.9 讓 _ HDL-C < 35 mg/dl (0.9 mmoVl) 
Hypertension Hypertension 
Cigarette smoking Cigarette smoking 
Diabetes Diabetes 
Family history ofmyocardial Family history ofMI or sudden death 
infarction (MI) or sudden death age < age < 55 in a male parent or sibling or 
55 in parent or sibling prior to age 65 in a female parent or 
sibling 
Male gender Male > 45 years of age 
Obesity “ Female > 55 years of age or premature 
menopause without oestrogen 
replacement 
History ofperipheral or History ofperipheral or 
cerebrovascular disease cerebrovascular disease 
taportant changes in the recommendations of 1993 concerned the greater 
recognition ofthe significance ofthe menopause as a risk factor for CAD. The 
recommended concentrations ofLDL-C and HDL-C remained unchanged, but 
the revised list included the presence of a family history of a myocardial 
infarction (MI) or sudden death prior to age 65 years in a female parent or 
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sibling, any female aged 55 years or more or any female with a premature 
menopause not using oestrogen replacement. Previously no risk factors 
specific for the female gender had been included in the NCEP list of 
recommendations, but after 1993 the importance of the menopause and 
hormone replacement was acknowledged. 
(i) The relationship between individual lipid and lipoprotein risk factors 
and the risk of CAD 
(a) Total cholesterol 
The relationship between raised cholesterol concentrations and a heightened 
risk ofCAD was recognized in the early 1950's (Gertler et al, 1950; Steiner et 
al, 1952). Since then, confirmation of this association has been provided 
through numerous basic research and epidemiological studies including the 
Framingham Study (Kannel et al, 1971), the British Regional Heart Study 
(Shaper et al，1985), the Multiple Risk Factor Intervention Trial (MRFIT) 
(Stamler et al, 1986), The Lipid Research Clinics Coronary Primary Prevention 
Trial (Bush et al, 1987)，the Stockholm Prospective Study (Carlson et al, 1979) 
and the Prospective Cardiovascular Munster Study (PROCAM) (Assman et al, 
1986). The largest of these was the MRFIT Study, which measured semm 
cholesterol in 356,222 healthy males aged 35 to 57 years and examined CAD 
death rates over 6 years. For each five year age group, the relationship 
between serum cholesterol and CAD death rates was continuous, graded and 
strong. 
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The role of TC as a risk factor has also been established in large cross-
population studies such as The Seven Countries Study where deaths resulting 
from CAD were examined in 11,579 men aged 40-59 years in 15 cohorts from 
North America, Europe and Japan (Keys at al, 1984&). Serum cholesterol 
concentrations were a significant risk factor in all ofthese countries apart from 
Japan, where the number ofcoronary deaths were too few for evaluation. 
Migration studies have also shown that elevated concentrations of TC are a 
predictor of CAD risk. In a study of Japanese men living in either Japan, 
Hawaii or California, mean concentrations of TC were lower in all age groups 
for those living in Japan compared with either Hawaii or California. The death 
rates due to CAD were correspondingly lowest in Japan and highest in 
California, and dietary differences appeared to be the main contributing factor 
QSfichamen et al, 1975). 
Most of these larger studies were performed in males, but there is also 
considerable evidence to show that cholesterol concentrations are an important 
marker of CAD risk in females. A summary of studies in women is presented 
in Table 3. 
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Table 3. A summary of prospective observational studies in women 
investigating the relationship between elevated cholesterol concentrations and 
CAD risk. (Adapted from Moreno and Manson，1993). 
STUDY~ NUMBER ~ A G E “ FOLLOW-UP p 
(Years) 
Busselton ^ 21-70+ 3 <0.01 
(Welborn et al, 
1969) 
Evans County M ^ ^ ^ ^ ~ ~ 
(Tyroler at al, 1971) 
Gothenberg M ^ ^ ^ ^ ~ ~ 
(Bengtsson, 1973) 
Busselton ^ 4 ^ ^ ^ ~ ~ 
(Cullen et al, 1983) 
Framingham ^ ^ ^ ^ " ^ 
(Castelli et al, 1986; 
Kannel，1987) 
Lipid Research 2 ^ 4 0 ^ ^ � 0 . 0 5 
Clinics 
(Bush et al, 1987) 
Rancho Bernardo ^ 5 ^ 0^ <0.05 
(Barrett-Connor et 
al，1987) 
Charleston U ^ ^ ^ ^ ~ ~ 
(Keil et al, 1987) 
Nurses Health Study 120,345 30-55 4 <0.05 
(Stampfer et al, 
1988 )^ 
Donolo-Tel Aviv ^ 2 5 ^ ^ 〈。厕~" 
(Livshits et al, 1989) 
Scotland ^ ^ ^ ^ ~ ~ " 
(Isles et al, 1989) 
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In 8 of these 11 observational studies, elevated concentrations o fTC were a 
significant predictor of increased CAD risk in women. In two of the other 
studies there was a trend towards an increased risk ofthe disease which did not 
reach statistical significance (Bush et al, 1987; Bengtsson, 1973)，and in the 
only study where no relationship was demonstrated (Cullen at al, 1983) a 
combination of low statistical power and a narrow range of cholesterol 
concentrations in the study population may have influenced the results. 
Further evidence for the importance of raised concentrations of TC has been 
provided through various primary prevention trials. Muldoon et al (1990) 
conducted a meta-analysis of6trials on serum cholesterol reduction involving 
periods totaling 119,000 person years during which there were 1,147 deaths. 
Women were included in two of these studies, but only data from men were 
used in the meta-analysis. Mortality from CAD in these trials was significantly 
lower in those receiving interventions to reduce TC concentrations than in 
controls (p<0.01). The two mixed studies were the Colestipol-Upjohn Study 
(Dorr et al, 1978) and the Minnesota Coronary Survey (Frantz et al, 1989). 
These examined 5,848 women, and treatment resulted in a significant reduction 
in TC concentrations in each ofthese studies. In the colestipol study there was 
no significant difference in CAD mortality between the treatment and control 
groups, but for those in the Minnesota study who completed 2 years of 
treatment, the rates ofmyocardial infarction and sudden death in women aged 
45 to 55 years were lower than in controls. A similar trend was present in 35-
39 year olds, but the number of subjects completing treatment was too small to 
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achieve statistical significance, and the investigators concluded that the results 
may have been different if the treatment period had been longer. 
I 
There have been five secondary prevention trials involving women, but in two | 
I 
I 
of these the data were not analyzed by gender. The three studies in which | 
women were examined separately were the Arteriosclerosis Specialized Center 
I 
i 
ofResearch Intervention Trial (Kane et al, 1990)，the Scotland Study (Research 
Committee of the Scottish Society of Physicians, 1971) and the Newcastle 
Study (Physicians of the Newcastle Upon Tyne Region, 1971). In the 
Arteriosclerosis Trial, regression of atherosclerotic lesions in the coronary 
arteries of borderline significance was found in women but not in men 
(p=0.05). In both the Scotland Study and in the Newcastle Study, fatal and 
non-fatal infarct rates were lower for women in the treatment group, but the 
differences were not significant. In the Newcastle Study, however, the total 
infarct rate was significantly lower in treated women (p<0.05), but not in men. 
Therefore, regardless ofthe study design, there is strong evidence to show that 
elevated concentrations of TC are a risk factor in women as well as in men. 
Treatments which decrease concentrations of TC are associated with a lower 
incidence ofCAD and a reduced mortality and morbidity. 
(b) LDL-C 
Both the first and the second reports of the National Cholesterol Education 
Program identified LDL-C as the primary target of their cholesterol lowering 
efforts (NCEP, 1993). Definitive evidence for a positive association between 
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elevated concentrations of TC and CAD risk has been summarized in the 
preceding section. There is also strong evidence to show that this risk is 
mediated in the most part through LDL, which is the major cholesterol carrying 
lipoprotein. Animal studies have shown that dietary induced increases in LDL 
like lipoproteins induce atherosclerosis (Strong and McGill, 1967) and 
epidemiological studies have demonstrated an independent association between 
LDL-C concentrations and the incidence of CAD (Kannel et al, 1979). LDL 
has also been identified in atherosclerotic plaques (Hoff et al, 1979), and 
concentrations are particularly high in the conditions familial 
hypercholesterolaemia and familial defective apo B-lOO, both of which are 
associated with a high incidence ofpremature cardiac disease (Grundy, 1995). 
There have, however, been relatively few prospective studies in which the 
primary aim has been to examine the importance ofLDL-C concentrations as a 
risk factor in women. LDL-C was a significant positive predictor of CAD in 
women in the Framingham Study, but it was less powerful than HDL-C. By 
contrast, in the Lipid Research Clinics Study, LDL-C was not proven to be a 
significant independent predictor (Jacobs et al, 1990). 
It is possible that LDL has a less important role in women than in men. There 
is an increase in the proportion of small, dense LDL particles in all subjects 
who have CAD and other conditions related to atherosclerosis, and individuals 
with more dense LDL particles tend to have a more atherogenic lipid profile 
(Slyper, 1994). It has been suggested that women may have a greater 
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proportion of the less dense LDL particles than men, and this would explain 
the weaker association with CAD in women. 
Therefore although elevated concentrations of LDL-C have a primary role in 
the development of atherogenesis, they may be a less important risk factor for 
CAD in women than in men. 
fcJ HDL-C 
HDL-C promotes the transport of extrahepatic cholesterol back to the liver, 
after which it is eliminated. This 'reverse cholesterol transport' explains why 
an increase in HDL-C concentrations can reduce the risk of CAD. HDL-C may 
also prevent the entry of cholesterol into the atherogenic process or even 
remove cholesterol from atherosclerotic lesions. It is not known whether HDL-
C has a similar effect on Lp(a). Nearly all of the large prospective studies 
which have examined the relationship between concentrations of HDL-C and 
the incidence of CAD have found HDL-C to be a strong inverse predictor of 
risk. A summary of studies investigating the association between 
concentrations ofHDL-C and cardiovascular events is presented in Table 4. 
31 
1 
Table 4. A summary of studies investigating the association between 
concentrations of HDL-C and cardiovascular events. (Adapted from Gordon 
and Rifkind，1989). 
STUDY ASSOCLVTION OF NON-
HDL-C WITH CAD CARDIOVASCULAR 
MORTALITY 
j Honolulu Heart Study Inverse trend Not reported 
(Rhoads et al, 1976) 
I Framingham Study Inverse trend No trend 
fGordon et al, 1989) 
Minnesota Study Inverse trend* Positive trend 
(Keys, 1980) 
Lipid Research Clinics Inverse trend No trend 
Follow-up Study(USA) 
(The Lipid Research Clinics 
Program, 1984^) 
Lipid Research Clinics Inverse trend No trend 
Coronary Primary 
Prevention Trial 
(Gordon et al, 1986) 
Multiple Risk Factor Inverse trend No trend 
Intervention Trial 
nVatkins et al, 1986) 
British Regional Heart Study Inverse trend* Not reported 
(Shaper et al, 1985) 
Tromso Heart Study Inverse trend Not reported 
(Miller et al, 1977) 
Oslo Heart Study Inverse trend Not reported 
(Enger et al, 1979) 
Finland Study Inverse trend* No trend 
(Keys et al, 1984^) ： 
Prospective Cardiovascular Inverse trend Not reported 
Munster Trial 
(Assman and Schulte，1992) 
Lipid Research Clinics No trend Positive trend 
Follow-up (USSR) Study 
(Levy and Klimov, 1987) - _ 
Israeli Ischaemic Heart Inverse trend No trend 
Disease Study 
(Goldcourt and Medalie, 1979) 
• Not Significant (p>0.05) 
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In 9 of these studies there was a significant inverse relationship between 
^ 
concentrations ofHDL-C and CAD risk，in 3 others there was a non significant 
trend and in the remaining study no trend was detected. 
As with most other studies which have examined risk factors for CAD, male 
subjects have usually been chosen to investigate the significance of HDL-C. 
There have, however, been 3 studies in which HDL-C concentrations were 
examined in women. These were the Framingham Study (Gordon et al, 1977)， 
the Lipid Research Clinics Follow-up Study (Bush et al, 1987) and the Donolo-
Tel Aviv Study (Livshits et al，1989). In each of these，HDL-C was a strong 
inverse independent predictor of CAD risk, and in the LRC Follow-up Study, 
except for age, HDL-C concentrations were the most powerful predictor of 
CAD death in women (Bush et al，1988). Evidence from the Framingham 
Study suggested that the protective effect of HDL-C in women was 
approximately twice as great as the atherogenic effect of LDL-C, and that a 
50% reduction in CAD risk could be predicted from a 10 mg/dl increase in 
HDL-C. These conclusions were similar to those ofthe Lipid Research Clinics 
Study, where a 42% decrease in incidence was found with a 10 mgMl increase 
in HDL-C. Reduced concentrations ofHDL-C are therefore also predictive of 
CAD risk, and this relationship may be stronger in women than in men. 
(d) HDL-C subfractions 
The HDL-C sub-fraction (d=1.063-1.21 g/ml) comprises particles which fall 
approximately into two groups, HDL2-C (d=1.063-1.125 gAnl) and HDL3-C 
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(d=1.125-1.21 g/ml). A third group (HDLi-C) is only a minor component, and 
there is contradictory evidence concerning the relative importance of these 
subfractions as predictors ofrisk (Thompson, 1993). A review by Miller (1987) 
of studies comparing the predictive power of HDL-C with that of the 
1 
subfractions reached no conclusion as to which was superior. All were cross-
sectional studies of individuals who had experienced a cardiac event, but the 
findings of four other prospective studies in which measurements were made 
before the event took place yielded conflicting results. In one of these, both 
HDL2-C and HDL3-C concentrations were reduced in cardiac patients，but the 
difference was greater for HDL2-C (Gofman et al, 1966). Li the second, 
multivariate analysis was performed and HDL3-C but not HDL2-C was a more 
accurate predictor (Sweetnam et al, 1990)，and in the third, HDL2-C was a 
strong predictor whilst HDL3-C was not (Salonen et al, 1991). In the fourth， 
neither measurement added to the information provided by that of HDL-C 
alone (Stampfer et al, 1991"). 
Evidence from both cross-sectional and prospective studies is therefore 
contradictory, and although it appears as if each of the subfractions provide 
protection against CAD，there is no convincing evidence at present to suggest 
that either is a better predictor ofrisk than is the measurement ofHDL-C itself. 
As a result ofthis remaining doubt, measurements of each of the subfractions 




Apoproteins have many physiological roles in lipoprotein metabolism which 
includes their function as structural proteins for lipoprotein particles, their 
i 
action as co-factors for enzymes and ligands for cell-surface receptors and their 
role in the transport of lipids. As was the case for the HDL-C subfractions, it 
has been suggested that the apoproteins may be more accurate predictors of 
CAD risk than the values oftheir related lipoproteins. 
Apoproteins A-I andA-II (Apo A-I andA-II) 
A review of 13 studies examining the predictive value of the apoproteins A-I 
and A-II found that in 7 ofthese apo A-I was the strongest inverse predictor, in 
one other it was apo A-II and in 6 studies HDL-C had a greater predictive 
power than either of the apoproteins (Miller, 1987). Four studies conducted 
since then have all found apo A-I to be a more accurate inverse predictor than 
HDL-C. Of these, three were nested case-control studies and the fourth a 
cohort study (Ishikawa et al，1978; Salonen et al, 1985; Stampfer et al, 1991^ 
Cremer et al, 1989). 
There is less evidence to show that apo A-II concentrations are inversely 
associated with CAD risk, and further investigations are required to determine 
whether the measurement of either ofthese apoproteins adds to the predictive 
power of HDL-C. For this reason HDL-C and apo A-I concentrations are 
commonly measured, but apo A-II is usually omitted. 
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Apoprotein B (Apo B) 
Apoprotein B is the major apoprotein in chylomicrons, VLDL, IDL and LDL 
as well as being a component of Lp(a). Apart from its structural role, apo B 
also mediates the cellular uptake and degradation of LDL. Multiple 
retrospective, cross-sectional studies have been performed comparing apo B 
concentrations in patients with CAD against those of controls, and these have „ 
consistently demonstrated a positive association with CAD risk. Whilst there 
is a constant 1:1 ratio of apo B molecules per LDL and VLDL particle, the 
amount of cholesterol in these particles varies widely, and it has been 
suggested that the measurement of concentrations of apo B may be a better 
assay of atherogenicity than that of LDL (Sniderman and Silberberg, 1990). 
This has since been confirmed in a number of other studies which have found 
apo B to be a more sensitive predictor (Genest et al, 1992^ Levinson and 
Wagner, 1992). Apart from this, apo B concentrations accurately predict 
recurrent disease after coronary artery bypass grafts (Campeau et al, 1984). 
There have only been 5 prospective studies which have examined the 
relationship between concentrations of apo B and CAD risk, and there were 
methodological problems in a number of these. The largest demonstrated an 
association with apo B which was independent of concentrations of TC and in 
this study apo B had the strongest relationship of all the lipoproteins with the 
risk of CAD. A 10% increase in apo B was associated with a 22% increase in 
CAD mortality (Wald et al, 1994). 
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Therefore, whilst the measurement of apo B may be superior to that of LDL-C 
in predicting CAD risk, further prospective studies are necessary to determine 
its role in the management of those suffering from or at risk of CAD. Both 
LDL-C and apo B continue to be measured in most studies on the lipid profile. 
0) Triglycerides 
Triglycerides contribute to the process ofatherogenesis by increasing foam cell 
production and interfering with coagulation and fibrinolysis. They are also 
found in the walls of atherosclerotic vessels. Whereas consistent relationships 
between CAD risk and elevated concentrations of TC and LDL-C and reduced 
concentrations of HDL-C have been demonstrated, the evidence for 
hypertriglyceridaemia as a risk factor is less convincing. This may be due to 
the different associations of the TG containing lipoproteins. The metabolic 
pathways of TG and HDL-C are closely connected, and it is difficult to 
separate their roles in the atherogenic process. In cross-sectional studies, their 
concentrations have been shown to be inversely correlated (Davis et al，1980), 
and they share other correlates such as obesity and cigarette smoking. 
In most of the early studies investigating the relationship between 
concentrations of TG and CAD risk，TG were found to have a significant 
positive association, however univariate rather than multivariate analysis ofthe 
data had been performed. Subsequent retrospective analyses after controlling 





the relationship between TG concentrations and CAD upheld (Fager et al, 
1981; Hamsten et al, 1986; Al-Mutaseb et al, 1989). 
Whilst TG are not an established independent risk factor in males, they do | 
、 i 
！ 
appear to be a stronger predictor in females. This was suggested by the results 
of the Framingham Study (Gordon et al, 1977)，the Evans County Study I 
j 
(Heyden et al, 1980), the Lipid Research Clinics Prevalence (LRCP) Study 
(Miller Bass et al, 1993) and the Gothenberg Heart Study (Bengtsson, 1993), 
all ofwhich were prospective studies which included women. In each ofthese， 
concentrations of TG were independently associated with an increased risk of 
CAD. TG remained a positive predictor in the Evans County and LRCP 
studies even after adjusting for other lipids and risk factors, and these two 
studies also found that mortality due to CAD increased with increasing TG 
concentrations. 
Therefore, although there is less evidence concerning the importance ofTG as 
a risk factor for CAD than for some other lipids and lipoproteins，they have 
been implicated in the process of atherosclerosis in both men and women and 
they continue to be measured in most studies ofthe lipid profile. 
(3) Characteristics of the Lipid Profile in Chinese Populations 
An increasing number of coronary related deaths have been reported in Hong 
Kong, Taiwan and Singapore and this appears to have been due at least in part 
to the development ofamore atherogenic lipid profile. Most studies performed 
recently in mainland China have not revealed any definite alterations in the 
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lipid pattern, although Tao et al (1992) found that concentrations of TC and 
LDL-C in their study group were similar to those ofthe Chinese population in 
Hong Kong, and that concentrations ofTG were somewhat higher. In addition, 
lipid profiles were more atherogenic in urban than in rural populations, and the 
urban inhabitants had a correspondingly higher incidence of CAD. Table 5 
summarizes studies of the lipid profiles in Chinese populations from different 
parts of Asia. A comparison between concentrations of Lp(a) in the Chinese 





Table 5. A comparison ofthe lipid profiles in Hong Kong and in other Chinese 
populations. — ^ 
1 ^ pTC LDL-C HDL-C TG 
STUDY Ages (rnrnom) (mmol/l) (mmol/l) (mmoW) 
Mean (SD) Mean (SD) Mean (SD) Mean (SD) 
I CHINA 
Bdlh；^ 45-54 M4.20 - M L 1 4 -
(Yangetal , 1986) (0.88) (0.24) 
F 4.35 F 1.11 
(0.82) (0.25) 
Beijing 25-64 M4.16 “ - M 1.34 _ 
(Yao et al, 1988) (0.86) (0.30) 
� F 4.22 F 1.42 
(0.93) (0.29) 
Beijing/Guangzhou 35-54 B e i j m g ~ " B e i j i n g " " B e i j i n g ~ ~ Beijing 
( T a o e t a l ， _ ^？！顯，^3SV2.45^ L57Vl.61^ ^75VS.24^ 
F F F F 
4.78V4.402 2.68V2.2l' 1.74Vl.7l' 2.84V3.2l' 
Guangzhou Guangzhou Guangzhou Guangzhou 
M M M M 
4 70V4.10' 2.90V 2.43' 1.47Vl.57^ 2.89V 2.02^ 
F F F F 
4.85V4.0l' 2.98V 2.39^ 1.44Vl.42' 2.42V2.19^ 
I Beijing M52.5 M4.14 - M 1.18 _ 
(Cobbaert and (6.0) (0.88) (0.26) 
Kesteloot, 1992) F53.5 F 4.45 F 124 
(4.6) (0.67) (0.24) 
Shanghai “ 0-102 M4.14 _ - ^ 2 ^ 5 1 
(Zhuang et al, (0.88)i ^^^¾ 




F3.83 F 1.97 
(0.70)2 (0.83)2 
M= Male F=Female l=Urban 2= Rural 
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Table 5. (Continued) 
I I p f c LDL-C HDL-C TG 
STUDY Ages (mmol/l) (mmol/l) (mmol/l) (mmol/l) 
I Mean (SD) Mean (SD) Mean (SD) Mean (SD) 
CHINA (ContM) ^ … 
Hefei 40-54 F4.35 - F1.45 F4.01 
OVuetal,1990) (0.94) (0.53) (3.44) 
Wuhan 30-59 l f I ^ ~ M 2.41 ~ M 1 . 4 4 ~ ~ " M2.54 
(Stehle et al，1991) 
TABVAN ~ " 、， 
(Chen et al, 1995) M 49.4 M M M M 
r (12.7) 5.3(1.1) 3.5(1.0) 1.4(0.4) l . l ( U ) ) 
F 47.6 F F F F 
(13.0) 5.2(1.1) 3.3(1.0) 1.5 (0.5) 1.0(0.8) 
I STNGAPORE 
mu2hes et al, 18-69 M 5.74 M 4.22 M 0.85 M 1.37 
S o ) ' (0.05) (0.04) (0.01) (0.03) 
^ F 5.91 F 4.37 F1.04 F1.09 
(0.05) (0.04) (0.01) (0.03) 
(Teoetal,1992) 43.5 M5.57 - M1.27 -
(14.3) (0.98) (0.38) 
F 5.41 F 1.62 
(0.78) (0.50) 
HQNG KONG … � 
(Ho and Chan, 19-30 M4.74 - - ^2^51 
1974) (0-73) (^f) 
F 4.66 F 2.07 
(1.06)、 （0.54) 
(Choand DonnanJ5O.59 l T i : i ? — ^ ! - ¾ f } f S 
1 Qoo\ F 5 48 F 1.26 F 1.54 
1988) M 5 88^ M0.92^ M2.40^ 
F5.864 F l . i 9 4 F 1.36^ 
OVoo and Lam, 70.2 5.5 (1.1) 3.3 (1.2) 1.3 (0.4) 1.6 (1.2) 
1990) (11.4) 
3= Lower Socio-economic 
4= Higher Socio-economic 
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Table 5. (Continued) • P 
p f c LDL-C HDL-C TG 
STUDY Ages (mmol/l) (mmol/I) (mmol/l) (mmol/l) 
Mean (SD) Mean (SD) Mean (SD) Mean (SD) 
HONG KONG 45-54 M 4.72 M 3.01 M 1.22 M 1.08 
(Lau et al, 1993) (1.07) (1.05) (0.28) (0.58) 
^ F 4.55 F 2.75 F 1.60 F 0.69 
(0.60) (0.55) (0.29) (0.30) 
rFong et al, 1994) 45.4 M 5 . 4 8 ~ " M3.56 M1.25 M 1.22 
(14.1) (0.05) (0.05) (0.02) (1.03) 
F5.46 F3.50 F1.42 F1.00 
(0.06) (0.06) (0.02) (1.03) 
3= Lower Socio-economic 
4= Higher Socio-economic 
In 3 of 4 surveys conducted in and around Beijing in the mid-1980's, mean 
concentrations ofTC were found to be lower than in most developed countries, 
but were higher than in the southern city of Guangzhou, hv the first of these, 
the lipid profiles of 495 male and 561 female inhabitants of Beijing were 
I compared with those of Caucasians living in the Belgian city of Antwerp (Yang 
et al, 1986). Concentrations of TC were lower in all age groups in Chinese 
subjects, and maximum mean values in the Chinese were similar to the 
I minimum values found in the Belgians. The second survey formed part of the 
I Sino-Monica-Beijing study which was established to monitor trends and risk 
factors for CAD as part of the WHO Monica Project (Yao et al, 1988). Low 
concentrations of TC and relatively high HDL-C concentrations were also 
found in this random sampling of 1,673 individuals carried out in 1984/85. 






(Luepker et al, 1985), mean values were on average more than 1.0 mmoLl 
lower in the Chinese. A third study conducted in 1983/84 but not published 
until 1992 compared the lipid profiles of rural and urban dwellers of Beijing 
with those in Guangzhou (Tao et al, 1992). This was part of the PRC-USA 
collaborative research study on cardiovascular and cardiopuhnonary 
epidemiology. The survey included 4,280 males and 4,695 females aged 35-54 
years. In both males and females, age-specific mean TC and LDL-C values 
were higher in the urban populations, and in general higher in Beijing than in 
Guangzhou. HDL-C concentrations in Beijing exceeded those in Guangzhou 
and were higher in females than in males. Values of TC and also TG tended to 
be greater in this study than in others carried out in this region, and were 
similar to those found later in Hong Kong. Another study of Beijing 
inhabitants formed part of a comparison made between three Asian (Tibetan, 
Korean and Chinese), one African O^igerian) and one European (Belgian) 
population (Cobbaert and Kesteloot, 1992). Concentrations of TC were lower 
in the Chinese women than in any of the other groups apart from the Tibetans, 
and overall the Chinese women had the highest concentrations ofHDL-C. 
A survey conducted in Shanghai provided similar results to those of Beijing. 
Concentrations of TC were slightly lower in urban males and females than had 
been found in either Beijing or Guangzhou, whilst the mean values in the rural 
population approached those of rural Guangzhou inhabitants (Zhuang et al, 
1986). Studies in more remote areas of China have also demonstrated low 
,i 




Shanghai, concentrations of TC were low and those of TG relatively high, but 
concentrations of both were higher in postmenopausal than in premenopausal 
women (Wu et al, 1990). In a study comparing the lipid profiles of 2,047 
healthy male subjects from the remote Wuhan province in central China 
(approximately 1,000 km east of Shanghai) with those of 7,580 Japanese and 
j 6,052 German males, concentrations of both TC and LDL-C were noticeably 
lower in the Chinese subjects than in the other two groups, but a statistical 
analysis was not performed (Stehle et al, 1991). There were no Chinese 
subjects with concentrations ofTC above 7.8 nrnuM, but 0.1% ofthe Japanese 
and 5% ofthe Germans had values in this range. 
In Taiwan, Chen et al (1995) performed a population-based study in a military 
1 community which examined the lipid profiles of 3,032 men and 3,314 women, 
j 
Mean values of TC and LDL-C were higher than those of mainland China, 
whilst TG concentrations were similar. Concentrations of TC > 6.2 mmoLl 
were present in 14.9% of women and concentrations of LDL-C > 4.1 mmoVl 
were found in approximately 15.0%. HDL-C concentrations < 0.9 mrnom 
.^  I 
were found in 6.0% of women and TG concentrations > 2.8 mmoLl were 
present in 1.8%. 
1 
i The results of two studies in the Chinese population of Singapore revealed that 
I concentrations of TC and LDL-C were higher and HDL-C lower than in 
I 
mainland Chinese. One of these was a comparison between the lipid profiles 




significant differences in the concentrations of TC，LDL-C, and TG, although 
concentrations of HDL-C in females were higher in the Chinese than in the 
I 
j other two groups (Hughes et al, 1990). The other was a lipid screening 
I programme performed in 1988 which consisted of 527 male and 538 female | 
I 
volunteers (Teo et al, 1992). The mean TC level in Chinese women was 5.41 j 
mmoVl, and this value was lower than that of Indians but higher than in the 
; 
I Malays. Chinese females had the lowest HDL-C concentrations of the three 
ethnic groups. The measurements of TC were higher than had been reported in 
a previous study conducted in the 1970,s (Chua et al, 1978). No significant 
differences in the lipid profile of the same ethnic groups were found in a 
j 
similar study conducted some years later among 167 healthy Singaporean 
women (Loke et al, 1993). However mean concentrations of TC and TG were 




j had lipid concentrations which placed them at risk for CAD. 
•'[ 
Studies on the Chinese population in Hong Kong suggest that concentrations of 
..} 
•j 
\ TC are increasing in both sexes at all ages. In a small survey reported from the 




concentrations were 4.74 mmol/1 in males and 4.66 rnniom in females (Ho and 
^ 
Chan, 1974; Ho and Chan, 1975). Corresponding values of TG were 2.51 and 
2.36 mmorn respectively. When compared with young adults from either 
Denmark or the United States, concentrations ofTC were significantly lower in i • 
these young Chinese subjects, but were higher than in the more recent studies 
conducted in mainland China. 
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Another survey was performed amongst residents in the Hong Kong New 
Temtories between 1983 and 1985 (Cho and Donnan, 1988). This showed that 
i 
5% of females aged 20-39 years, 20.5% of those from 40 -59 years and 38.0% 
aged 60 years and above had TC concentrations above 6.2 rnrnom. Mean 
concentrations of TC were above 5.0 rnrnom in males and females from both 
upper and lower socio-economic groups, and were higher than those reported 
in China. Further evidence to support a trend towards a more atherogenic lipid 
profile was provided by Fong et al (1994). In this study, the lipid profiles in 
825 Chinese adults in Hong Kong with a mean age of 45.4 (土 14.1) years were 
examined. The mean TC concentrations increased slowly with age in men，and 
were lower in women before the ages 40-49 years. After this, concentrations 
rose steeply in women and exceeded those ofmen by 50-59 years of age, with 
LDL-C following a similar trend. Women had consistently higher 
concentrations of HDL-C at all ages，and whilst concentrations of HDL-C 
showed a steady decline with age, those of TG increased in both sexes. It was 
estimated that 8.4% ofwomen aged 20-39 years, 28.5% from 40-59 years and 
55.30/0 who were 60 years and above had concentrations of TC above 6.2 
mmoVl Similar values of TC and LDL-C had been found in an earlier study of 
healthy Hong Kong Chinese adults aged 40-60 years (Lam et al, 1990)，but as 
only a graphic representation of results was provided, this study has not been 





The largest of the Hong Kong studies involved 910 male and 603 female 
employees recruited from either a public utility company or a general district 
hospital (Lau et al, 1993). All subjects were less than 65 years old. 
Undesirable values of TC (> 6.2 rnrnom) were found in 16.1% of males and 
5.3% of females, and 21.4% of males and 11.1% of females had LDL-C 
concentrations > 4.1 mmoVl. An age related rise in both TC and LDL-C was 
seen in both sexes, and in women there was a reduction in HDL-C with 
advancing age. After the age of60 years, however, concentrations ofboth TC 
and LDL-C declined. These data were supported by another study of 314 
apparently healthy subjects in an elderly Chinese population in Hong Kong 
(Woo and Lam, 1990). Both sexes were represented in the survey where the 
( mean age of the subjects was 70.2 years. As may have been expected because 
of the more advanced age of these subjects, concentrations of TC and LDL-C 
were higher and HDL-C lower in this group, but were comparable with 
previous studies of older Caucasians in both the United States and in Europe 
(Heckers et al，1982; Rifkind and Segal, 1983). 
Ofinterest, unlike studies in western populations where TC concentrations tend 
to be higher in males, concentrations of TC in Chinese females were higher 
than in males in more than half the studies listed. Concentrations of LDL-C 
were also frequently higher in Chinese females, but in all except one study 
HDL-C concentrations exceeded those of males. There is no apparent 
？ 
explanation for these discrepant findings. 
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]n summary, therefore, the Chinese population in Hong Kong has a more 
atherogenic lipid profile than that of mainland China, and in Hong Kong, 
i 
Singapore and Taiwan the proportion of the population with abnormal lipid j 
values more closely approximates that found in developed countries in which | 
the incidence ofCAD is higher. The diet ofthe mainland Chinese population is 
high in carbohydrate and relatively low in fat, with the fat content contributing 
some 15-30% ofthe total caloric intake. This compares with about 40% in the 
North American diet. Saturated fats contribute 25-27% to the Chinese diet and 
370/0 to the American diet (The Lipid Research Clinics Population Studies Vol 
II., 1982), which in part explains the differences which have been described. 
Studies of ethnic Chinese who have emigrated into western societies have 
shown that concentrations of TC are higher than in those who remain in their 
place of birth (Pinnelas et al, 1992). For all age groups examined, Chinese 
subjects living in the United States for an average of 15 years had higher 
concentrations of TC than both urban and rural Chinese in Shanghai. 
Concentrations of TC in Chinese living in New York were similar to those of 
Caucasians in the same city. 
As will be discussed in the following section, the relationship between 
abnormal lipid values and CAD risk appears to apply equally to Chinese 
individuals, and if the trend towards a higher incidence of lipid abnormalities 
continues, then CAD mortality can be expected to increase in Hong Kong and 
in neighbouring regions ofAsia. 
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(i) Lipid abnormalities and the risk ofCAD in Chinese populations 
Elevated concentrations of TC and LDL-C and reduced concentrations of 
HDL-C are all risk factors for CAD in the Chinese, as has been demonstrated 
in most studies from mainland China, Taiwan and Hong Kong. A summary of 





Table 6. A comparison of lipid and lipoprotein values between Chinese 
subjects with and without CAD. 
TC LDL-C HDL-C TG 
STUDY I i ^ Cases |Controls Cases Controls Cases |Controls Cases Controls 
CfflNA 
j 
Shanghai 21-60+ M4.82 M4.01 - - " " “ _ 
(Tungetal, F5.13 F4.16 
1958) 
Naniinc 20-69 M5.59 M5.41 M3.39 M3.16 M1.71 M1.92 M3.42 M2J9 
S 7 a l 1982) (1.14) (0.88) (0.93) (0.78) (0.41) (0.35) (1.86) (0.93) 
(Caietal ,1^2j ^,^09 F5.62 F3.81 F3.21 F1.90 F2.10 F3.06 F2.82 
(1.11) (1.01) (1.01) (0.91) (0.24) (0.35) (1.35) (1.48) 
Ti«„ii„ 40-60 M5.02 M4.64 M3.06 M2.64 M1.36 M1.53 M4.14 M3.39 
S = r t _ f f (0.98) (0.96) (0.88) (0.8^  (0.32) (0.38)冗)(1.86) 
etal 1990) F5.65 F4.82 F3.32 F2.69 F1.50 F1.68 F4.53 F3^47 
e ， ~ (1.24) (0.96) (0.88) (0.85) (0.35) (0.41) (2.67) (1.84) 
W"h5ui 40-59 4 12 4.02 2.85 2.45 1.02 1.46 2.69 2.98 
S S n L d t (0.49) (1.77) (0.49) (0.59) (0.26) (0.36) (0.70) (2.02) 
et al, 1991) 
TAWAN 
^ , , pt al 1993� 28-78 4 74 4.82 3.03 3.00 0.75 1.11 4.16 3.37 
OVuetal,1993) 丨口丄）^^ ^^ ^ (【卩今）（ioi) (0.21) (0.34) (1.89) (2.69) 
HONGKONG 
rWooetall993) Cases 5.40 4.90 3.70 3.10 1.10 1.30 1.45 1.02 OVooetal,1993) Cases ( � � （ 。 ⑷ （ 。 ⑵ ( o . l 2 ) (0.04) (0.06) (0.10) (0.07) 
Controls 
58.9 
Consistently higher concentrations of TC have been found in Chinese subjects 
with CAD than in controls. Tung et al (1958) measured TC in 3,451 
‘ 
Shanghainese patients with different of types of heart disease. Overall, the 
mean level of TC was 4.82 mmol/l. In survivors of myocardial infarction it 
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was 4.34 mmorn, and in healthy Chinese, 4.01 rnrnom. A study from Nanjing 
compared the lipid profiles of 1,101 healthy Chinese men and women with 
those of521 males and 26 females with CAD (Cai et al, 1982). The diagnostic 
criteria were a history ofmyocardial infarction, typical angina pectoris，severe 
arrhythmias, ischaemic ECG changes or a positive exercise test. 
Concentrations of LDL-C and TG were significantly higher and HDL-C 
significantly lower in female patients than in controls. Similar findings were 
demonstrated in the northern city of Tianjin, about 150 km from Beijing 
(Schwartzkopff et al, 1990). Concentrations of TC, LDL-C and TG were 
significantly higher and HDL-C lower in the 154 males and 69 females with a 
history of MI than in 216 males and 219 females used as controls. This was 
also the case in the Wuhan province of central China, where raised values of 
TC and LDL-C were found in 2,045 male industrial workers aged 40-59 years 
with a history ofmyocardial infarction (Bernhardt et al, 1991). Concentrations 
ofTC, LDL-C and TG were significantly lower in the Chinese subjects than in 
a comparable group ofmales from Gottingen in Germany (6,029 male workers 
aged 40-59 years), and hypercholesterolaemia (>5.2 rnrnom) was present in 
only 5.6% ofthe Chinese but in 63.5% ofthe German subjects. 
One study conducted in Taiwan among Chinese subjects with angiographic 
evidence ofCAD also showed that concentrations ofHDL-C and apo A-I were 
I lower and that of apo B was higher than in 119 controls matched for age and 





concentrations ofTC, LDL-C and TG between the 2 groups, making this one of 
the few studies in which these variables were not predictors ofCAD risk. 
A similar pattern was found in Hong Kong in 89 Chinese men who were 
studied 3 months after suffering a myocardial infarction (Woo et al, 1993). 
Mean concentrations of TC, LDL-C and TG were significantly higher and 
HDL-C significantly lower than in 56 controls. 
Li the recently conducted Eastern Stroke and Coronary Heart Disease 
Collaborative Project, the association between concentrations of TC and the 
risk of stroke and other major causes of death was examined in more than 
120,000 individuals from 18 cohorts in China and Japan (MacMahon, 1996). 
The period of observation was over 700,000 person years, during which time 
there were 500 deaths due to CAD. A 0.6 mrnom increase in the level of TC 
was associated with a one third increase in CAD risk. 
These studies confirm the relationship between abnormalities ofthe basic lipid 
profile and CAD risk in Chinese populations. The following section discusses 
the approach to the management of individuals with an abnormal lipid pattern. 
(4) The Management of Elevated Concentrations of Lipids and 
Lipoproteins 
The identification and treatment of CAD risk factors is thought to have been 
responsible for the lowering of CAD related mortality by approximately 25% 
in the United States between 1968 and 1987 ^sFational Center for Health 
Statistics, 1989). Although concentrations of cholesterol are genetically 
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influenced, they may also be modified by changes in diet and lifestyle and by 
the use of a variety of pharmacological agents. The approach to the 
management of raised concentrations of Lp(a) will be discussed in a later 
section ofthis chapter. 
(i) Recommendations for the management oflipid abnormalities 
The second report ofthe Expert Panel on Detection, Evaluation, and Treatment 
j 
ofHigh Blood Cholesterol in Adults (Adult Treatment Panel II) O^CEP, 1993) 
also contained the National Cholesterol Education Program's updated 
recommendations for the management of individuals with 
hypercholesterolaemia. Reference to this Report was made earlier in this 
chapter. The revised recommendations were based upon the initial 1988 
Report and presented a clinical approach to the primary prevention of CAD. 
A summary ofthe approach to management depending upon the measurements 
oflipids and lipoproteins is presented in Tables 7 and 8. The recommendations 
for the management of abnormalities of the lipid profile differ little from one 





Table 7. Primary prevention of CAD based on total cholesterol and high | 
density lipoprotein concentrations (Adapted from NCEP, 1993). 
[ i c HDL-C ACTION 一 
I Dcsirdblc 
TC < 200 mg/dl HDL-C > 35 mg/dl Repeat TC and HDL-C within 
(5.2mmoyi) (0.9 mmoVl) 5 years or with physical 
examination 
Provide education on general 
population eating pattern, 
physical activity, and risk 
factor reduction 
HDL-C < 35 mg/dl Do lipoprotein analysis 
(0.9 rnrnom) 
Borderline-High R i s k ~ 
TC 200-239 mg/dl HDL-C > 35 mg/dl Provide education on dietary 
(5 2-6 2 _ m ) (0.9 rnrnom) and modification, physical activity 
< 2 risk factors and risk factor reduction 
Re-evaluate patient in 1-2 years 
and repeat TC and HDL-C 
Reinforce nutrition and 
physical activity education 
Do lipoprotein analysis 
HDL-C < 35 mg/dl 
(0.9 mmol/l) and 
> 2 risk factors 
High Risk 1. 1 • 
TC > 240 mg/dl Do lipoprotein analysis 
(6.2 rnrnom) 
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Table 8. Primary prevention ofCAD in adults based on low density lipoprotein 
cholesterol concentrations. (Adapted from NCEP, 1993). 
I LDL-C I ACTION ACTION | 
I Desirable 
LDL-C<130mg/dl Repeat TC and HDL-C 
(3.4mmoW) within5years 
Provide education on 
general population eating 
pattern, physical activity, 
and risk factor reduction 
Borderline-High Risk~"| •亡 . 
LDL-C 130-159 mg/dl P ^ d e mformation on ! 
(3.4-4.1mmol/l)and< the SteplDietand | 
2RiskFactors PhysicalActmty 
Re-evaluate annually, 




Reinforce Nutrition and 
丨 Physical Activity 
Education 
LDL-C 130-159 mgMl Do clinical evaluation Initiate Dietary Therapy 
(3.4 - 4.1 rnrnom) and > 2 Evaluate for secondary 
RiskFactors causes 
Evaluate for Familial 
Disorders 
Consider influences of 
age, sex, and other CAD 
Risk Factors 
LD?'c>*l60 mg/dl (4.1 Do clinical evaluation Initiate Dietary Therapy 
mmoW) Evaluate for secondary 
causes 
Evaluate for Familial 
Disorders 
Consider influences of 
age，sex, and other CAD 
I Risk Factors | 
55 
Dietary therapy remains the first line of treatment for elevated concentrations 
oftotal cholesterol, with drug therapy being reserved for those with additional 
risk factors for developing CAD. 
(a) Diet and Exercise 
The aim of dietary therapy is to reduce concentrations of total cholesterol 
whilst maintaining a nutritionally adequate eating pattern. Dietary cholesterol 
reaching the liver downregulates LDL receptors, which reduces LDL uptake 
and increases concentrations of TC. Saturated fat increases cholesterol 
concentrations, also by the downregulation ofhepatic LDL receptors, but both 
monounsaturated and polyunsaturated fats reduce concentrations ofLDL-C and 
TC. An excessive intake of calories leads to obesity, and this increases fasting 
and postprandial TG concentrations and reduces concentrations of HDL-C. 
Diets which are high in total fat (>30% of calories), saturated fat (>10% of 
calories) and cholesterol (>180 mg/1000 calories) are associated with elevated 
concentrations of TC and LDL-C and this promotes the formation of 
atherosclerosis (Blankenhom et al, 1993). A reduction in cholesterol and 
caloric intake and in the proportion of saturated fats reduces concentrations of 
. 
TC，whilst weight loss reduces TG concentrations and increases concentrations 
of HDL-C. This in tum lowers CAD mortality (The Lipid Research Clinics 
Program, 1984^ Muldoon et al, 1990; Manson et al, 1992). The magnitude of 





intervention is difficult to estimate, but it has been suggested that a 1% 
reduction in the serum level of TC will result in a 2-3% decrease in CAD risk. 
Whilst most studies have shown an increase in HDL-C and a reduction in TG 
concentrations in association with the lowering of LDL-C concentrations, there 
I 
have been no randomized studies which have examined individuals whose 
primary abnormality is either a low HDL-C or an elevated TG level. 
Dietary and exercise interventions which aim to achieve an ideal body weight 
are usually undertaken simultaneously. The principles of dietary management : 
include: 
I 
(1) Reducing total fat intake to < 30% of total dietary energy intake. j 
(2) Reducing saturated fat intake to < 10% oftotal dietary energy intake. 
(3) Partially replacing saturated fats by monounsaturated and polyunsaturated 
fats. 
(4) Reducing dietary cholesterol to < 300 mg/day. 
(5) Increasing intake ofcomplex carbohydrates and soluble fibre. 
The effect of dietary intervention appears to vary between men and women. In 
men, weight loss increases HDL-C and reduces LDL-C concentrations, whilst 
in women，it has been found to decrease HDL-C but to have no appreciable 
effect on LDL-C concentrations (Brownell, 1981). Combinations of diet and 
exercise lower concentrations of TG and raise HDL-C concentrations in men, 
but they increase TG and only marginally alter HDL-C concentrations in 




lipid profile (Duncan et al，1991)，and exercise decreases the risk ofmyocardial 
丨. 
infarction and sudden cardiac death (Scragg et al, 1987). 
A minimum of 6 months of intensive dietary therapy and counselling has been 
j 
recommended by the NCEP Expert Panel before initiating dietary therapy. 
Drug therapy is recommended as an addition to dietary therapy rather than as a 




(b) Lipid Lowering Drugs 
The most commonly used drugs and their methods of action are listed below: 
I (a) Bile acid binding sequestrants - bind bile acids in the intestinal lumen. 
I (b) HMG CoA reductase inhibitors - oppose the action of the rate limiting 
1 enzyme involved in endogenous cholesterol synthesis. 
1 
(c) Fibric acid derivatives - increase LDL receptor concentrations, but their 
main effect is on VLDL and TG concentrations, probably by activating 
lipoprotein lipase. 
(d) Probucol _ reduces both LDL-C and HDL-C concentrations, and the anti-
oxidant properties of this drug may cause the inhibition of LDL-C uptake by 
macrophages. 
j (e) Nicotinic acid derivatives - inhibit fatty acid release from adipocytes which 
j suppresses TG synthesis and secretion ofVLDL. 








The second Adult Treatment Panel report of the NCEP classifies these into 
major drugs (bile acid sequestrants, nicotinic acid and HMG CoA reductase j； 
inhibitors) and others (fibric acids and probucol). In practice, combination 
i 
therapy is frequently used to achieve target LDL-C concentrations, especially 
. j 
in the presence of combined hyperlipidaemias when monotherapy provides an 
inadequate response. Combination therapy may also be needed if the side 
effects of one drug in a large dose are too severe, and lower dose combinations ： 
may be more cost effective than high dose monotherapy. 
At the present time, hormone replacement therapy is listed as a possible 
alternative or adjunct to drug therapy in those with elevated LDL-C 
concentrations. Although hormone replacement therapy is not usually 
prescribed primarily to improve the lipid profile, the effects of oestrogens and 
progestogens on lipid metabolism are a major component of the 
cardioprotective action ofHRT. 
I 
I  v.；!l'  
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- j 
3. CORONARY ARTERY DISEASE AND LIPID ABNORMALITIES 
IN WOMEN 
The following sections discuss the lipid response to endogenous hormones and 
also the influence of oral contraceptives on the lipid profile. The effects of the 
oral contraceptives are included to demonstrate the difference between these 
drugs and those used for hormone replacement. The influence of endogenous 
謹 .’ 
and exogenous hormones on Lp(a) will be summarized later in this chapter. 
1 
i 
(1) Lipids and the Menstrual Cyde 
； j 
I The follicular phase of the menstrual cycle is associated with increasing 
concentrations of oestrogen in the presence of low concentrations of 
5 progesterone. Oestrogens remain relatively high during the luteal phase of 
ovulatory cycles，but are opposed by high concentrations of progestogens 
released from the corpus luteum. Exogenous hormones appear to have a 
greater influence on the basic lipid pattern than do endogenous oestrogen and 
i progesterone. Most studies have found that the phase of the menstrual cycle 
has no consistent effect on serum lipids (Demacker at al, 1982; Tikkanen et al, 
I 1986), although in one study (Woods et al, 1975), higher TG concentrations 
!： 
were found in the luteal phase. Gustafson et al (1974), however, described 
significantly higher concentrations of TG and TC during the follicular phase. 
From these studies it does not appear as if there are any clinically significant 
pi '•.( 
lipid changes in ovulatory menstrual cycles. 
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(2) Lipids, Pregnancy and Coronary Artery Disease 
Pregnancy is associated with high concentrations of oestrogen as well as |； 
progesterone. Concentrations of both hormones rise progressively and reach a 
plateau near term, and during this time increases in the concentrations of all � 
！ 
classes of lipoproteins have been demonstrated. TG concentrations rise 2-3 
times，and TC concentrations increase by 50-60% (Montes et al, 1984; Desoye 
et al, 1987). LDL-C concentrations have also been shown to be 45-50% higher 
at term, although this follows a first trimester reduction in concentrations 
(Fahraeus et al, 1985). HDL-C concentrations rise during early pregnancy 
(Shibata et al, 1987) and peak at mid-gestation, after which there is a decline to 
15% above nonpregnant concentrations at term (Desoye et al, 1987; Fahraeus 
et al，1985). Factors apart from concentrations ofsex steroids therefore appear 
to have an over-riding control over the basic lipid pattern during pregnancy, as 
the hormone changes which occur would not be expected to increase the 
concentrations of TC and LDL-C. 
The increases in TC and TG concentrations during pregnancy do not appear to 
substantially increase the risk of developing CAD. Table 9 summarizes studies 
which have investigated the association between pregnancy and subsequent 
coronary events. 
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Table 9. A summary of studies which have investigated the association between 
pregnancy and subsequent coronary events. (Adapted from Barrett-Connor and 
Bush, 1991). 
i • 
I A U T H O R ~ I DESIGN NO. OF AGE AT CAD OBSERVED 
CAD CASES EVENT ASSOCLVTIONS 
Winkelstein~ Case-control 50 Mean 64 years Parity* 
I et al, 1958 | : 
Winkelstein~" Case-control 59 50-80 5+pregnancies 
I and Rekate, N 
I 1 9 6 4 — i 
Parrish Autopsies 24 40+ Nil ； 
et al, 1967 —— ： 
Bengtsson Case-referent 96 50+ 3+ pregnancies 
et al, 1973 — — 
m u ^ f c ^ 145 <45 Nil 
I 1 9 7 4 
Talbott Case-control 80 25-64 Nil 
I et al, 1981 | — 
Rosenberg Case-control 556 25-49 Nil 
I et al, 1983 | — 
r i ^ Case-control 159 <60 4+ pregnancies* 
I et al, 1984 | — ^ . ^ 
f l ^ p ^ 120,543 45-74 Parity* 
1985 certificates 
t ^ Case-control 11 ^ Nulliparityvs 
etal,1986 suddendeath* 
r c ^ { c ^ ^ ^ ^ 
I et al, 19Sr I — 
L a V e c c h i a ~ ~ Case-control 202 <55 Firstpregnancy 
etal, 1987^  <20years* 
Croft and Case-control ^ 8 20-60+ Nil 
Hannaford, 
I 1989 -
Talbott Case-control ^ ^ Nulliparityvs 





By far the largest of these studies was that of Beral (1985), in which 120,000 
death certificates from England and Wales were examined to investigate the 
association between parity and the incidence of CAD. There was a significant 
20% increase in CAD deaths in parous compared with nulliparous women. 
However in this and other studies in which a positive association was shown, 
the effect of social class on mortality was often not considered, and if the 
results had been adjusted taking this into account, the effect of parity may not 
have been so pronounced (Croft and Hannaford, 1989). Other factors which 
may have affected these results included the omission of undocumented 
pregnancy losses, infertility in the nulliparous groups due to anovulation and 
the use of oral contraceptives. 
In 8 ofthe 14 studies no association was found between parity and CAD nsk, 
which suggests that even if pregnancy does have some effect on the risk of 
subsequent CAD, this influence is not strong . 
(3) Lipids, Coronary Artery Disease and Oral Contraceptives 
Most studies examining the incidence of CAD in current users of OC have 
found that the risk is greater in older women taking relatively high dose 
preparations. The largest sample group to be examined was in The Nurses' 
Health Study, where the 7,074 users of OCs at the baseline examination had a 
significantly higher risk of developing CAD (RR 2.5; 95% CI 1.3-4.¾ than 
non-users (Stampfer et al, 1990^). Part of this risk may have been due to 




older, higher dose preparations containing the more androgenic progestogens of 
the gonane group of 19-nortestosterone derivatives lower HDL-C and HDL2-C 
concentrations. However, the medium and low dose contraceptive preparations 
have fewer metabolic effects, especially those which have the oestrane rather 
than the gonane group of progestogens (Crook et al, 1988). Even so, the low 
dose triphasic oral contraceptives containing oestranes such as norethindrone 
lower HDL-C concentrations and increase those of LDL-C QS[otelovitz et al, 
1989). The latest oral contraceptives which have less androgenic progestogens 
such as desogestrel and gestodene appear to have only a minimal effect on 
lipids (Runnenbaum and Rabe, 1987; Chez, 1989). 
Whilst the lipid effects of oral contraceptives could be expected to increase 
CAD risk, these changes may be opposed by other effects of oestrogen and 
possibly progestogens on factors such as coronary artery blood flow. There is 
now supportive evidence to suggest that women with a low CAD risk who use 
oral contraceptives containing less than 50 i^g of ethinyl oestradiol do not have 
a heightened risk of CAD (Mant et al, 1987; Porter et al, 1987). Nor does there 
appear to be an increased risk in otherwise well women with a past history of 
oral contraceptive use. In past users, the RR in the Nurses Health Study was 
calculated to be 0.91 (95% CI 0.74-1.12) (Stampfer et al, 1988^ Stampfer et al, 
1990b). A meta-analysis of studies examining previous use of oral 
contraceptives and their relationship with cardiovascular disease also showed 
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no increase in the incidence of myocardial infarction among past users (RR 
1.01 [95% CI 0.9-1.4]). A summary ofthese studies is presented in Table 10. 
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Table 10. Past use of oral contraceptives and the risk of coronary heart 
disease. (Adapted from Barrett-Connor and Bush, 1991). 
A U T H O R ~ DESIGN NUMBER O F ” RISKESTIMATE 
CAD EVENTS (95% CI) 
Mann and Inman, Case-referent 153 0.6 
1975' -
Mann et al, Case-control 63 0.9 
1975^ 
Mann et al, Case referent 106 1.1 
1976 
Shapiro et al, Case-control 234 1.2 (0.8-1.7) 
1979 
Pettiti et al, Cohort 26 0.8 (0.4-1.7) 
197 9 
Rosenberg et al, Cohort 156 1.0 (0.7-1.6) 
198 0 
Slone et al, Case-control 536 1.2 (0.9-1.4) 
198 1 
RCGP*， Cohort 17 2.0 (0.2-17.6) 
1981 
Stampfer et al, Cohort 485 0.9(0.6-1.0) 
1988b L_ 
* Royal College ofGeneral Practitioners 
The risk is greater in older women who smoke and use oral contraceptives. It 
has been estimated that these women have a 30-fold increase in the risk of 
myocardial infarction (Rosenberg et al, 1985; Notelovitz et al, 1989), and as a 
rule women over 35 years ofage who smoke are advised to use another form of 
contraception. 
It therefore appears that whilst the older oral contraceptives have some adverse 
effects on lipids, the newer preparations do not significantly alter the lipid 
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profile nor do they increase the risk of CAD in healthy young women who are 
non-smokers. 
(4) Lipids, Coronary Artery Disease and the Menopause 
A comparison between studies which have examined the influence of the 
menopause on the risk of CAD is difficult, as frequently no distinctions have 
been made between a physiological and a surgical menopause, and often 
:j 
j 
different end points for the definition of cardiac disease have been chosen. 
Sample sizes have also varied widely, but even taking these problems into 
consideration, there remains strong evidence to suggest that the menopause 
increases the risk of CAD above that which would be expected solely on the 
basis of advancing age. An early menopause is associated with a greater risk of 
developing CAD. Table 11 summarizes the results of studies which have 
investigated the association between CAD risk and menopausal age. 
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Table 11. A summary of studies investigating the association between CAD 
risk and the age at menopause. (Adapted from Barrett-Connor and Bush, 
1991). 
~ A U T H O R “ “ D E S I G N ~ NUMBER “ A G E A T ~ " RISK 
OF CAD MENOPAUSE ESTIMATE 
CASES 
Wuest et al, Autopsy review - <45 =2,0 
195 3 
Rivin and Autopsy review 37 <50 =2-3 
Dimitroff, 
195 4 r 
Winkelstein Case-control 50 =46 =2.1 ！ 
et al, 1958 i 
Oliver and Case-control 10 <35 =10 
Boyd, 1959 — 
Robinson et al, Case-control 16 <45 =3.0 
1959 
Novak and Autopsy review 124 - =1-3 
Williams, 1960 
Ask-Upmark,~Case-control~" 28 >45 = 10.0 \ 
1962 : 
Bengtsson Case-referent 96 <50 = 1.5 ' 
et al, 1973 
Ritterband Case-control 42 <45 1.0 ！ 
et al，1963 
Sznajderman~~" Case series 35 <40 7.0 
and Oliver, 
196 3 
Oliver, Case-referent 145 <45 1.2 
197 4 
Mann and Case-referent 153 - 0.8 
Inman, 1975^ 
Johansson et al, Case-control 17 < 3 0 =3.0 
197 5 
Kannel et a l , ~ ~ C ^ 6 _ Natural 3 1 
1976 Surgical 4.6 
Beard et aI, Case-control ^ 9 ~ ~ “ ~ " ^ Natural 1.3 
1984 Surgical 1.6 
Colditz et a l , ~ C ^ ^ " Natural 1.2 
1987b Surgical 2.2 
LaVecchia, Case-control ^ - Natural 0.8 
1987» Surgical 0.7 
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Despite the differences in the methodology and sample sizes，in nearly all 
studies the relative risk was reported to be higher in postmenopausal than in 
premenopausal women. This relationship appears to hold irrespective of the 
age at which the menopause occurs (Gordon et al, 1978; Bush et al, 1983). The 
risk is also higher for women who have had a surgical rather than a 
physiological menopause. This was the conclusion of the Nurses Health Study 
(Colditz et al, 1 9 8 7 � w h e r e 121,700 female registered nurses aged 30 to 55 ^ 
i. 
years from 11 states were surveyed to study the relationship between the i 
menopause, heart disease and the use of hormones. After controlling for age 
and cigarette smoking, women with a natural menopause who had not taken 
HRT had no appreciable increase in CAD risk over premenopausal women (RR [ 
1.2; 95% CI 0.8-1.8), but the risk doubled in those who had undergone bilateral ： 
^ 
oophorectomy and had never taken oestrogen (RR 2.2; 95% CI 1.2-4.2). 
Further evidence linking oestrogen deficiency and CAD was provided in the 
same study where it was found that the risk of CAD appeared to be eliminated 
by the use ofoestrogen (RR 0.9, 95% CI 0.6-1.6). 
At least some of the risk of developing CAD after the menopause has been 
attributed to the development of a more atherogenic lipid profile. 
Concentrations of TC, LDL-C and TG increase with age in both sexes, but are 
significantly higher in men than in women in the 20-50 year age range (Heiss 
et al，1980; Connor et al, 1982). After the age of 50, however, concentrations 
of TC and LDL-C rise more in women. Concentrations of TG approach those 
ofmen, but HDL-C concentrations remain higher in women than in men at all 
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ages. Data from the Framingham Study suggest than in women over 65 years 
of age, elevated concentrations of TC confer a higher risk of coronary artery 
disease than they do for men (Harris et al, 1988; Castelli et al, 1989). 
A number of different study designs have been used to compare the lipid 
profiles of premenopausal and postmenopausal women. These studies have 
been performed using aged-matched controls (Taylor et al, 1981; Svanberg et 
al，1982), cross-sectional sampling of women of the same age (Hallberg and ! 
• I 
Svanborg, 1967; Bush et al, 1984) and cross-sectional sampling of women of 
i 
different ages (Pansini et al, 1993; Nilsson et al, 1994). hi nearly all of these j 
- I 
studies, women who had undergone a surgical menopause had higher 
concentrations of TC, LDL-C and TG and lower concentrations of HDL-C than 
controls. Cross sectional studies of premenopausal and postmenopausal 
women of the same age have demonstrated similar changes, with the highest 
concentrations of TC being present in those women who had been menopausal 
longest (Hallberg and Svanborg, 1967). 
There have also been a number ofprospective studies which have examined the 
effect of the menopause on concentrations of lipids and lipoproteins. Among 
these were the Healthy Women's Study (Matthews et al, 1989)，in which lipid 
measurements obtained before and after the menopause in 69 women over a 5 
year period were compared with matched pairs who did not reach their 
menopause. There was over twice the increase in LDL-C concentrations in 
those who become menopausal compared with controls, and there was also a 





I relatively recent study from Denmark (Jensen et al, 1990) longitudinal changes 
I 
j in the lipid profile were examined for 2-3 years in women undergoing a natural 
I . 
I menopause and cross-sectional sampling was performed in premenopausal and 
postmenopausal women over a period of 1 to 3 years. The results included 
1,360 examinations covering 270 woman years. Significant increases in the 
concentrations of TC, LDL-C and TG were found within 6 months of the last 
menstrual period, and HDL-C concentrations also decreased significantly, 
'?• 
although this reduction began in the premenopausal years. 
Similar results were found in a recent cross-sectional study of 601 Hong Kong 
Chinese women, 551 of whom were premenopausal. Concentrations of TC, 
LDL-C and TG were significantly higher in the postmenopausal group, 
although there was no significant difference in concentrations of HDL-C (Ko 
et al，1995). 
These studies provide good evidence to show that postmenopausal women have 
a more atherogenic lipid profile than premenopausal women, and these changes 
occur in association with a higher incidence of CAD. The following section 
provides a more detailed description of the effects of exogenous oestrogen and 
progesterone on CAD risk. 
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4. EXOGENOUS OESTROGENS, PROGESTOGENS AND 
CORONARY ARTERY DISEASE 
The following section is restricted to a discussion of the lipid effects of 
oestrogen and progestogen and a summary of studies on the incidence of CAD 
in users of HRT. Although oestrogens have other actions which influence 
CAD risk, these are not directly concerned with the subject matter of this 
thesis. 11 
；[! 
(1) Effects of Oestrogens on Lipids and Lipoproteins 
Oestrogens were recognized in the early 1950's as being capable of lowering ‘ 
concentrations of p-lipoproteins (corresponding to LDL-C) (Barr et al, 1952)， '' 
“ I： 
but the high dose synthetic compounds available at that time were associated 
with an increased thrombotic risk. Oestrogens have since been administered for 
il 
many years in contraceptives and for hormone replacement therapy, and when ;丨1 
I 
given orally, almost all forms have been found to lower concentrations of TC � 
and LDL-C and to increase those of HDL-C and TG. These effects have been 
demonstrated in both normal and hyperlipidaemic women and in those with 
either a natural or a surgical menopause. In the Lipid Research Clinics 
Program Prevalence Study, the lipid profiles of 4,756 white men and women 
aged 20-59 years were measured and the differences between users and non-
users of exogenous sex hormones were examined (Heiss et al, 1980). LDL-C 
concentrations were lower in hormone users from the age of 40 years onwards, 
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and the difference in concentrations between users and non-users increased 
with advancing age. In all age groups above 30 years，HDL-C concentrations 
were higher in oestrogen users than in non-users, and this difference also 
increased with age. In the Atherosclerosis Risk in Communities (ARIC) Study, 
the lipid profiles of 15,800 black and white participants ofboth sexes aged 45 
to 64 years were investigated in four communities from the United States 
nS[abulsi et al, 1993). Out of this group, 4,958 postmenopausal women were ：[) 
: | ! 
chosen who were free of cardiovascular disease at the time of the study. | | 
;.:':>• 
Current users of oestrogen had significantly lower concentrations of LDL-C |,：| 
. i l 
than non-users, and HDL-C concentrations were higher m those usmg 麵 
‘;iiij; 
hormones. The most recent trial of note was the Postmenopausal :| 
'. L;i 
j ''"tt! 
EstrogenyTrogestin Mervention (PEPI) study, which was a 3 year, multicentre 
randomized, double-blind placebo controlled trial of the effect of 4 HRT j| 
i')|; 
treatment regimens (The Writing Group for the PEPI Trial, 1995). A total of 
I 
875 postmenopausal women were involved. LDL-C concentrations decreased � 
with all oestrogen/progestogen regimens and values were significantly lower on 
treatment than with placebo. Each treatment regimen resulted in higher 
concentrations of HDL-C than did placebo. In both the LRCP and ARIC 
Studies, users of hormones had higher TG concentrations than did non-users, 
and in the PEPI Trial, TG concentrations also increased in all active treatment 
arms and differed significantly from placebo. 
The changes in lipids and lipoproteins are dependent on the dose of oestrogen 
being administered. Adjusting for sample size and treatment duration, Bush and 
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Miller (1987) found that natural oestrogens in the form of 2 mg oestradiol 
valerate daily reduced concentrations of TC and LDL-C by 4% and 16% 
respectively and increased HDL-C and TG by 15% and 4%. Lobo (1991) 
analyzed the results of 15 prospective studies ofthe effect oforal oestrogens on 
lipids and lipoproteins and found similar changes. These results are 
summarized in Figure 1，and were calculated on a dose equivalent to 0.625 
\i 
conjugated equine oestrogen daily for at least 3 months. 丨、 
丨：?! 
L;.::. 
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Figure 1. Average percentage changes in lipids and lipoproteins 
from 15 studies using oral oestrogen treatment (Lobo, 1991). 



















I The metabolism of lipoproteins is complex, and is affected by a large number 
F 
I 
! of other variables including gender, heredity, age, diet, weight, exercise, 
I alcohol intake, smoking and a variety of drugs (Bush et al, 1988). The studies 
I 
I described above provide good evidence to show that oestrogens influence 
！ 
atherogenic lipids and lipoproteins in a direction which favours a reduction in 
atherogenesis. The mechanisms of action of oestrogen on the metabolism of 
^ 
individual lipids and lipoproteins is discussed below. �:‘ 
1 
1!.: 
i:|:i^  _ 
rr: _ 
(i) Oestrogens and VLDL 1¾ 
_ 
Oestrogens increase VLDL secretion and also the hepatic uptake of VLDL :¾ 
！ 'i3 
1 ^¢1 
remnants. At the same time, they augment hepatic TG production (Glueck et al, i 
|:i| 
1975; Knopp, 1991). Oestrogens also decrease the percentage of VLDL 丨！ 
‘ i'| 
particles which are converted into LDL (Walsh et al，1991)，but the rate of | 
4i| _ 




(ii) Oestrogens and LDL 
• 1: 
Oestrogens decrease LDL concentrations by raising the LDL clearance rate 
through an oestrogen induced increase in receptor synthesis (Walsh et al, 
1991). They also increase the production of LDL, but the effect on catabolism 





Oestrogens do not alter the permeability of the vessel wall to lipoproteins 
(Haarbo et al, 1994), but they reduce LDL degradation and accumulation, and 
this precedes the oestrogen induced reduction in atherogenesis (Wagner at al, 
1992； Wagner et al, 1993). Another important mechanism by which oestrogens 
are thought to provide cardioprotection is by the inhibition of biological 




(iii) Oestrogens, HDL and apo A-I | 
;,t: •, 
'、)i 
HDL is characterized by the polypeptide apoprotein E (apo E), and oestrogen | 
. 力 
administration is associated with a decrease in concentrations of this ;< 
i'i| ；., 
apoprotein (Applebaum-Bowden et al, 1989; Muesing et al, 1992). It has been : 
争 . 
suggested that a reduction in apo E may contribute to the increase in HDL i | 
丨丨, 
i ：‘ 
concentrations found with oestrogen treatment by decreasing the overall | 
I 
clearance rate, but no effect of oestrogen on HDL apo A-I clearance has been ：； 
!f 
demonstrated (Walsh and Sacks, 1991). Oral oestrogens increase 4 
.j 
concentrations of HDL-C, in particular the HDL2-C subfraction, and this | 
I 
appears to be in part due to suppression of the enzyme hepatic lipase, which is 
responsible for the catabolism of HDL and conversion to HDL3. A decrease in 
hepatic lipase activity would promote a longer residence time for HDL 
• i. 
particles, however apo A-I residence time is similar in premenopausal and in 
postmenopausal women (Schaefer et al, 1983). Oestrogens also appear to 
increase the rate of synthesis of HDL (Schaefer et al, 1983)，and evidence for 
oestrogen induced increases in apo A-I production have been provided in both 
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animal and human studies (Walsh and Sacks, 1991; Kushwaha et al，1990). 
Oestrogens increase hepatic mRNA transcription and translation in rats and 
mice (Srivastava et al，1993) and have also been shown to increase apo A-I 
synthesis in cultured human hepatoma cells (Archer et al, 1986). 
(iv) Oestrogens and TG 
TG synthesis is driven by the uptake of free fatty acids in the liver cell. ^^  I 
Synthetic oestrogens increase production of TG in the liver (Kissebah et al, | | 
丨‘：巧： i.rt ；.； 
• |;:^ || 
1973) and this effect may occur through the induction of fatty acid-binding ��;: 
'iki' 
f | 
proteins in the liver cell membrane (Ockner et al, 1980). The oestrogen induced | | 
ivi： 
elevation in concentrations of TG takes place in a dose dependent manner y 
^ 
\i l'V 
(Adams et al, 1980). | i 'i| 
！..:: 
Although oral oestrogens increase concentrations of TG, the net effect of | 
|! 
oestrogen on lipids and lipoproteins is to provide a less atherogenic basic lipid 鳴 
.V 
1^ 
profile and reduce CAD risk. 
• I 
(2) Effects ofProgestogens on Lipids and Lipoproteins 
Progestogens inhibit most of the steps involved in the transport and removal of 
cholesterol from the tissues, but the effects of progestogens on lipid 
metabolism are less clearly understood than are those of oestrogen (Lobo, 
1991). 
In clinical practice, synthetic rather than natural progestogens are most 





orally. The synthetic progestogens belong to either the pregnane (C-21) group 
derived from 17a-hydroxyprogesterone (medroxyprogesterone acetate, 
dydrogesterone, megestrol acetate) or the oestrane (C-19) group derived from 
19-nortesterone (norethisterone, norethindrone, levonorgestrel, desogestrel). 
Norethisterone acetate is derived from norethisterone, and a newer generation 
of 19 nor-progestogens including norgestimate, desogestrel and gestodene are 
• \ . 
levonorgestrel derivatives. These are more progestogenic and can be used in a | 




C-21 derivatives have been found to partially reverse oestrogen induced � 
,¾ 
lowering of LDL-C (Jensen et al, 1986; Ottosson et al, 1985), but the C-21 | | 
. . |:>;1' 
group have a higher affinity for progesterone receptors than the C-19 steroids '; 
H| j : l',j|;! 
and have minimal oestrogenic and androgenic activity. The C-19 group have | 
1: 
i»!'：： 
greater androgenicity, with norethisterone having a less pronounced effect than | | 
I t 
levonorgestrel, although the levonorgestrel derivatives appear to be less | 
androgenic than norethisterone. 
• ！ 
There have been contradictory reports on the lipid effects of the C-21 ； 
progestogens. Whilst some studies have shown no significant effects 
(Silfverstolpe et al, 1979; Tikkanen et al, 1981; Bames et al, 1985) others using 
high doses of medroxyprogesterone acetate (MPA) have demonstrated large 
h 
reductions in concentrations 0fHDL2-C (Lehtonen et al, 1985; Fahraeus et al, 
1986). Norethisterone has been shown to increase LDL-C and apo B 




(Silfverstolpe et al, 1979; Hirvonen et al, 1981; Farish et al, 1986). 
Levonorgestrel has also been found to reduce VLDL TG concentrations, and to 
raise LDL-C and lower HDL-C concentrations (Silfverstolpe et al, 1979; Kuusi 
et al, 1985). Other clinical studies have also suggested that the addition of 
progestogens to oestrogen replacement therapy reduces the beneficial effect of 
oestrogens on the lipid profile (Rijpkema et al, 1990; Lobo, 1991; Miller et al, 
1991). Natural progesterone, however, does not appear to significantly affect [js 
lipoprotein concentrations, and the newer progestogens with greater | 
;..:,i[J „i?；' ,-i .¢1:1 
oestrogenic activity have been found to have favourable effects on lipoproteins � 
_ 
(Gevers Leuven et al, 1990). | | 
、::.!? 
. . i|il 
In the Postmenopausal Estrogen/Progestin Interventions Trial (The Writing f 
fl 
Group for the PEPI Trial, 1995)，HDL-C concentrations increased significantly j 
|J..;i 
in all treatment groups, but increases were higher in those treated with | 
#): 
. .¥: 
oestrogen alone or oestrogen/micronized progesterone than in those taking || | 
:::::::; 
oestrogeny^medroxyprogesterone acetate. There were similar significant 1' 
reductions in LDL-C concentrations and increases in TG concentrations in all 
treatment groups compared with placebo. TC concentrations were significantly 
lower in women treated with oestrogenAnedroxyprogesterone acetate than with 
the other treatments. 
In summary, therefore, whilst the more androgenic progestogens oppose the 
effects of oestrogen on lipids and lipoproteins, the newer progestogens appear 
to have little or no adverse effect, and some combined oestrogen>^progestogen 
preparations may even improve the lipid profile. 
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(3) Hormone Replacement Therapy and Coronary Artery Disease 
The ability of oestrogen to reduce atherosclerosis was demonstrated in an 
animal model in the early 1950's (Stamler et al, 1953), soon after Barr et al 
(1952) showed that women had higher concentrations of a-lipoprotein 
(corresponding to HDL-C) and lower concentrations of p-lipoprotein than men. 
A short time later oral oestrogen was used to treat hypercholesterolaemia in 
. . ' x 
male survivors ofmyocardial infarction, and an increase in the a:p lipoprotem | 
丨对: 
ratio was achieved in 70% of cases. This prompted the first large study in 4 
;| 
humans investigating the relationship between the use of oestrogen and the | | 
incidence of CAD. This was the Coronary Drug Project, in which male | 
^ | | 
survivors of myocardial infarction were treated with either 5 mg conjugated i | 
equine oestrogens or placebo (The Coronary Drug Project Research Group, |-(|' 
_ . 
1970; The Coronary Drug Project Research Group 1973). In this study, more � ， I |i^  
subsequent cardiovascular and other problems occurred in the treated than in | 
、一, 
the placebo group. The incidence of non-fatal and fatal coronary events was 
i •+ 
also higher in the Veterans Administration studies on the use of 
diethylstilboestrol in the treatment of prostatic cancer (Blackard et al, 1970), 
and these results generated a belief that oestrogens increased rather than 
reduced CAD risk. 
The early studies examining CAD in women using oral contraceptives also 




earlier, the association was subsequently found to apply only to women with 
other CAD risk factors. 
It was not until 1978 that oestrogens were reported as being beneficial in the 
treatment of dyslipidaemia in postmenopausal women (Tikkanen et al, 1978). 
),• 
This was followed in 1985 by the publication of the results of two large 
observational studies on the use of oestrogen which appeared in the same issue 
of the New England Journal of Medicine, but which yielded conflicting results. \ 
f 
In the Nurses' Health Study (Stampfer et al, 1985)，the RR of CAD among ever | | i'''^  ：'i '. 
•…'A.： :'fi ； 
users of oestrogen was 0.5 (95% CI 0.3-0.8) and in past users 0.3 (95% CI 0.2- � 
| l 
0.6). In the Framingham Study, however, the RR in ever users was 1.76 ;^  
啡: 
(p<0.01) (Wilson et al, 1985). Differences in the age group of the patients and ! 
\Sl 
. . : 1 . . 
the cardiovascular end points were proposed as explanations for the dispanty | 
between results, but the Framingham data were later reanalyzed, and a possible j|： 
,,ti,,' 
. i f 
protective effect of oestrogen was then found in women in the 50-59 year age | 
•• 'i.|:... 
“ , 
range (Eaker and Castelli, 1987). ； 
Since then, the weight of evidence has strongly favoured a cardioprotective 
effect of HRT in healthy postmenopausal women as well as in those women 
with an increased risk of heart disease. The studies which were hospital based 
showed an increased risk with oestrogen use but carried the greatest potential 
bias. A summary ofthese hospital based studies is presented in Table 12. 
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Table 12. Hospital based studies on the use of oestrogen and the risk ofCAD. 
AUTHORS “ l C T ” NUMBER % ~ R R (95% CI) 
OF CASES OESTROGEN AGE-ADJUSTED 
USERS 
Rosenberg et 40-75 366 2.4 0.71(0.34-1.46) 
al, 1976 
Jicketal , 39-45 14 50 4.25 (0.96-18.84) 
1978" \ 
I 




Rosenberg et 30-49 99 18 (currentuse) 1.39(0.71-2.74) | 
ai，i980 24(pastuse) 1.88 (1.09-3.24) _ 
— t-;i: 
-4： 
, ：：!;  
Szklo et al, 35-64 39 28 0.8 | | 
1984 ‘ 
i , i;i ：‘ 
iii' 
丨:'、: 
La Vecchia et <55 168 5 (currentuse) 1.85 (0.68-5.01) i | 
ai，1987b 3 (^ast use) 1.01 (0.31-3.27) s. 
These studies have been criticized because controls were not usually chosen to 
exclude women with oestrogen related disease, and physicians selecting the 
cases may have been less likely at that time to prescribe oestrogen because of 
concerns about immobilization, drug interactions or other problems. The 
treatment groups may also have been biased towards the inclusion of women 
who were more health conscious and to have a lower risk of CAD regardless of 
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treatment. The hospital based case control studies showed a variation in 
relative risk from 0.5 to 4.2，with most studies demonstrating no significant 
association. 
Neighbourhood and community based studies, on the other hand, are 
considered to be less subject to bias, and have shown a consistent 
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Table 13. Neighbourhood or community based studies on the use of oestrogen 
and the risk of CAD. 
AUTHORS AGE NUMBER|% OESTROGEN ~ R R (95% CI) 
OF CASES USERS AGE-ADJUSTED 
Talbott et al, 3 ^ ~ ~ ~ ~ ^ 5 0.34 (0.09-1.30) 
1977 i 
Pfeffer et al, 50-98 m 8.7 (currentuse) 0.68 (0.32-1.42) 
1978 30 (ever use) 0.86 (0.54-1.37) 
Rossetal, ^ 1^3 = 0.43 (0.24-0.75) 
1981 '!|| 
Bain et al, 3 ^ 1 ^ ~ ~ 27 (current use) 0.70 (0.50-1.10)~ 1 
1981 53 (ever users) 0.90 (0.60-1.20) ;| 
Adam et al, ^ ^ ~ ~ 3(cur ren tuse )~" 0.97 (0.41-2.28) , 
1981 12 (ever use) 0.65 (0.29-1.45) 1 
Beardetal, 4 ^ ^ ^ 0.55(0.24-1.30)* : 
1989 J 
Thompson 4?：^ ^ - 1.12(0.79-1.57) :v 
et al, 1989 iii 
Rosenberg ^ ^ ^ " 0.90 (0.70-1.20) i： 
et al, 1993 � 
* Risk factor adjusted 
The relative risk in these studies ranged from 0.3-1.1，with meta-analysis 
producing a combined relative risk of 0.80 (95% CI 0.68-0.97). 
There have also been five cross-sectional studies which have investigated the 
relationship using coronary angiography (Table 14). 
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Table 14. Cross-sectional angiographic studies on oestrogen use and CAD. 
AUTHORS ~ l G E ~ NUMBER| % OESTROGEN RR (95% CI) 
OF USERS 
CASES 
Sullivan e t ~ " Mean 62.8 2,888 4.4% current 0.44 (0.29-0.67) 
al, 1988 users 
Gruchow et 50-75 ^ 15.5%current 0.37 (0.29-0.46) 
al，1988 users 
\ 
McFarland 35-59 ^ 41% ever 0.50 (0.3-0.8) | 
et al, 1989 users ^ 
, ^ 
,:;|} 
Sullivan et T 7 ^ ^ ~ ~ 10.5% 0.16(0.04-0.66) ； 
al, 1990 ； 
11 
Hong et al,~~ Mean58in ^ ‘ ^ 0.13 (-) ；； 






These studies also provide strong evidence in favour of the use of oestrogens. � 
Although different criteria were used to define the incidence and degree of 
coronary artery occlusion, in all studies there was significantly less occlusion 
in those who were using or had recently been using oestrogen than in non-
users. Regression analysis showed that oestrogen had an independent 
protective effect against coronary occlusion. A follow-up study ofwomen with 
angiographically proven CAD undergoing cardiac catheterization also showed 
that the only significant factor in predicting survival was the use of oestrogen 
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(Sullivan et al, 1990). The combined relative risk from these studies was 0.40 
(95% CI 0.33-0.48). 
Further evidence has been provided by a large number of prospective cohort 
studies which, with the exception ofthe Framingham Study, have also shown a 
cardioprotective effect with oestrogen (Table 15). 
\ 
: | 






. J . :V 
r| 
i: 













Table 15. Prospective cohort studies demonstrating a cardioprotective effect 
ofoestrogen (adapted in part from Stampfer et al, 1991 )• 
AUTHORS AGE NUMBER % RR (95% CI) 
OF OESTROGEN Age-adjusted 
CASES USERS 
Potocki, 1971 60-70 ~ 158 52% 一 0.31 (0.04-2.57) 
I Hammond et al, M^^ ^ " " " 49% 0.33 (0.19-0.56) 
i 1 9 7 9 1 ^ 
I Nachtigall et al, Mean 55 168 50% 0.33 (0.04-2.82) 
I 1 9 7 9 
I Bush et al, 1983 一 40-69 2270 8.5% 0.34(0.12-0.81) � 
i T a(Tertv and 45-60 124 49% ^ 
I = 二 9 8 5 0 .17(_-1.06 I 
Stampfer et al, 30-55 32,317 35%Currentusers 0.3 (0.2-0.6) | 
1985 18% Past users 0.7 (0.4-1.2) /^  
57%Everusers 0.5 (0.3-0.8) �;{ 
^ 
Framingham Heart 50-84 1,234 10%Currentusers 1.94(-) ； 
Study 14% Past users 1.76(-) ^ 
Wilson et al ,1985 - ~ ! 
Framingham H e a r t " ~ 5 0 ： ^ 695 15% 0.26 (0.06-1.22) ^ 
Study ‘ 
Eaker and Castelli, 60-69 602 8% 1.68 (0.71-4.00) ij 
1987 fj 
Bush et al, 1987 40-69 “ 2,270 26% ~ 0.37(0.16-0.88) '; 
Pettiti et al, 1987 i «-^^ ^ � ] 44% Ever users 0.9 (0.2-3.3) f 
C r i Q u i e t a l , 1 9 8 r " 50-79 “ 1,868 39% 0.75 (0.45-1.24) |j'； 
Henderson et al, 40-101 8,807 14%Currentusers 0.47 (0.20-2.00) : 
1988 43% Past users 0.62 (0.43-0.90) 
Henderson et al, ^ ^ “ 0.80 (0.70-0.87) 
1 9 9 1 
Croft and 20-60 Nested 6.5% Ever users 0.8(-) 
Hannaford, 1989 
Avila et al, 1990 50-64 24.900 14% Current users 0.7 (0.4-1.3) 
Sullivan et al, l 9 ^ >55 2,268 — 10.5%Everusers__0.16(0.04-0.66)* 
Van der Giezen et 5 4 ： ^ 13,083 6.3% 0.6(0.30-1.1) 
al, 1 ^ 
Stampfer et al, 3 0 ： ^ 48,470 72% 0.56 (0.40-0.80) 
1 9 9 1 ^ 
Falkeborn et al, ^ l T " 23,174 49% 0.81 (0.71-0.92) 
1 9 9 2 
* Risk factor adjusted 
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The Leisure World study involved around 9,000 women and showed that 
oestrogen users had approximately a 50% reduction in the incidence of acute 
myocardial infarction, a similar reduction in the incidence of stroke and a 20% 
decrease in total mortality (Henderson et al, 1991). The Nurses Health Study 
comprised 48,470 postmenopausal women who were studied over a period of 
10 years (Stampfer et al, 1991^). The follow-up revealed a relative risk of 
major CAD of 0.56 in oestrogen users. A recent meta-analysis of all of these � 
studies confirmed that in all except hospital-based studies (in which there was 
a small, non-significant increase in risk), oestrogens had a cardioprotective 
effect (Psaty et al, 1993). The RR for all studies combined was 0.56 (95% CI 
0.50-0.61). 
Although the evidence presented above strongly suggests that oestrogens 
reduce the incidence of CAD in postmenopausal women，it has been suggested 
that biases may have been present in the majority of these studies which may 
have accounted for at least half of the benefit attributed to oestrogen (Barrett- � 
Connor, 1991). These biases included the possibility that women who were 
using HRT had a healthier lifestyle in general and also received better medical 
care. 
Two important double-blind randomized trials of the effect of HRT on CAD 
are currently being performed. The first of these is the HERS study (Heart 
Estrogen/Progestin Replacement Study) which is investigating the effect of 
0.625 mg conjugated equine oestrogen and 2.5 mg MPA given in a continuous 
regimen. This study is being conducted in 18 centres in the United States, and 
89 
the results of 4-5 years of follow-up should be available around the year 2000. 
The other study is larger and has a longer follow-up period. This is the WHI 
OVomen's Health Initiative) study, which is also being conducted in the United 
States and involves 40 centres, with more planned for inclusion later. Unlike 
the HERS study, this examines a healthy population, and will therefore need to 




5. LIPOPROTEIN (a) 
Much more is known about the relationship between abnormalities of the basic 
lipid profile and the risk of CAD than there is concerning the role of Lp(a). 
Compared with the other lipid risk factors, Lp(a) has a number of 
characteristics which separate it from the other lipoproteins, but it also has a 
major role in the process of atherogenesis and in thrombosis. 
Lp (a) was first described by Berg in 1963 (Berg, 1963), and is a cholesterol ！ 
,.'! 
rich lipoprotein which has been identified in the plasma of higher primates and 
in the European hedgehog, but in no other known animal species. Although the 
physiological function of Lp(a) is unknown, elevated concentrations are 
associated with an increased risk of coronary artery disease, cerebrovascular 
disease and also peripheral vascular disease. 
丨| 
(1) Biochemistry ofLipoprotein (a) J 
Lp(a) represents a class ofplasma lipoproteins which vary in size and density, 
but which resemble the LDL particle apart from having a molecule of the 
carbohydrate rich apoprotein, apo (a), attached to apo B via a disulphide bond. 
Lp(a) has a larger particle size than LDL, a higher molecular weight, a more 
buoyant density and also a higher protein and carbohydrate content. A 
schematic representation ofLp(a) is shown in Figure 2. 
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Figure 2. A schematic representation of the structure of lipoprotein Lp(a). 
Apoiipoprotein (a) y ^ ^ ^ ^ - ^ S T ^ ^ ^ ^ < ^ ^ ^ ^ ^ f " ^ ^ 
^ ^ f ^ 〔 " ^ ^ ^ " ^ \ 
: & ¢ ^ ' 丨 
'^ *'***^  Apoiipoprotein B 
Lipoprote!n (a) 
The apo (a) portion is remarkably polymorphic, with 34 size isoforms having 
H. 
• ^ 
been identified (Gaw and Hobbs, 1994). This is responsible for a marked ! 
heterogeneity in Lp(a) properties and density distribution, with a molecular � 
weight which varies from approximately 300,000 to 850,000 Da (Gaubatz et al, 
1990). Those Lp(a) particles which contain larger apo (a) isoforms (> 500 Da) 
have a greater size, density and molecular weight than those with smaller 
isoforms. They also tend to be richer in protein and contain less lipid than the 
smaller forms (Fless et al，1984), and are associated with the presence oflower 
plasma concentrations. 
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Although early studies suggested that Lp(a) was transmitted as an autosomal 
dominant trait (Berg, 1968), subsequent investigations have shown that Lp(a) 
occurs in all individuals in varying concentrations, and that a single gene 
determines the plasma level (Utermann, 1990). Variation in the size of apo (a) 
is controlled by a gene on chromosome 6，and certain phenotypes are 
associated with greater CAD risk, as demonstrated by Zhong et al (1995) in 
Chinese survivors of myocardial infarction and stroke. Li this study, the 1^ 
distribution of the phenotype frequency differed significantly in patients | 
,!： 
compared with controls, with B，S1 and S2 phenotypes occurring more often. : 
On the other hand, a high frequency ofthe large S4 allele was thought to be the 
reason for low concentrations of Lp(a) in healthy Chinese subjects in 
Singapore (Sandholzer et al，1992). Further evidence for a genetic control of 
Lp(a) concentrations was provided by a study in twins in which concentrations 
J 
of Lp(a) were found to be significantly more similar in monozygotic than in the ！丨 
dizygotic variety (Austin et al, 1992). The contribution of inheritance to the � 
determination of plasma concentrations of Lp(a) appears to be much stronger 
for this than for other lipoproteins. 
The apo (a) part of Lp(a) contains triple-looped disulfide domains called 
kringles which are very similar to those found in plasminogen, a proenzyme 
critical to the process of fibrinolysis (McLean et al, 1987). The similarity in 
structure to plasminogen arises from the localization of the apo (a) gene on the 
long arm of chromosome 6. This lies adjacent to the plasminogen gene, where 
it may have arisen by an unequal crossing over. Plasminogen is a precursor of 
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• � 
a protease that under appropriate conditions cleaves the proteins in the fibrin of 
I 
t 
blood clots. The structural similarities between Lp(a), LDL and plasminogen 
may be responsible for the enhancement of cholesterol deposition and also for 
the promotion of thrombosis. 
In vivo studies on Lp(a) metabolism have been limited by the knowledge that 
Lp(a) is present only in humans and in a limited number of animals. Whilst 
neither the metabolic pathway nor the molecular basis of the pathogenicity of ) 
Lp(a) is as well understood as that of other atherogenic lipoproteins, indirect | 
,p 
evidence suggests that Lp(a) is formed predominantly in the liver (Scanu and 
Fless, 1990). Regulation of Lp(a) concentrations appears to be determined 
more by its rate of synthesis than by its degradation (Krempler et al, 1980), 
,it. 
< ； 
although this has yet to be fully determined. It does not originate from either 丨 
VLDL, LDL nor chylomicrons (Krempler et al, 1980)，but its major 丨 
I 
component, apo B-lOO，is primarily of hepatic origin, and Lp(a) contains only 丨  
this apoprotein and not apo B-48 which arises from the intestine. Messenger � 
RNA for apo (a) has only been found in the liver, and this further supports an 
hepatic origin (McLean et al, 1987). Additional clinical evidence includes the 
observation that patients undergoing liver transplantation adopt the apo (a) 
isoform ofthe donor (Kraft et al, 1991) and that liver disease is associated with 
a reduction in concentrations of Lp(a) at a stage when other lipoprotein 
fractions are unaffected (Marth et al, 1982). Low concentrations of Lp(a) have 
also been reported in many patients with cholestasis, and concentrations tend to 
increase after treatment (Kostner, 1990). 94 
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There is contradictory evidence concerning the relationship between Lp(a) and 
LDL-C catabolism and this will be investigated in one of the studies 
contributing to this thesis. A number of studies have reported that Lp(a) can 
bind to the LDL receptor, and this would suggest a shared pathway (Floren et 
al, 1981; Krempler et al, 1983). This has been supported by studies in 
transgenic mice where the overexpression of LDL receptors resulted in an 
increase in Lp(a) catabolism (Hofman et al, 1990)，and also by the fmding that 'j^  
''l 
individuals with an LDL receptor defect have elevated Lp(a) concentrations ; 
(Utermann, 1989). 
';:i^  
Iodine labeling studies of Lp(a) and LDL in rabbits suggest that the uptake of 
V. 
both lipoproteins is greater in the liver than in other organs (Kostner, 1993), 
‘I 
but Lp(a) catabolism appears to be faster than that of LDL. Other organs 丨 
demonstrating uptake include the adrenals, the spleen, the ovaries and the ^ 
!、： 
kidneys. Of particular interest was the finding that the kidneys and ovaries take 丨^ 
up 30-50% more Lp(a) than LDL. This is consistent with the observation in � 
humans that patients with renal disease have higher Lp(a) concentrations than 
the normal population (Dieplinger et al, 1993). 
However not all studies have agreed that Lp(a) and LDL share a common 
metabolic pathway. Martmann-Moe and Berg (1981) compared the uptake in 
fibroblasts from normal subjects and from individuals with familial 
hypercholesterolaemia and concluded that Lp(a) did not appear to be a ligand 
for the LDL receptor. Further evidence suggesting a separate pathway was 




investigated in 5 patients with homozygous familial hypercholesterolaemia, in 
i 
which there is little or no LDL receptor activity (Rader et al, 1995). Using 
I 
iodine labeled Lp(a) and LDL, catabolism was markedly decreased for LDL 
but that of Lp(a) was unaffected. 
I In summary, the overall weight of evidence suggests that Lp(a) in its native 
state has a weaker affinity for the LDL receptor than does LDL itself，but that 
i � 
reduced Lp(a) lacking in apo(a) may have a similar affmity for the receptor as ,'： 
''l| 
LDL (Armstrong et al, 1985; ZawadzJd et al, 1988). The correlation between .| 
changes in Lp(a) and other lipoproteins in response to oestrogen will be 
I 
investigated in one of the studies to be described in a later chapter. A close 
correlation between changes in Lp(a) and LDL and related lipoproteins would 
. '''M 




(2) Pathophysiology ofLipoprotein (a) 镇 
i 
Lp(a) may be involved in a number of disease processes where it acts as an � 
acute phase reactant. Elevated concentrations have been reported after both 
myocardial infarction and a number of surgical procedures (Maeda et al, 1989), 
but these fmdings have been inconsistent (Slunga et al, 1992). Raised 
concentrations have also been found in patients suffering from acute 
myeloblastic leukaemia (Niendorf et al, 1992)，hypothyroidism (de Bruin et al, 
1993) and end-stage renal disease (Dieplinger et al, 1993). However the main 
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Although not all of the mechanisms by which Lp(a) promotes the development 
: 
of atherosclerosis are fully understood, it appears to affect a number of 
processes which are involved in the formation of atherosclerotic plaques. These 
include lipid deposition in the vessel wall, thrombus formation, smooth muscle 
proliferation, and endothelium dependent vasodilatation. 
(i) Role in lipid deposition in the vessel wall ^ 
,¾ 
Oxidation of LDL is necessary for the accumulation of cholesterol by | 
1.,,. 
. . • ,A；'' 
monocyte-derived macrophages, and an excessive amount of lipid I 11' 
accumulation leads to the formation of foam cells and fatty streak lesions ^ 
:() 
(Witztum and Steinberg, 1991). That portion of Lp(a) similar to LDL also 
'!'W 
appears to undergo oxidative modification and this allows it to be taken up by 
macrophages, after which it is deposited preferentially compared with LDL 丨 
I 
(Cushing et al，1989). Lp(a) as well as LDL has been found in the arterial wall • 
'I 
of coronary arteries examined at autopsy (Hajjar et al, 1989), in biopsies of the � 
aorta (Rath et al, 1989) and in saphenous vein grafts after bypass surgery 
(Cushing et al，1989). The necessity for oxidation of Lp(a) prior to its 
accumulation in the vessel wall is supported by the finding that antioxidants 
protect Lp(a) against macrophage uptake C^aruszewicz et al, 1992^ 
•: 
Namszewicz et al, 1992^). 
•； . . 
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(ii) Role in thrombosis 
Fibrinolysis is essential for the prevention ofthrombotic ischaemic events as it 
facilitates the elimination of fibrin clots. As apo(a) is structurally similar to 
plasminogen, it has been suggested that Lp(a) may have a prothrombotic effect 
by interfering with the action of plasminogen. Whilst amino acid substitutions 
may make it incapable of plasmin type fibrinolytic activity, it does seem 
capable of acting as a competitive inhibitor of plasminogen activation ^ 
15 
QS[achman, 1992). Various studies have suggested that Lp(a) may compete with f 
,!t ‘ 
:¾:: 
the binding of plasminogen to fibrinogen or fibrin monomer (Harpel et al, 
.4 
11' 
1989)，with the streptokinase mediated activation ofplasminogen (Edelberg et :) 
‘. • ：!I: 
al, 1989)，and with the tissue plasminogen activator mediated lysis of fibrin !'：； 
«yi' 
clots (Loscalzo et al，1990). If all of these actions took place in vivo, this 
would strongly support a prothrombotic role for Lp(a), and further explain its � 
<(i 
. ® 
role in the thrombotic processes taking place after rupture of atherosclerotic ^ 
、 
plaques. 
(iii) Role in smooth musde proliferation 
Atherosclerosis is a fibroproliferative disease, and smooth muscle cell 
proliferation and migration are features shared by both primary atherosclerosis 
and restenosis. Lp(a) has been shown to promote smooth muscle cell migration 
(Kojima et al, 1991) and proliferation (Grainger et al, 1993)，and this is another 
explanation for the association with an increased risk of premature CAD and 
restenosis after angioplasty. 
98 







(iv) Role in endothelium dependent vasodilatation 
It has recently been suggested that there may be a relationship between 
elevated concentrations of Lp(a) and the presence of endothelial dysfunction in 
patients with familial hyperlipidaemia. Endothelium dependent vasodilatation 
is impaired in children with this disease, and the degree of impairment 
correlates with the level of Lp(a) (Sorensen et al, 1994). Mpairment of ^ 
liil 
adaptive vasodilatation is thought to be an early event in the process of i| 
ii. 
.¾!, 
atherogenesis, and this may be mediated via endothelium-derived relaxation :: 
'0 
factor (nitric oxide). _ 
• 泊： 
Jn summary, Lp(a) is involved in a number of different processes which ;; 
"'i/ '\ 
promote atherogenesis and thrombosis, and this is due in part to structural .¾,;/ 
similarities between Lp(a), LDL-C and plasminogen. I 
I 
I 
(3) Distribution ofLipoprotein (a) in Chinese and in Other Populations � 
Whilst Lp(a) is present in all humans, concentrations vary widely within and 
betweenpopulations. Early studies ofinterpopulation differences performed by 
Berg (1979) were qualitative in nature, and reported positive testing in 
approximately 35% of selected white populations, 34% of blacks and 30% of 
Eskimos. With the development of quantitative assays, however, 
concentrations were shown to have a marked inter-racial variation, with mean 
values usually lying within the range 10-20 mg/dl in white and 20-40 mg/dl in 
black populations. Cross-sectional studies in Chinese populations have 
99 
demonstrated relatively wide variations between different sample groups, but 
this may have resulted from the use of different assay methods, hi general, 
concentrations appear to be similar to those of Caucasians. 
hi nearly all studies, the distribution of values in Caucasian and in Chinese 
I populations has been found to be positively skewed, with the lowest 
concentrations occurring with the highest frequency. In black populations, 
\ 
however, there appears to be a more normal distribution. ！丨^ 
：丨 
Values above 30 mg/dl are considered to represent a significant risk factor for 丨 / 
the development of CAD. Dahlen et al (1986) calculated a RR of 1.6 and 3.6 ) 
"^ 
respectively for threshold concentrations of 30 and 40 mgMl. Kostner (1989) 
suggested that the lower limit may be nearer to 25 than 30 mg/dl after fmding a 
doubling of risk of myocardial infarction in individuals with concentrations J 
¢: 
above this value. 
|j 
A summary of studies which demonstrate interpopulation differences in Lp(a) 丨_ 
V . 




Table 16. Interpopulation differences in concentrations ofLp(a). 
I STUDY~fAGi CHEVESE CAUCASLiN AFRICA- OTHER 
AMERICAN 
/NIGEMAN 
Mean (SD) Mean (SD) Mean (SD) Mean (SD) Mean ( S D ) _ 
AIbers M46.4(15.3) - M9.3(12.5) - -
et al,1974 F 44.6 (14.9) F10.1(13.4) 
Schriewer M42.1(10.8) - M39(<0.01-93) - -
etai,1984 F 36.4 (13.2) F 50 (<0.01 • 100) 
I Guyton Caucasian - “ 
et al, 1985 M 37.0 (9.6) M 17.0 (2.3) 
F 34.9(10.1) F 15.5 (2.2) 
I A-American 
M31.7(11.5) M31.3(2.8) > 
F 31.7(7.3) F 33.7 (2.3) {,j3 
b ^ Caucasian - M 10.8 (15.4) M23.9 (23.1) - “ 
et al, 1987 29.5 (7.1) F 10.5 (14.6) F 23.8 (11.2) ^ , 
I A-American �‘ 
29.3 (7.1) � 
Sandholzer Caucasian 
et al, 1991 Austrian 36.8 (11.6) Austrian 14.1 (19.4) '| 
Hungarian 37.5 (9.5) Hungarian 8.3 (11.0) 
Icelandic 40.7 (11.1) Icelandic 13.5 (17.7) 
lndian31.9(14.0) 二 ‘ 
Malaysian 33.3 (13.4) 20.yi5.y) 
Chinese46.7 (13.1) 7.2(13.1) Malays= ” 
Sudanese23.3(7.9) Sudanese 12.9(17.9) ‘ 
45.7 (25.9) 
h 5 ^ - ^ J ^ - - M31.9(36.2) -
etal,1991 ^32.8(41.5) 
L _ I 
I Woo,Lam, M 6 8 ( l l ) 27.6(28.0) - - ‘ � 
1990;Woo, F 7 3 ( l l ) � 
Lam, 1991 
Cobbaert, Chinese M 12.8 
Kesteloot; M 52.5 (6.0) (13.8) 
1992 F53.5 (4.6) F15.6 
Caucasian (15.6) M 12.6 (13.4) 
M 45.6 (14.4) F 19.4 (21.5) 
F51.6 (12.6) ^ 
V Korean Korean … " / “ � 
M26.7(5.4) 二 / .6) 
=tl(2.0) S a n ^ 
" " 1 1 , , M10.1(11.7) 
M36.3(11.5) F i < 2 ( 9 U 
F 34.7 (8.2) . • F8.2(9.1) 
Nigerian Nigerian 
M 37.9 (14.0) M17.1(14.1) 
F33.5(10.2) F 18.4(13.1) 
Marcovina 18-30 - M6.6(7.0) M 12.3(8.3) _ 
| e t a l , 1 9 9 3 丨”.1(7.3) | F 13.6(8.6) 







STUDY f l G E CHINESE CAUCASL^ AFRICA- OTHER 
AMERICAN 
/NIGEmAN 
Mean (SD) Mean (SD) Mean(SD) Mean (SD) Mean (SD) 
Lyu 40-59 M15.0 - • " 
et al, 1993 (16.0) 
F 18.1 
(19.1) 
Gaw Chinese 14.7 “ 
et al, 1994 44 (16) (21.1) 
Caucasian 17.9(19.1) 
38 (9) 
A-American 37.7 (26.9) �� 
39 (10) ^ k ' 
H o w a r d ~ 23-35 - M6.1 M21.5 - ‘丨‘丨 
et aI, 1994 F 6 . 4 F 23.9 p, 
Nilsson 2 ^ - M11.6 - - ； 
et al, 1994 (0.51-129) 
F 21.2 t^l 
(0.16-133) 
"oP^ 5^5 - M21.1 - -
et al, 1994 F 2 1 6 
l f ^ ~ ~ 1 5 ^ “ - - ~ " ? 二 5 : 





(i) Caucasian populations � 
Lti one of the earliest quantitative studies, Albers et al (1974) measured Lp(a) 
concentrations in 586 males and 665 females in the United States with ages 
ranging from less than 20 to over 70 years. Mean Lp(a) concentrations were 
9.3 mg/dl in males and 10.1 mg/dl in females, but the sex difference was not 
statistically significant. The distribution ofvalues was markedly skewed to the 
right. 
Schriewer et al (1984) measured concentrations in 987 males and 477 females 




mg/dl in males and 50 (<0.01-100) mg/dl in females, but as in the previous 
study, the gender difference was not significant. Despite the high median 
values resulting from the skewed distribution, concentrations of Lp(a) 
exceeding 30 mg/dl were present in only 6.5% of males and 6.1% of females. 
In the Kristianstad Survey, Lp(a) was measured in an unselected population of 
203 men and women aged 20-80 years living in the southern part of Sweden 
gS[ilsson et al, 1994). The median values in this study were 21.2 mg/dl (0.16- ^^  
133) for females and 11.6 mgMl (0.51-129) for males, but this difference was “ 
not significant. There was also very little difference between the sexes in a : 
study of 248 healthy Turkish subjects where mean concentrations of Lp(a) ,丨 
丨::. 
were 21.1 mg/dl and 21.6 mg/dl in males and females respectively (Orem et al, ‘ 
！ fl 
：I： 
‘ I ： 
1994). Approximately 25% had concentrations exceeding 30 mg/dl. 丨 
Although interpopulation differences were demonstrated in these studies, there 
I 
were few in which gender differences were present. ^ 
hi �’.… 
(ii) African-American and other black populations 
Most studies have shown that Lp(a) concentrations are higher in black than in 
white populations and that the distribution of values is less skewed. The 
Coronary Artery Risk Development in Young Adults Study measured Lp(a) 
concentrations in 4,125 black and white men and women aged 23-35 years 
(Howard et al, 1994). Concentrations were approximately 3 times higher in the 
black volunteers ofboth sexes (21.5 vs 6.1 mg/dl in males, 23.9 vs 6.4 mg/dl in 
females). Parra et al (1987) measured concentrations in 81 healthy black 
103 
i'. i 
Ti^  , 
natives ofthe People's Republic of Congo and compared them with 81 healthy 
white males and females of French extraction. The subjects were matched for 
age and sex, and Lp(a) concentrations were also found to be significantly 
higher in black men and women (23.8 [士 23.1] mg/dl and 23.8 [± 11.1] mg/dl) 
than in white subjects (10.8 [士 15.4] mg/dl and 10.5 [士 14.6] mg/dl; p<0.001). 
In the largest study involving 4,165 Caucasians and African Americans from 4 
\ 
communities in the United States, the distribution of Lp(a) values was more | 
. i 、 � , 
skewed in the Caucasians, and the median values were higher in the African 'l| 
:;',i.;i,. •::/* 
Americans (3.7 mg/dl vs 11.6 mgM) (Marcovina et al，1993). Guyton et al | 
• 1 丨，,.: 
(1985) also found a more even distribution in healthy black subjects, and t 
l :¾,, 
concentrations of Lp(a) were on average twice that of Caucasians in both males •；； 
'"< 
i ‘ > 
and females. Higher mean concentrations of Lp(a) were also present in a | 
, jj:i:. 
cross-sectional sampling of 1,309 black Africans from the Seychelles aged 25- .;:1 
I 
64 years (males 31.9 [土 36.2] mg/dl, females 32.8 [± 41.5] mg/dl) (Bovet et al, s| 
、 , i 
1991). 
(iii) Chinese populations 
There have been a number of studies which have compared concentrations of 
Lp(a) in Chinese and in other populations using the same methodology, bi most 
of these concentrations in the Chinese have been found to be similar to those 
， .  
of Caucasians. Cobbaert and Kesteloot (1992) measured lipid concentrations in 






sex-matched samples each from males and females were analyzed. All subjects 
were living in their native country, with the Chinese subjects having been 
recruited from the north ofBeijing. Median concentrations ofLp(a) were 12.8 
mg/dl in Chinese males and 15.5 mg/dl in Chinese females. Corresponding 
values for Nigerians were 37.9 and 33.5 mg/dl, for Belgians 12.6 and 19.4 
mg/dl, for Koreans 14.3 and 9.9 mgMl and for Tibetans 10.1 and 8.2 mg/dl. 
Sandholzer et al (1991) examined differences in Lp(a) concentrations in the ^ 
'I'liI 
Chinese and in 6 other ethnic groups (Tyrolean, Icelandic, Hungarian, Malay, | 
•;'i, 
lhidian and Black Sudanese) in a total population of 1,150 subjects of both � 
« 
sexes. Mean values of Lp (a) were significantly lower in the Singaporean � 
Chinese (7.2 [土 13.1] mgMl) than in the other groups. The highest 
：,t' 
？ ‘. 'i 
concentrations were found in the Sudanese [45.7 (± 25.9) mg/dl]. Another ‘ 
. 、丨1 
study compared Lp(a) concentrations in 101 Chinese subjects, 174 American ’ 
l i ' 
Caucasians and 106 African Americans all selected at random from the Dallas- , 
Fort Worth area of the United States (Gaw et al, 1994). There was no 
significant difference between the median Lp(a) concentrations of the 
Caucasian and Chinese subjects [9.0 (<l-88) mg/dl vs 8.0 (<1-156) mg/dl], but 
that ofthe African-Americans was significantly higher (33.0 [<l-120] mg/dl) 
than the other two groups (p<0.001). 
In one study in which a deliberate bias was present in the selection of the two 
study populations, Lp(a) concentrations of 440 Taiwanese subjects at low risk 
for CAD were compared with those of 428 high risk subjects from the 
105 
: : 3 
Framingham Offspring Study (Lyu et al, 1993). The findings in this study 
differed from most others as no significant differences in Lp(a) values were 
present between the high and low risk groups (males, Taipei vs Framingham 
15.0 [土 16.0] vs 15.4 [士 17.5] and females, Taipei vs Framingham 18.1 [土 
19.1] and 14.3 [士 14.2]). All assays were performed in one laboratory, and as 





(iv) Hong Kong Chinese 
,;.',i; 
• 1 ' ' ' ' ^ 
There have been few studies in Hong Kong which have examined the . 
卜：:;' 
distribution of Lp(a) in either healthy subjects or in those with established :;f 
.:.!_ I 
•I, 1 • '1¾: 
cardiovascular disease. Woo and Lam (1990，1991) measured the lipid profile ；； 
"i'i.i 
1'丨: 
of 314 apparently healthy elderly Chinese subjects with mean ages of 68 years f 
i 
in males and 73 years in females. The distribution of LpW concentratimis was | 
,'Tr-i '4: 
skewed to the right with a mean value of 27.6 (± 28.0) mg/dl. Concentrations | 
、. 
equal to or above a threshold value of 30 mg/dl were found in 46/160 (28.7%) 
males and 47/153 (30.7%) females. 
In summary, Lp(a) concentrations in Chinese are similar to those of 
Caucasians, and in both populations the distribution of values is positively 
skewed. African-Americans and other black populations have higher 
concentrations, and values have a more normal distribution. 
(4) Lipoprotein (a) and Coronary Artery Disease 
106 
Elevated concentrations of Lp(a) are associated with an increased risk of 
cardiovascular disease in Chinese as well as in Caucasians. Although raised 
concentrations of Lp(a) have been shown to be a risk factor for stroke in the 
Hong Kong Chinese (Woo et al, 1991), no studies have been reported from this 
population describing the relationship with the risk of cardiac disease. 
Evidence that Lp(a) is a risk factor in the Chinese is, however, available from 
、、 




• - I |!;_1' I .丨\ i 
I •丨 
(i) Early studies • 
The initial studies investigating the relationship between Lp(a) and CAD risk 講 
:¾,, 




patients with proven or suspected CAD, 58 Swedish patients with a definite � 
ll.:: 
history of myocardial infarction, 75 healthy Swedish males aged 16-17 years % 
I； 
and 107 Swedish males aged 50-52 years. In the healthy subjects, the Lp(a) |： 
phenotype was present in 29% of the younger and in 26% of the older group of � _ 
subjects. It was found in 41% and 55% respectively of the Swedish and the 
Finnish patients, and the differences between healthy subjects and those with a 
history of CAD were highly significant (Swedish CAD patients vs healthy 
Swedes, p<0.05; Finnish CAD patients vs healthy Swedes, p<0.01). Frick et al 
(1978) measured Lp(a) in 39 women aged 10-62 years and 114 men aged 23-60 
years undergoing selective coronary angiography. The Lp(a) phenotype was 
present in 11.3% of subjects with normal coronary arteries, in 21.4% of those 
with a moderate degree of atherosclerosis and in 33.6% with severe 
107 
atherosclerosis (p=0.01). Higher numbers were reported by Berg (1979)，who 
studied 95 apparently healthy males aged 40-42 years and found that Lp(a) 
phenotypes were present in 60% who had one or more close relatives with 
CAD compared with 28% in those with no such history (p=0.01). 
Further retrospective studies in which Lp(a) concentrations were quantitated 
supported the positive correlation between Lp(a) and CAD risk (Kostner et al, 
V 
1981; Durrington et al, 1988; Sandkamp et al, 1990; Genest et al，1991; Genest | 
et al, 1992^ Parra et al, 1992; Sandholzer et al, 1992). % 
r I 
t 
(ii) Prospective studies i 
,ii: 
:i*:ij 
There have been a number of prospective studies which have examined the 
=¾' -‘I 
association between Lp(a) and the incidence of CAD. Amongst the earliest was | 
',I 
I 
a case-control study based on 776 healthy 50 year old males living in Sweden %,| 
• . I 
(Rosengren et al，1990). Follow-up was conducted over a 6 year period during |； 
. I 
which there were 26 deaths from CAD. The mean level of Lp(a) was 27.8 � 
mg/dl in cases and 17.3 mg/dl in controls, and multiple regression analysis 
showed a significant independent association with CAD risk (p=0.01). 
Another study of similar design involved 1,332 healthy males aged 45-72 years 
who were followed up for 8.6 years in Iceland (Sigurdsson et al, 1992). There 
were 105 episodes of fatal or non-fatal myocardial infarction, and 
concentrations of apo (a) were 230 U/1 in cases and 170 U/1 in controls 
(p<0.05). Measurements of apo (a) were assumed to closely approximate those 
of Lp(a), and these concentrations were also independently associated with 
108 
CAD. The only prospective study investigating Lp(a) as a risk factor for CAD 
in women was conducted amongst 3,634 subjects in Britain, 51 of whom 
developed CAD. Mean Lp(a) concentrations were higher than in controls, but 
due to the skewed distribution of Lp(a), the difference was not significant 
(Coleman et al，1992). 
Good evidence for the role of Lp(a) as an independent predictor of myocardial 
、、 
infarction as well as intermittent claudication and cerebrovascular disease was L ^  
，| 
provided by the Framingham Heart Study (Bostom et al, 1994). A sinking i | 
:fe 
prebeta lipoprotein band which is a putative marker of elevated Lp(a) | 
;:j< 
concentrations was found in 14% of 3,103 women followed up between 1968 _ 
/!,i, 
and 1975. Multivariate adjusted relative risks for band present versus band ， J / ！ 
••ii, ••, 1¾ 
absent were 2.37 (95% CI 1.48-3.81) for myocardial infarction, 1.61 (95% CI 省 
i'"'j . I 
1 13-2 29) for total coronary heart disease and 1.44 (95% CI L09-1.91) for 
麵：: 
'4 : 
total cardiovascular disease. | 
Concentrations of Lp(a) have not，however, been found to be predictive in all � 
studies. Alfthan et al (1994) investigated 7,424 healthy men and women aged 
40-64 years and recorded cardiovascular events over a 9 year follow-up period. 
Myocardial infarction or stroke occurred in 134 males and 131 females. The 
median Lp(a) concentrations were 7.3 mg/dl in male cases and 10.8 mg/dl in 
male controls. In females, the median concentrations were 11.3 and 9.1 mg/dl 
respectively, and the differences were not significant. 
The two largest studies differed in their conclusions. Concentrations of Lp(a) 
were measured in a nested case-control study of 14,916 male physicians aged 
109 
40 to 84 years participating in the Physicians' Health Study (Ridker et al, 
1993). Follow-up was conducted for an average of 60.2 months, during which 
296 subjects suffered a myocardial infarction. There was no significant 
difference in the median values of Lp(a) between cases and controls [10.30 
mg/dl in cases, 10.25 mg/dl in controls (p=0.73)]. The other study involved 
21,520 healthy males aged 35-64 years who were recruited between 1975 and 
1982 and followed up until 1987 (Wald et al, 1994). There were 2,229 deaths ^ � 




concentrations of apo (a) were 8.58 mg/dl in cases and 5.56 mgAU m controls. • 
'^ 1 
Multiple regression showed that concentrations of apo (a) were independently | | 
S, 
associated with CAD risk. 
ii/ v^, 
The most recent studies were a nested case-control study of 3,806 称 
!. 1 
j - . i . 
hypercholesterolaemic males aged 35-59 years participating in the Lipid | 
t l . 
Research Clinics Coronary Primary Prevention Trial (Schaefer et al, 1994) and | 
\ 
6,002 males aged 40-59.9 years taking part in the Gottingen Risk Incidence and � 
Prevalence Study (GRIPS) (Cremer et al, 1994). In each of these studies Lp(a) 
was an independent risk factor for CAD. 
(iii) Angiographic studies 
Additional evidence to suggest that Lp(a) is an independent marker of CAD 
risk has been provided by angiographic studies. Armstrong et al (1986) 
examined 40-60 year old males with at least 50% stenosis in one or more 
coronary arteries and calculated odds ratios as a measure of the association 
110 
between Lp(a) concentrations and the presence of CAD. A ratio of 2.7 
(p<0.001) was derived for Lp(a) concentrations > 30 mg/dl compared with low 
concentrations (< 5 mg/dl). Labeur et al (1992) conducted the largest single 
centre angiographic study which involved 323 women and 731 men. When 
they compared the highest quintile groups with the lowest for Lp(a) 
concentrations, the multivariable adjusted odds ratio was of borderline 
. 、 
significance for coronary artery stenosis in women (p=0.05), but not m men j_)j 
(p=0.18). Orem et al (1995) performed a cross-sectional study on 60 males and 丨 
:¾'); 
females aged 48 -71 years who had at least 50% stenosis in one or more ��‘ 
coronary arteries. The mean Lp(a) level in this group was 41 mg/dl, which was \ | 
ahnost double that of 65 healthy controls (21 mg/dl, p <0.001). , 
fti/1 
The largest collective study was the ECAT Angina Pectoris Study (Bolibar et f 
. 
al, 1995), in which Lp(a) concentrations were measured in 18 European 
|ii' 
medical centres among 2,500 men and women with suspected angina pectoris. f^  
Elevated concentrations of Lp(a) were significantly and independently 
associated with the presence of CAD defined by the presence of one coronary 
vessel with > 50% stenosis. 
Support for a relationship between elevated concentrations of Lp(a) and the 
presence of coronary artery stenosis has not, however, been provided in all 
angiographic studies. Molitemo et al (1995) compared Lp(a) concentrations in 
68 African-American males and females with angiographic evidence of CAD 
and compared them with those of 72 subjects with normal coronary arteries. 
111 
There were no significant differences in concentrations between those with [52 
(土 38) mg/dl] and without [54 (± 47) mg/dl] evidence of disease. Sorrentino et 
al (1992) also reported no significant difference in concentrations in a cross-
sectional study of African-Americans with and without coronary artery 
stenosis. In all cases, however, there was an indication for angiography 
(usually angina), and if the angiogram was normal, it was assumed that they 
• ‘�s 
were suffering from Syndrome X rather than from coronary artery stenosis. ‘ 
:V 
This syndrome is characterized by symptoms of angina pectoris in the presence 
• � . i .:.|^  丨 
'V. ！ 
of normal coronary arteries. It is more common in women, especially after a ：；丨 | 
hysterectomy (Drexler and Schroeder, 1994), but there have been no studies ！ 
• •'：< ； 
which have investigated whether Lp(a) could have some role in the aetiology of 丨 
i'h-/ i 
丨..I .::�I 
this syndrome. The failure to demonstrate differences in Lp(a) between these ( 
two groups ofpatients does not therefore exclude the possibility that Lp(a) may : 
i . 
/>i^ I 
be involved in the aetiology of their condition. | 
Angiographic studies have also consistently demonstrated a relationship 
between concentrations ofLp(a) and the risk ofrestenosis after coronary artery 
bypass surgery (Hoffet al, 1988; Terres et al，1995). 
(iv) Chinese populations 
Schwartzkopff et al (1990) measured Lp(a) concentrations in Tianjin in 
mainland China in 154 males and 69 females aged 40-60 years who had a 
history ofmyocardial infarction. Lp(a) concentrations were significantly higher 
112 
in the patients [34.3 (士 28.4) mg/dl] than in 216 male and 219 female controls 
[26.2 (± 25.9) mg/dl]. In another study from Nanjing, Zhuang et al (1993) 
quantified serum Lp(a) in 1266 healthy persons and compared these with 
survivors of myocardial infarction matched for age and sex. Mean values were 
23.6 (士 21.6) mgAU in survivors and 14.9 (士 12.0) mgMl in healthy controls 
(p<0.01). The 90th centile in the control group was 30 mg/dl, and 29/76 
X. 
(38.2%) of MI survivors had concentrations which exceeded this value. There i|| 
pf 
was no significant association between MI and concentrations of the other 
'• i, 
.，. 
lipids and lipoproteins, and it was concluded that Lp(a) was an independent _ 
:'‘''i 
'•V, 
risk factor in the Chinese. 
^ : 
. . ‘ , I ； 
In Taiwan, Wu et al (1993) compared concentrations of Lp(a) in 59 males and ； 
， 'v, 
,•丨 
females with proven stenosis in at least one coronary artery against those of ( 
礼, 
119 apparently healthy controls of a similar age. Lp(a) concentrations were • 
S�' 
y:. 
also significantly higher in cases [21.4 (± 15.9) mg/dl] than in controls [11.5 (± | 
* • ^ , ' H H : 
12.3) mg/dl] a><0.001). 
Remarkably similar results were obtained in a study of 162 Singaporean 
Chinese having at least 50% stenosis of one major artery on coronary 
angiography (Sandholzer et al, 1992). The mean concentration of 匕卩⑷ was 
20.7 [士 24.0] mgMl which was significantly higher than that of 211 normal 
subjects (8.9 [土 12.9] mg/dl) [p<0.01]. Concentrations of TC were also 





These authors also concluded that Lp(a) was a principal risk factor for 
cardiovascular disease. 
Elevated concentrations of Lp(a) therefore appear to be equally important as a 
risk factor in Chinese subjects as in Caucasians, and in most studies Lp(a) has 
been found to be an independent risk factor for CAD. 
X. 
If'll 
(5) Endogenous Hormones and Lipoprotein (a) 
M 
I :••;;; 
In view of the potential for exogenous sex steroids to influence Lp(a) � 
‘丨：;： 
concentrations, a summary of the effect of endogenous hormones on Lp(a) will "I 
I 
also be provided. As in the parallel section describing the effect of oral 
•'i • 
contraceptives on the basic lipid pattern, the relationship between oral :: 
i • I 
<)j 
contraceptives and Lp(a) will also be described. 
' •?" 
,i.i • 
,^: I' ,1 ： |i; 
, | i 
(i) Lipoprotein (a) and the menstrual cycle 
There are few data concerning the effects of the menstrual cycle on 
concentrations of Lp(a). Owens et al (1993) examined 9 premenopausal 
diabetic and 9 non-diabetic women and found no significant differences in 
concentrations between the follicular and luteal phases. In addition, in a small 
study of 20 women undergoing ovarian hyperstimulation for the treatment of 
infertility, favourable changes in the basic lipid profile were observed in 
association with rising oestradiol concentrations, but there was no significant 
change in the median concentration of Lp(a) (Seed et al, 1991). 
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The effect of endogenous hormones on Lp(a) concentrations has also been 
investigated in males in two population based studies conducted among 265 
healthy subjects from the United States and Finland (Haffner et al, 1994). No 
association between either sex-hormone binding globulin, total and free 
testosterone，oestradiol or dihydroepiandrosterone sulphate concentrations and 
Lp(a) concentrations was found. Marques-Vidal et al (1995) also found no 
、、 
correlation between concentrations of oestradiol, testosterone, testosterone | 
ii.:,j 
binding globulin and Lp(a) concentrations. This confirmed the results of a | 
i"i 
;.;;i, 
previous study of 98 healthy males aged 45 and 95 years (Denti et al, 1994). ) 
:;,ll 
No relationship was established between concentrations of Lp(a) and either ! 
’,丨:丨 
i；；?：.；, 
free testosterone, oestradiol or gonadotropin concentrations, although some 
. l{j 
associations were found between the sex hormones and other lipoproteins. , ! 
'•. I 
I . ) 
Endogenous sex hormones do not therefore seem to affect Lp(a) concentrations 叙 
S' i '\ . 
in healthy males or females. 丨| 
V' 
< ' J 
(ii) Lipoprotein (a) and pregnancy 
There are contradictory data regarding the effect of pregnancy on 
concentrations of Lp(a). Zechner et al (1986) in a longitudinal study of 42 
women during normal pregnancy found that Lp(a) concentrations increased 
during the first trimester and reached a maximum in the middle of the second 
trimester. This was followed by a gradual decline towards term, when 
concentrations were lower than in the first trimester. Concentrations 5-6 






i results were not supported in a cross-sectional study of 193 pregnant women ^ 
I 
i 
I by Panteghini and Pagani (1991)，where median values of Lp(a) increased 
！ steadily towards term and then decreased in the first week postpartum, 
i 
！ It is difficult to be certain which of these studies was the most reliable, 
although the latter used a more sensitive assay for Lp(a). In the earlier study, 
because of the limitations of the assay technique, only those subjects with 
、、 
concentrations of Lp(a) above 10 mg/dl were included. In addition, no L^  
;'iil 
consideration for the skewed distribution of Lp(a) values appeared to have been i':| :vQ ',;i 'i 
• 'r, 
made in the statistical analysis. : 
• 鄉 
Neary et al (1995) studied Lp(a) concentrations in matemal venous and ^ 
�':.:‘ i 
umbilical venous and arterial blood in 13 full-term pregnancies and in 25 ！ 
1 
healthy non-pregnant females. Lp(a) concentrations were significantly greater ( 
,,,. 
in the pregnant females (11.2 mg/dl) than in controls (5.0 mgMl) and there was h 
. || 
also a significant correlation between matemal and foetal Lp(a) concentrations | j 
(r=0.791, p<0.01), but not with other lipids or lipoproteins. "‘ 
(iii) Lipoprotein (a) and oral contraceptives 
There have also been few studies which have investigated the effect of oral 
contraceptives on concentrations ofLp(a), and no consistent changes have been 
observed. Kuhl et al (1993) studied 19 women taking a low dose biphasic 
preparation for 6 months and found a significant initial decrease in Lp(a) 
concentrations during the first 3 cycles, but concentrations increased thereafter. 
In the control cycle at the end of 6 months, concentrations were significantly 
116 
higher than before the start of treatment. In another study, mean Lp(a) 
concentrations in 25 users of oral contraceptives were compared with those of 
25 healthy controls and 35 women who had suffered thrombotic complications 
while taking oral contraceptives (Delplanque et al, 1993). There were no 
significant differences in Lp(a) concentrations between the 3 groups, but no 
mention was made of the duration of oral contraceptive use in those who were 
still users nor of the length of time those with thrombotic complications had ^ 
'!i| 
been treatment free. \ 
II,. 
:::¾ 
In the most recent study, Porkka et al (1995) studied the influence of oral )V 
_ 
contraceptive use in a cohort of 559 women aged 18，21 and 24 years. Lp(a) ! 
w, 




preparations (<3 mgM) than for those using triphasic/levonorgestrel , � 
contraceptive pills or taking no treatment (4.5 mgMl in each group) (p<0.01). , 
I' 
Studies to date have not therefore revealed a consistent effect of oral | i 
contraceptives on Lp(a) concentrations. 
(iv) Lipoprotein (a) and the menopause 
The menopause is associated with unfavourable changes in the basic lipid 
profile, and it also appears to result in an increase in concentrations ofLp(a). In 
one longitudinal study of 212 healthy middle-aged women who had samples 
taken three years apart, Lp(a) concentrations were significantly higher at the 
time of second sampling in those women who had become menopausal during 
that period (Meilahn et al, 1991). Heinrich et al (1991) in the PROCAM study 
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examined concentrations in a group of 864 men and 373 women and also 
showed that mean Lp(a) concentrations were significantly higher in 
postmenopausal than in premenopausal women (7.9 mg/dl versus 5.1 mgAil; 
p<0.001). 
Jn the Framingham Offspring Study, 1,284 healthy men and 1,394 healthy 
women (mean age in both groups 48 土 10 years) were examined and there was 
• 'V 
a significant association between age and Lp(a) concentrations in women but | 
i�j). 
not in men (Jenner et al, 1993). Lp(a) values were 19% higher in 
:A 
postmenopausal than in premenopausal subjects, and 8% higher after -
controlling for age, although this value was not statistically significant. Li this :| 
. I 
study 30 postmenopausal women were taking oestrogen, but the mean level m "：' 
-•(' 'I 
this group did not differ significantly from that of 58 age-matched 丨「 
？, 
postmenopausal controls. 
• . 'A ‘ 
In another cross-sectional study comparing Lp(a) concentrations in African- |； 
V. 
Americans with and without CAD, concentrations of Lp(a) were notably higher 
in postmenopausal than in premenopausal women in both groups (Molitemo et 
al, 1995). 
Concentrations were also found to be significantly higher in 76 healthy 
postmenopausal Chinese women 23.0 (± 22.4 mg/dl) when compared with 134 
healthy premenopausal women in Taipei 15.0 (士 15.8) mg/dl (Lyu et al, 1993). 
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The weight of evidence therefore suggests that concentrations of Lp(a) also 
increase in association with the development of a more atherogenic basic lipid 
pattem in postmenopausal women. 
From these studies it is evident that endogenous hormones have an inconsistent 
effect on concentrations of Lp(a). The only relatively constant fmding was an 
increase in concentrations of Lp(a) after the menopause, and the hypothesis 
• 、 * ^ 
that oral oestrogens reduce concentrations of Lp(a) is in part based on this | 
observation. It would be expected that the higher endogenous concentrations / 
. 1 
of oestrogen found during pregnancy would also reduce Lp(a) concentrations, 
'I 
but in pregnancy other factors may outweigh the influence of endogenous )丨 
hormones on Lp(a) concentrations. In addition, the failure of endogenous 
I.) '"^ (;‘ I i 
oestrogens to affect Lp(a) concentrations during the reproductive years does 丨  
i... 
not mean that exogenous oestrogens will have no effect in postmenopausal 
:¾! 
women. To date there have only been two small studies on the effect of oral ij, ! 
丨一，i 
contraceptives on Lp(a) concentrations, and these have shown no significant � 
effect. Again, this does not necessarily suggest that the hypotheses in this 
thesis will not be proven, as the use ofrelatively high dose synthetic oestrogens 
in women in the reproductive age group cannot be compared with that of using 
low dose natural oestrogen in postmenopausal women. 
(6) Lipoprotein (a), Diet, Exercise and Drugs 
Lp(a) differs from the other lipoproteins in that concentrations are largely 
genetically determined and are similar in both sexes. Lp(a) also behaves 
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differently in its response to treatments which usually improve an atherogenic 
basic lipid profile. These include dietary, exercise and pharmaceutical 
interventions. 
(i) Diet and exercise 
There have been contradictory findings regarding the effect of exercise on 
concentrations of Lp(a), although most studies have shown that exercise ��:� 
% 
increases rather than reduces Lp(a) concentrations. Hubinger et al (1995) 種 
. 、':丨: 
measured Lp(a) concentrations in middle-aged well trained Caucasian male 厂 
I 
endurance runners and compared them with age and body mass index matched ! 
{ | I. 
non-athletic controls. Mean Lp(a) concentrations tended to be higher in the ;: 
•'.：；'• ！ 
;‘v 
runners although not significantly so (15 mg/dl vs 12.5 mg/dl, p>0.05), but i.,| 
卜.• 




Ponjee et al (1995) investigated the effect of exercise over a 9 month period in � 
36 previously sedentary males and females. Median baseline Lp(a) 
concentrations were 3.2 mg/dl in males and 6.5 mg/dl in females. After 24 
weeks of training, Lp(a) concentrations had increased significantly in each 
group, and had ahnost doubled after 36 weeks oftraining. Cardoso et al (1994) 
also found relatively high concentrations of Lp(a) in long distance runners and 
in body builders. 
The only opposing evidence was provided by the Cardiovascular Risk in 
Young Finns Study (Taimela et al, 1994)，in which a physical activity index 
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was calculated in 2,464 children and young adults aged 9-24 years. There 
were no significant differences in Lp(a) concentrations with respect to age or 
gender, and concentrations were significantly but inversely correlated with the 
level ofphysical activity. 
There have also been contradictory findings regarding the effect of diet on 
concentrations ofLp(a). In the earliest study, a short term high cholesterol diet 
�*****s» 
was found to have no effect on Lp(a) concentrations in 2 healthy human | 
volunteers, although apo B concentrations increased significantly over this ：；| 
,'i 
•’：丨！ 
period (Albers et al, 1977). When a lacto-vegetarian diet was fed to 36 : 
i 
subjects of both sexes for 6 weeks, although there were significant reductions | 
':丨丨： 
in TC and LDL-C, there was no change in Lp(a) (Masarei et al, 1984). Kostner : | 
I • t‘ j 1¾ 
et al (1984) also found no effect of diet in 12 hypercholesterolaemic subjects (| 
who had suffered a previous myocardial infarction. Another study involved 
、•“ i '(jj I 
treatment of 15 obese patients with a low calorie diet and another 5 obese | j 
patients with a starvation diet, but neither of these produced a change in Lp(a) � 
concentrations. Diet may，however, have an effect in obese individuals with 
high concentrations of Lp(a). This was suggested by Muls et al (1993) who 
treated 54 normolipidaemic obese Dutch women and found that a 10 kg weight 
loss was associated with a reduction in Lp(a) concentrations in 9 women who 
had initial concentrations exceeding 30 mg/dl, but had no effect in the 45 
women with values below this. 
However both Mensink et al (1992) and Nestel et al (1992) found that diets 
rich in trans-monounsaturated fatty acids raised Lp(a) concentrations, but this 121 
was not confirmed by Lichtenstein et al (1993)，who found no changes in 
subjects with moderate hypercholesterolaemia treated with three different diets, 
one of which was enriched with trans-fatty acids. Brown et al (1991) found 
that neither a high cholesterol diet nor a diet rich in saturated or 
polyunsaturated fatty acids had a significant effect on Lp(a) concentrations. 
Support for the regular intake of a moderate amount ofred wine was provided 
by Sharpe et al (1995) who showed a reduction in concentrations in a small ^^ 
i^l 
丨‘.':} 
group of20 volunteers during a study lasting 10 days. 1： 
. . 'v'^ i.； 
These data suggest that the initial approach to the management of patients with ； 
S 
abnormalities of the basic lipid profile is unlikely to be successful in the ！ 
'i: 
treatment ofelevated concentrations ofLp(a). This limits the treatment options f. 3 
.,'i,' 
I； 





(ii) Lipid lowering drugs jk 
'M ： i: 
Whilst this thesis is not primarily concerned with the influence of drugs other � ’ 
than oestrogen and progestogen on concentrations of Lp(a), in order to 
emphasize the potential importance of the effects of these hormones on Lp(a) 
concentrations, a brief summary of studies which have examined the outcome 
of treatment with other drugs will be provided. These show that most of the 
commonly prescribed lipid lowering drugs are ineffective in reducing 
concentrations ofLp(a). 
(a) Bile acid binding sequestrants 
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One study of the effect of bile acid sequestrants was conducted among 19 
hypercholesterolaemic subjects who were treated at random with either 8 or 16 
g of cholestyramine for 6 weeks (Vessby et al, 1982). This was followed by a 
changeover period lasting a ftirther 6 weeks, and then a final period of 6 weeks 
with a dose of 4 g daily. Although there was a favourable effect on both HDL-
C and LDL-C, Lp(a) concentrations remained unchanged. Subsequent studies 
have verified these findings (Berglund, 1995). j : 
:,i(l ： 
(b) HMG'CoA reductase inhibitors 、丨 
• ,.:4 . 
Varying doses of both lovostatin and simvastatin have been used in the ； 
treatment of hypercholesterolaemic subjects, but no significant changes in >, 
Lp(a) concentrations have been documented (Thiery et al, 1988). Haffher et al 
'%' 
•\ 
(1995) compared the effects of placebo with that of 3 different treatment ！ 
regimens using simvastatin in 343 subjects over a 24 week treatment period, ， 
|.:丨 
and similarly there was no apparent reduction. The effects of another HMG- , 
丨1^  I ！ 
CoA reductase inhibitor, fluvastatin, have also been found to be inconsistent. � 
In the European Fluvastatin Study, Lp(a) concentrations were examined in a 
double-blind placebo controlled trial of 429 patients who remained 
hypercholesterolaemic after 14 weeks of dietary treatment (Dallongeville et al， 
1994). A dose of 5 or 20 mg daily was associated with a significant reduction 
in concentrations of Lp(a), but there were no changes with doses of 2.5 or 10 
mg. Jacobson et al (1994) studied 74 patients with elevated LDL-C 
concentrations following an American Heart Association phase I diet and 
randomized them to treatment with either fluvastatin 20 mgMay or placebo for 
123 
6 weeks. Immediate release niacin was then added to both regimens for a 
further 9 weeks. Lp(a) decreased by 37% in those receiving fluvastatin/niacin, 
but concentrations were unaltered with fluvastatin alone. 
(c) Fibric acid derivatives 
The influence offibric acid derivatives on Lp(a) concentrations has been found 
to be inconsistent (Berglund, 1995). Whilst treatment with bezafibrate reduced 
concentrations of Lp(a) by up to 13%, gemfibrozil had little, if any, effect ^ 
. 丨：丨！  
(Maggi et al，1993). 1 
I 
(d) Nicotinic acid derivatives :: 
SI 
The rate of synthesis of Lp(a) appears to be of prime importance in controlling | 
. :¾ 




level，which explains why this drug may be more effective than others in i,| 
reducing concentrations of Lp(a). Whilst initial studies showed no effect of 
|Ji 
nicotinic acid on Lp(a) (Kostner et al, 1984), there have since been a number of ((;! 
larger studies which have shown that this drug is useful either when used alone 、人 
or in combination. Seed at al (1993) reported a 36% decrease in Lp(a) 
concentrations in hypercholesterolaemic individuals with baseline 
concentrations exceeding 30 mg/dl who were given nicotinic acid each day for 
2 months, and Gurakar et al (1985) found reductions in Lp(a) concentrations of 
24% and 45% respectively in type II hyperlipidaemic patients treated with 
either niacin/neomycin or neomycin. 
In a study of 31 hyperlipidaemic patients treated for 6 weeks with 4g of 
nicotinic acid daily, Lp(a) concentrations were reduced by almost 40% (95% 124 
CI 28-47%) (Carlson et al, 1989). These findings were supported by the results 
of another study in which the effects of treatment with either lovostatin or 
niacin were compared in 136 subjects treated for a 26 week period. There was 
a 35% reduction in Lp(a) concentrations with niacin, while no effect was 
observed with lovostatin (Illingworth et al, 1994). 
(e) Fish oils 
、 
As with most of the lipid lowering agents, a consistent effect of fish oils has !:� 
t'iiil 
not been demonstrated, although there are insufficient data to be certain that 、！ 
iS 
they are ofno value (Berglund, 1995). ; 
� Others \ 
Lu et al (1994) reported a significant reduction in Lp(a) concentrations over a 
‘1 
period of 3 months in 128 hyperlipidaemic patients treated with the Chinese ( 
herbal medicine Jian Yan Ling, but there are no other known studies which 
1 . 1 I: 
h;.t 
have examined the effect of Chinese herbal medicine on this lipoprotein. ii j 
wl 
. : i 
The data from these studies support a beneficial effect of nicotmic acid on “ 
raised Lp(a) concentrations, but the other groups of lipid lowering drugs are 
not as effective. 
(7) Exogenous Hormones and Lipoprotein (a) 
At the time the studies in this thesis were initiated, there had been few reports 
concerning the effects of the administration of oestrogen or other sex steroids 
on concentrations of Lp(a). The results of these studies were confusing, as 
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reductions in concentrations had been described using oestrogens, progestogens 
and also androgens under a variety of clinical circumstances. 
The studies involved in this thesis commenced in 1992. The first report ofthe 
influence of sex steroids on Lp(a) had been published in 1984, when Albers et 
al (1984) examined 10 normolipidaemic postmenopausal women aged 67-81 
years with osteoporosis who had been treated for 6 weeks with the anabolic 
\、: 
steroid stanozolol. Mean concentrations ofLp(a) decreased from 5.7 (士 5.5) 難 
。？ 
to 1.2 (士 0.7) mgAU during the treatment period (p<0.01), but there was no 
•：；!, 
、'i,\ • 
appreciable change in apo B concentrations, and it was concluded that Lp(a) _ 
: ' ' ' ! I 
must be under separate metabolic control from LDL-C. Another study t „： 
i . J :，:"'〉 
described the effect of treatment with 5 mg twice daily of the relatively ; 
••:1. I '\ 
androgenic progestogen norethisterone (Farish et al, 1991). This was given to 9 f 
'-j^u 
postmenopausal women unsuitable for treatment with oestrogen, and after 2 
l 4 i , 1 ； 
、 : 
months the median Lp(a) concentrations decreased from 30 (9-80) mgMl to 16 |![ 
：i � j 
(6-22) mg/dl, with the greatest reductions occurring in those with the highest 
pretreatment concentrations. Crook et al (1992) examined changes in Lp(a) 
concentrations in 26 premenopausal women with endometriosis treated for 6 
months with the anabolic steroid danazol. Median Lp(a) concentrations at 
baseline were 8.1 (1-58) mg/dl in the treatment group and 4.5 (1-15) mg/dl in 
controls. After 6 months, the concentrations were 2.0 (0-29) and 3.6 (1-17) 
mg/dl in the treatment and control groups respectively (p<0.001), and in this 
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study there was also evidence to suggest that Lp(a) metabolism differed from 
that ofLDL-C. 
The first study describing a reduction in Lp(a) concentrations in association 
with the administration ofHRT was not reported until 1991 (Soma et al, 1991). 
A more complete description ofthis work was published in 1993, and although 
it may have been expected that initial studies would have examined the effect 
of oestrogen alone, this trial investigated the effect of a combined cyclical : � 
i ' l i ! l 
regimen of treatment, t i the initial study, a 50% reduction in Lp(a) v 
;：'!：• 
concentrations was found in 10 postmenopausal women treated for 12 months ’ 
I 
with 1.25 mg of conjugated equine oestrogens daily and MPA 10 mg for 10 !j 
::.;.'.. 
days each month (Soma et al, 1991). Concentrations at baseline were 21.7 (士 
9.1) mgAU in the treated group and 16.9 (士 6.6) mg/dl in the 20 controls Q^S). , j 
4 
After 6 months, concentrations were 11.1 (± 5.2) mgMl m the treated group and i';i >i. 1. ! I 
16.3 (士 6.9) mg/dl in the controls (p<0.05), and after 12 months, 10.6 (± 6.5) |rj 
*«vi,i3 
mgMl in those who had received treatment and 16.7 (± 6.3) mgAil in controls 
(p<0.05). This study was later expanded to include 31 subjects receiving 
treatment and 24 controls (Soma et al，1993). Mean baseline values were 22.4 
mg/dl in the treated group and 18.4 mg/dl in controls. At 6 months, the mean 
values were 11.0 mg/dl in the treated group and 17.5 mg/dl in controls 
(p<0.001), and at 12 months, 11.0 mg/dl in the treated cases and 18.7 mg/dl in 
controls (p<0.01). Treatment was discontinued after 12 months, but Lp(a) 
concentrations were measured in 16 patients (7 from the controls and 9 treated 
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patients) 12 months later. Concentrations were 20.6 mg/dl in those who had 
been controls and 19.0 mg/dl in those who had been treated. These values did 
not differ significantly from those before the commencement of treatment. It 
was unclear whether oestrogen or the progestogen had the dominant effect on 
Lp(a) concentrations, and the timing of sampling with respect to the cyclicity 
of progestogen administration was not stated. This factor has not been 
• • x ^ 
considered in most studies on combined cyclical HRT, but will be examined in 丨、 
i'|l!l 
one ofthe studies to be described in a later chapter. This is the only follow-up 曾 
¢. 
study of its type and showed that the effects of HRT on Lp(a) do not persist for 丨： 
^ 
long after the treatment is discontinued. | 
1 . 1 . : 
. i?y, 
Muesing et al (1991) then compared the effect ofunopposed conjugated equine 
:./ 
计 
oestrogen 1.25 mg daily with that of conjugated equine oestrogens 1.25 mg ,] 
daily combined with MPA. This study was conducted among 16 
‘r ：’ i . f^!: 
postmenopausal women who were treated for 4 months， and Lp(a) ^ \ 
concentrations decreased from 7.22 mg/dl at baseline to 6.06 mg/dl in those � 
taking oestrogen alone and to 5.36 mgMl in the group taking combined 
treatment. The reductions in Lp(a) concentrations in this small study were not 
statistically significant. 
Lobo et al (1992) investigated 69 women aged 40 - 55 years who had 
undergone either a hysterectomy or else a hysterectomy and bilateral salpingo-
oophorectomy and who were randomized to be given either an exercise 
programme, conjugated equine oestrogens 0.625 mg daily, conjugated equine 
oestrogens plus exercise or else treatment with transdermal oestrogen. Each of 128 
• 'N 
these regimens lasted 6 months, and this study was unique as it was the only 
one in which the effect of transdermal oestrogen was investigated. The mean 
Lp(a) level in the total study group was 15.2 (± 0.8) mg/dl before the 
commencement oftreatment. Although decreases in Lp(a) concentrations were 
found with both groups receiving conjugated equine oestrogen, the difference 
was not significant. There were also small but non-significant reductions in the 
\ 
other two treatment groups. | 
,v)l 
To summarize the results of these early studies, available evidence suggested I 
抄 
that oestrogen and progestogen combinations produced a reduction in Lp(a) 感 
concentrations in postmenopausal women, but no evidence was available to 1 
‘.,.，( 
• V. i 
show that oestrogen administered orally or by another route had a significant 
I :i:. 
effect. In most ofthese studies the sample groups were small and the reduction j | 
4 
was not statistically significant. 
;》 
During the period in which the studies in this thesis were being performed, a I� 
^�J 
number of other relevant publications appeared in the literature. These 
described the use ofunopposed as well as combined HRT regimens, but there 
were no publications on the effect of percutaneous treatment on Lp(a). The 
only placebo controlled crossover study of unopposed oestrogen was that of 
Sacks et al (1994) which investigated the response to either 0.625 or 1.25 mg 
conjugated equine oestrogens in 31 healthy postmenopausal women treated for 
3 months. The mean Lp(a) concentration was 20.4 (土 14.6) mgAH at baseline, 
and this decreased by 2.9 (± 1.0) mg/dl with 0.625 mg (p<0.01) and by 3.2 (士 
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1.0) mg/dl with 1.25 mg of conjugated equine oestrogen Q)<0.01). This 
represented a reduction in Lp(a) concentrations of 14% and 16% respectively. 
The first of the more recent studies on combined cyclical HRT examined the 
effect of this treatment on 27 healthy postmenopausal women treated with 2 
mg 17p-oestradiol daily and dydrogesterone 10 mg for 14 days each month 
(Van der Mooren et al, 1992). This study was of 12 months duration and Lp(a) 
、 
concentrations decreased from a pre-treatment mean of 30.3 (士 46.7) mgMl to !�j 
:)f 
25.0 (± 37.5) at 6 months and to 23.9 (士 38.2) mg/dl after 12 months ) H '' 
'；\ i 
(p<0.001). This represented a 17.5% reduction in the first 6 months and 21.1% | 
after 12 months. This study was continued for another 12 months, and although ! 
• i^I.: 
,:i': 
concentrations of Lp(a) were maintained, there was no further decrease (Van 
' \ 
j i 
der Mooren et al, 1993). Mendoza et al (1994) also studied the effect of 
t" 
combined cyclical HRT in 21 postmenopausal women treated with 0.625 mg ^| ； 
"> ‘ 
conjugated equine oestrogens daily and 5 mg MPA for 10 days each month and • j 
'">M>J . 
recorded a reduction in Lp(a) concentrations from 20 to 15 mg/dl after 3 cycles 
(p<0.001). Julius et al (1994) examined the effect of daily conjugated equine 
oestrogens and medrogestone given for 11 days each month for 3 cycles and 
found that Lp(a) concentrations decreased in all patients with baseline values 
above 10 mg/dl, and Gevers Leuven et al (1995) performed a very similar study 
in 114 women treated for 13 cycles using the same regimen but failed to show 
a significant response. Baseline concentrations of Lp(a) were 15 (4.4-38) 
mg/dl in those receiving oestrogen alone and 10 (3.7 - 25) mgAil in those on 
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1 ¾ 
combined treatment (p=0.38). There was a decrease in Lp(a) concentrations in 
each treatment group with the reduction being greater with combined 
treatment, but neither change was significant. The relative reductions were 
1.9% and 9.2% for unopposed and combined treatment respectively. 
Kim et al (1994) compared the effects of unopposed oestrogen and combined 
cyclical treatment in 184 postmenopausal women aged 33-68 years. Subjects 
. j . X. 
acted as controls (n=29, Group A) or were given 0.625 conjugated equme ^ 
\?. 
oestrogens plus 10 mg MPA (n=67, Group B)，0.625 conjugated equine | 
:,¾ 
oestrogens plus 5 mg MPA (n=65, Group C) or 0.625 conjugated equine ； 
";'i 
oestrogens alone (n=23, Group D). The progestogens were given for 10 days | 
V. 1 
each month, but the total treatment period was only 2 months. There was no ； 
‘'i I • 
significant change in the mean Lp(a) concentration in controls, but there were 丨  
decreases from 36.7 (土 30.9) to 28.5 (士 24.4) mg/dl in Group B (p<0.001), 丨 
:),: 、：丨 
from 36.5 (士 35.2) to 28.1 (士 30.7) in Group C (p<0.001) and from 31.2 (± | l 
�4: 
33.8) to 24.6 (士 30.4) mg/dl in Group D (p<0.001). The reductions in the three 
treatment groups were 14.7%, 22.2% and 25.7% respectively, and there was a 
positive association between baseline concentrations of Lp(a) and the 
magnitude ofthe reduction in response to treatment. 
There has only been one study on the effect of continuous combined rather 
than cyclical treatment in which Marsh et al (1994) treated 57 postmenopausal 
women less than 60 years of age with 1 mg oestradiol and 0.15 mg desogestrel 
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for 12 months. Over this period there was a reduction of 17.6% in the median 
value ofLp(a) (p<0.05). 
Another important study was that of Nabulsi et al (1993) which was a cross-
sectional examination of the relationship between the use of HRT and various 
cardiovascular risk factors including Lp(a). Concentrations were measured in 
15,800 subjects and were 13% lower in those who had been receiving either 
、 
unopposed [9.9 (士 10.5) mg/dl] or combined treatment [7.9 (土 8.3) mg/dl] than (勒 
\ ) ' , 
in controls who had never used HRT [11.8 (± 12.0) mg/dl]. All ofthe earlier i 
,'i - , 
, . i | , • : 
• • • !;、•:]. 
large cross-sectional studies had only investigated changes in the basic lipid | 
“‘》,.： 
profile, and the results ofthis study provided further support for the favourable I 
(:i,,i 
effect ofHRT on Lp(a). / 
I ! 
\ 
Merestingly, studies on oestrogens and Lp(a) have not been confined to f 
V " 
women. Evidence for the favourable effect of oral oestrogen was also provided d i 
• " i , ‘ 
in a study of 31 elderly males with prostatic carcinoma treated with either oral ！丨 
,�J: 
oestrogen or orchidectomy (Henriksson et al, 1992). Lp(a) concentrations 
decreased from 13.4 (<1.2 - 43.4) mgAil to 6.6 (<1.2 - 19.3) mg/dl in the 
oestrogen treated group (p<0.001) but increased from 14.1 (< 1.2 - 57.7) mg/dl 
to 16.8 (<1.2 - 58.8) mg/dl in those having an orchidectomy (p<0.01). This 
represented a 51% reduction in the oestrogen treated patients and a 20% 
increase in those treated surgically. 
These studies differed greatly in the choice of subjects, duration and type of 





these differences, in most studies Lp(a) concentrations decreased in users of 
HRT, but there were large differences in the magnitude ofthese reductions. 
、 .| 
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1. RECRUITMENT OF CASES 
Four studies concerning the effect of HRT on Lp(a) and other atherogenic 
lipids and lipoproteins will be described. bi this section the general 
methodology applicable to all ofthese studies will be discussed. 
(1) Method ofRecruitment � 
1¾ 
All of the cases selected for inclusion in these studies were recruited from the 丨 1 
•i'： 
Menopause Clinic of the Department of Obstetrics and Gynaecology, The 丨 
>j 
Chinese University of Hong Kong at the Prince of Wales Hospital. This is a 
i'i  
public outpatient clinic which was established in 1990 and currently serves 
* ； 
approximately 800 postmenopausal women. Most cases are referred internally | 
I •‘ 
‘‘, ；j 
for consideration of hormone replacement therapy after a surgical menopause, \ 
• I 
. ( 
with a smaller proportion having had a spontaneous menopause. Of those ( 
| l | 
women with a spontaneous menopause, a disproportionately large number have j 
become menopausal before the usual age of the menopause. Under these 
circumstances a referral to the clinic is more likely than if the menopause takes 
place at the expected time. The low number of referrals from outside the 
hospital is thought to be due to the paucity ofmenopausal symptoms and a lack 
of awareness of the long term complications of the menopause in Hong Kong 
Chinese women. 
M all of the cases recruited, a complete medical history, a screening physical 
examination and a gynaecological examination were performed at the first visit 
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to the clinic. Blood pressure, weight and height were recorded and urine was 
tested for albumin and glucose. As is usual practice, an explanation of the 
risks and benefits of hormone replacement therapy and a description of the 
standard methods of treatment were provided. This was conducted in the 
Cantonese language, which is that most commonly used in Hong Kong. 
Under the normal clinic protocol, women who have had a hysterectomy are 
• , 、 、 
offered treatment with either oral or percutaneous oestrogen. Usually this ! 
• 'l 
decision is made according to personal preference, but if there is a history of 
'ji, 
hypertension, glucose intolerance, oestrogen related thrombosis or any other 
r'.i 
appropriate indication, then the percutaneous method is advised to avoid the 
hepatic "first pass" effect. ； 
\ 
Women who have had a natural menopause are treated with either a combined 丨 j 
• [ 
cyclical or a continuous combined regimen. The combined cyclical regimen | :;I ‘ •, \ 
involves the daily use of oral oestrogen and the administration of an oral ^ j 
progestogen for 12 days each month. This is the most commonly prescribed 
regimen, but continuous combined treatment is offered to those women with an 
established menopause for 3 or more years who are less likely to experience 
irregular bleeding with this method of treatment. In the continuous combined 
regimen, oestrogen as well as a progestogen are prescribed every day, and this 
is expected to result in amenorrhoea and improve patient compliance. As most 
of the women recruited into these studies had recently reached their 
menopause, it was decided to examine the effect of combined cyclical rather 
than continuous combined treatment. The nature of the studies was described 
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to all of those suitable for inclusion, and consent to participate was obtained 
before the commencement oftreatment and before randomization. 
Recruitment commenced in July 1992 and was completed by June 1993. The 
results ofthe assays oflipids and lipoproteins were available by March 1995. 
(2) Inclusion and Exclusion Criteria 
•“•, 
These studies required the recruitment of cases of both surgical menopause and ；丨  
,,/' 
spontaneous menopause. In the studies which examined the effects of 
^., 
I' •: 
unopposed oestrogens on the lipid profile, all participants had undergone a 
total abdominal hysterectomy and bilateral salpingo-oophorectomy for benign 
gynaecological conditions. 
For the study on the effects of combined cyclical HRT, all of the subjects had 
undergone a spontaneous menopause. The diagnosis was made clinically and 
confirmed by the measurements of gonadotropin and oestradiol concentrations. 
Due to referral bias, there was a greater number of women in this study who 
had undergone an early or premature menopause than would have been 
expected in an unselected population. In such cases，underlying conditions 
which may have predisposed to a premature menopause were excluded before 
enrollment. In particular, this included selective screening for Addison's and 
thyroid disease, rheumatoid arthritis and hypoparathyroidism. No attempt was 
made to distinguish between cases of true menopause and the resistant ovary 
syndrome, as the hormonal consequences are the same. 
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Li all of the studies the majority of women were recruited at their first 
attendance to the clinic. A small number ofpatients had been using some form 
ofHRT prior to their recruitment, and agreement was given to have a minimum 
3 month "washout" period free of all treatment before resuming treatment 
according to the study protocols. 
General inclusion criteria were a confirmed diagnosis ofmenopause, a desire to 
•^k'； 
receive HRT and an agreement to consent to the study protocols. Exclusion |； 
criteria were a history of breast or endometrial carcinoma and hepatic or renal 
disease demonstrated by abnormal biochemistry. Those using any drugs 
known to affect the lipid profile were also excluded, as were women with a 
recognized lipid disorder. 
(3) Sample Sizes 
The null hypothesis in these studies is that the treatment has no effect on Lp(a) 
concentrations. In arriving at a decision about the null hypothesis, two types of 
errors need to be considered. A Type I error is when a significant result is 
obtained which rejects the null hypothesis when the null hypothesis is true, a 
so-called false positive result. The probability of committing a Type I error is 
denoted a. A Type II error involves failing to reject the null hypothesis when 
it is true (a false negative). The probability of committing a Type II error is 
denoted P. The power of a test is the probability that a study of a given size 
will detect as statistically significant a real difference of a given magnitude 
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(Altman, 1991). This is the probability of rejecting the null hypothesis when it 
is in fact false i.e. Power = l-p. The sample size can be calculated from the 
power and the Type I error. A larger sample size increases the power of the 
study for any given Type I error. The power requirement is commonly chosen 
as 80-90%, and in these studies a power of 80% and a of 0.05 were chosen. 
The sample size required may be calculated from formulae (Sokel and Rolf, 
‘•K. 
1981) or from precalculated tables (Machin and Campbell，1987). The only \ 
complete data available from previous studies on which to base the expected 
response to treatment was that of Soma et al (1991). In this study there was a 
reduction in Lp(a) concentrations from 21.7 (± 9.1) mg/dl to 10.6 (士 6.5) mg/dl 
with 12 months of treatment. This represented a reduction of 51%, which was 
higher than the 16% reported by Muesing et al (1991)，but in the latter study no 
original data were supplied. Using these figures, the statistical hypothesis to be 
tested in these studies was that a reduction in LpW of 6.0 mg/dl (equivalent to 
a percentage response between 25 and 30%) occurs with treatment. This value 
was chosen as a conservative estimate ofthe expected reductionin the level of 
Lp(a), with a standard deviation of 8.0. 
The sample size for the crossover study was calculated using the SAS 
programme for calculating sample size for an AB/BA crossover (Meinert and 
Tonascia, 1986). Using this method, it was calculated that the minimum 
number of subjects in each group should be 30. The calculation of sample size 
for an open longitudinal study differs from that of a crossover study. In the 
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longitudinal studies, it was calculated that the minimum number of subjects 












The oestrogen and progestogen preparations used in these studies were selected 
from those routinely prescribed in the Menopause Clinic. The oral oestrogen as 
well as the progestogen are available in most countries, and the percutaneous 
gel is becoming more widely accepted. In France it is the most common 
method of administering oestrogen to postmenopausal women. The type of .„ 
;^ 
oestrogen used in all of the studies was 17p-oestradiol, which is a natural 
oestrogen with few metabolic side effects. The other advantage ofusing 17p-
oestradiol is its availability in both oral and percutaneous forms. Placebo 
packs of the oral preparation were also made available for use in these studies. 
The progestogen chosen was medroxyprogesterone acetate, which is the most 
widely used progestogen for hormone replacement therapy, and being a 
member of the C-21 group it has relatively low androgenicity. The 
pharmacokinetics of these preparations are described below. 
(1) Pharmacokinetics ofOral 17p-Oestradiol 
The oral oestrogen was provided in a 2 mg tablet form of micronized 17p_ 
oestradiol (Estrofem, Novo Nordisk, Bagsvaerd，Denmark)，which is 
chemically and biologically identical with endogenous human 17p-oestradiol. 
A 2mg dose was used as it is the lowest which has been shown to alleviate 
menopausal symptoms and to prevent osteoporosis (Birkhauser and Hanggi, 
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1994). The minimum dose required to reduce the incidence of CAD has not 
been determined. The structure of oestradiol is shown in Figure 3. 
Figure 3. The chemical structure of oestradiol. 
OH 
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Oestradiol 
Orally administered micronized 17p-oestradiol is well absorbed from the 
gastrointestinal tract and reaches peak plasma concentrations within 4-6 hours. 
The steady state plasma level ranges from 70-100 pg/ml. The half life is 
approximately 14-16 hours, and more than 90% is bound to plasma proteins. 
In the liver, 17p-oestradiol is oxidized to oestrone, which in tum is converted 
to oestriol. The oestrogens are excreted in bile and undergo reabsorption from 
the intestine. The 17p-oestradiol and its metabolites are eventually excreted in 
the urine (90-95%) as biologically inactive glucuronide and sulphate 
conjugates or in faeces (5-10%) in the mainly unconjugated form. 
The placebo was identically packaged to the active treatment and contained the 
same base compounds. The contents of each placebo tablet are listed below. 
Active ingredients: Nil 
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other ingredients: Lactose monohydrate 38.9 mg 
Maize starch 38.9 mg 
Gelatin l.OOmg 
Talc 0.80 mg 
Magnesium stearate 0.40 mg 
Fihn coating: l.Omg 
Methylhydroxypropylcellulose 0.821 mg 
Triacetin 0.043 mg 
(2) Pharmacokinetics of Oral Medroxyprogesterone Acetate 
V;i 
The oral progestogen was provided in a 5 mg tablet of MPA (Provera, Upjohn ‘ 
Company, MI, USA), which is a 6a-methyl analogue 17a-
hydroxyprogesterone. This dose was used as it is the lowest which has been 
shown to prevent oestrogen induced endometrial hyperplasia (Gelfand and 
Ferenczy, 1989). The structure ofMPA is shown below. 
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Progesterone is inactivated largely in the liver, and the characteristic product of 
the breakdown is pregnane-3a, 20a-diol (Bunke, 1972). This is excreted in 
urine conjugated with glucuronic acid. The turnover rate of endogenous 
progesterone is high and its half-life is only a few minutes. Orally 
administered MPA accumulates in the liver and is excreted through the biliary 
system. The extent of conjugation to glucuronic acid appears to be less than 
*-. 
that of progesterone，and marked uptake in the kidneys had also been found. |;i 
• i 
There is extensive "first pass" hepatic metabolism, and 21% of a dose of MPA 
. i 
has been found as a urinary metabolite only 20 minutes after oral 
administration (Adlercreutz et al, 1983). Li another study, peak serum 
concentrations of MPA of 1.7 ngAnl were found 2.7 hours after a single 5 mg 
dose，and the main metabolite was a 6p-17a-dihydroxy-21-acetoxy derivative 
(Upjohn Company, in-house data). 
(3) Pharmacokinetics ofPercutaneous 17p-Oestradiol 
When oestrogen is given orally, 20-25% is metabolized in the gastrointestinal 
wall and another 70-75% within the liver (Longcope et al, 1985). This hepatic 
metabolism alters the oestrone/oestradiol ratio and increases the activity of 
several liver enzymes which can theoretically produce unwanted side effects. 
The percutaneous oestrogen is an hydroalcoholic gel containing 60 mg of 17p-
oestradiol in 100 g of excipient (Oestrogel, BI Excelsior, Paris, France). The 
dose is 2.5 g ofgel (1.5 mg 17p-oestradiol) applied once daily and spread out 
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over a large area of skin excluding the vulva and breasts. The gel dries within 
two minutes and has no smell. 
After application, the 17p-oestradiol binds to the stratum comeum within a few 
minutes and diffuses into the epidermis, dermis and vascular system within 2 
hours. Approximately 10% of the percutaneous dose reaches the vascular 
system. At steady state, mean concentrations of 60-80 pg/ml of 17p-oestradiol 
*^ •, 
are achieved, producing comparable circulating concentrations with that of oral l!il 
/ 
administration. The metabolic clearance rate is the same as for endogenous or 
orally administered 17p-oestradiol. 
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3. DATA COLLECTION AND ANALYSIS OF SAMPLES 
(1) Collection and Storage of Samples 
All participants in the study were given written and verbal instructions to report 
for blood sampling at 8 a.m. on a specified day, having fasted from all food and 
liquids except water from 10 p.m. the night before. For all assays, blood was 
drawn from an antecubital vein with minimal stasis, with the tourniquet applied 
»<•, 
for the shortest possible time. ;；；| 
‘ / 
i. 
(2) Methodology and precision of measurements 
All assays were performed in the Department of Chemical Pathology at the 
Prince ofWales Hospital and the methods of analysis are described below. The 
methods of measurement of gonadotropins, 17p-oestradiol and the basic lipids 
and lipoproteins are well established and will be described in less detail than 
that ofLp(a). 
(i) Lipoprotein (a) 
When assays for Lp(a) were first developed, measurements were made using 
radial inmiunodiffusion, electroimmunoassay and then radioimmunoassay. 
Other approaches have involved the use oflatex immunoassays, enzyme-linked 
immuoabsorbant assays (ELISA) and immunonephelometric and 
immunoturbinometric assays (Albers and Marcovina, 1994). The variation in 
size ofLp(a) particles discussed earlier can lead to inaccuracy ofmeasurement 
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f: 
of Lp(a) concentrations. This is theoretically the case for the newer 
nephelometric and turbinometric methods, although a high correlation has been 
found between these and the ELISA methods (Levine et al, 1992). The size 
heterogeneity of Lp(a) results from the number of kringle 4 type 2 repeats 
present in the apo (a) isoforms, and this may vary from as few as three to over 
forty (Lackner et al, 1993). The immunoreactivity of antibodies against these 
“，, 
antigenic determinants can therefore be expected to vary according to the size ,^  
i 
ofthe apo (a). 
The assay used in these studies (Mercodia AB, Uppsala, Sweden) was a solid 
phase two-site immunoradiometric assay in which two monoclonal antibodies 
are directed against separate antigenic determinants on the apo (a) molecule. 
The first is specific for the kringle 4 type 2 repeats and the second specific for 
kringle 4 domains other than type 2. During incubation, apo (a) in the sample 
reacts with ^^^I-anti-apo (a) antibodies and anti-apo (a) antibodies bound to 
Sepharose particles. The antigen-antibody complex is separated by the 
addition of decanting suspension followed by centrifugation and decanting. 
The radioactivity of the pellet is directly proportional to the concentration of 
Lp(a) in the sample. This method would be expected to give a reliable 
measurement of Lp(a) regardless of apo(a) size. Marz et al (1993) found a 
good correlation between measurements using this assay and another using an 
enzyme immunoassay. In the samples studied, there were no cases having a 
substantially lower signal using the 2 monoclonal antibody method than with 
the enzyme immunoassay method using 2 polyclonal antibodies. As the tracer 
147 
in the immunoradiometric assay appears to recognize an epitope present on 
kringle 5 rather than on the repetitive kringle 4, the assay should be insensitive 
to variations in the number of kringle 4 repeats and therefore size 
polymorphism. 
The concentration of apo (a) in the two-site imunoradiometric assay is 
expressed as U/1, where one unit of apo (a) is equivalent to 0.7 mg Lp(a). This 
* 、 
conversion factor has been used in all of the measurements recorded in the ；) 
,,,,/ 
results sections so that comparisons can be made with measurements obtained 
in previous studies where Lp(a) concentrations have been expressed as mg/dl. 巧 
The storage of samples provided a potential source for error in the 
measurement ofLp(a) concentrations. Samples were stored at minus 20 degrees 
celsius for up to 18 months. The final samples had been stored for longer than 
those taken for baseline testing，but in general, those taken at a specific time 
(e.g. 6 months after the commencement of one of the treatment regimens) were 
assayed after being stored for similar periods. Panteghini and Pagani (1993) 
found no differences between plasma and serum measurements of Lp(a) 
concentrations, and the storage of specimens at minus 20 degrees celsius for up 
to 3 months did not affect their results. A study by Jauhiainen et al (1991) 
found no change in Lp(a) concentrations in sera stored for up to 8.5 years at 
minus 20 degrees celsius, and this was confirmed by Albers and Marcovina 
(1994). Biological variation was not measured in this study, as no significant 
change in concentrations over time had been reported with this assay. 
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As described above, Lp(a) was assayed using a two-site immunoradiometric 
method. The manufacturers specifications for the assay were followed which 
gives no measurable crossreactivity with plasminogen up to a concentration of 
5 g/l, and no cross-reactivity with apo B. The assay showed a between-run 
coefficient of variation (CV) of 7.2% at a low level of apo (a) (mean 12.3 
mg/dl) and 4.67% for high concentrations (mean 45.7 mg/dl). This compares 
^-'^ 
closely with that of other studies (Van der Mooren et al, 1992). Intra-assay CV 丨丨 
„；' 
‘.丨， 
was 2.6%. The detection limit was 0.14 mg/dl Lp(a) calculated as two 
j. 
standard deviations above the zero standard. 丨 
The methods used to measure gonadotropins, oestradiol and the other lipids 
and lipoproteins are summarized below. 
(ii) Follicle stimulating hormone (FSH), Luteinizing hormone (LH) and 
oestradiol (E2). 
Serum FSH, LH and E2 were assayed using microparticle enzyme 
immunoassay (MEIA) with the Abbott IMx analyzer and reagents (Abbott 
Laboratories, Abbott Park, IL, USA). In this method a sample is incubated 
with appropriate antibodies (anti-P-LH or anti-P-FSH or anti-E2) coated on 
submicron particles. The antigen-antibody complexed particles are captured on 
glass fibre, to which a labelled (alkaline phosphatase) second antibody (anti-a-
LH or anti-a-FSH or anti-E2) is added. Following addition of the substrate 
4-methylumbelliferyl phosphate a fluorescent product is measured by the 
instrument. 
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Merassay coefficients of variation (CV) of the LH assay were 5.4%, 3.8%, 
2.5% and 3.8% at concentrations of5.2, 44, 73 and 86 U/1 respectively. Those 
of FSH were 3.1% and 3.6% at 5.4 and 25 U/1 respectively. For E2, the CVs 
were 8.6%, 4.4% and 6.4% at 568, 1741 and 4090 pmoVl Over the study 
period the accuracy of the assays was found to be satisfactory with < 8% bias 
from consensus values in a United Kingdom External Quality Assessment 
• ^ � 
Scheme (EQAS). 5'! 
.•‘ 
(iii) Lipids, lipoproteins and apoproteins 
Serum total cholesterol (TC) and triglycerides (TG) were assayed 
r,' 
enzymatically on the Dimension AR analyzer (Du Pont Company, Wilmington, 
DE, USA) using reagents from Du Pont. Cholesterol esterase, cholesterol 
oxidase and horseradish peroxidase were used for TC, and lipoprotein lipase 
and glycerol dehydrogenase for TG measurements. 
High density lipoprotein cholesterol (HDL-C) was measured after precipitation 
of apoprotein B containing fractions with phosphotungstate. Low density 
lipoprotein cholesterol (LDL-C) was calculated from the formula ofFriedewald 
et al (1972): LDL-C = TC - HDL-C - (TG/2.2). 
The HDL-C subfractions (HDL2-C and HDL3-C) were assayed by a double 
precipitation procedure using dextran sulphate 50 kDa and magnesium chloride 
(MgCl2) (Bachorik et al, 1986). The first precipitation removed VLDL-C and 
LDL-C (1% dextran sulphate and 0.5 mol/1 MgCl2). Further precipitation with 
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1% dextran sulphate and 1.5 mol/1 MgCl2 resulted in a supernatant containing 
HDL3-C. This was assayed enzymatically on a Cobas Bio centrifugal analyzer 
(Roche Diagnostics, MontClair, USA). 
Apoproteins A-I and B (apo A-I and B) were assayed by rate 
immunonephelometry (Array Analyzer and reagents, Beckman Instruments， 
Brea, CA, USA). 
'•'*•N 
Merassay CVs of the TC assay were 3.0% and 2.2% at 3.3 and 6.8 mmoLl g 
1' 
respectively, conforming to the recommendation of the US Adult Treatment 
Panel of the National Cholesterol Education Programme. Those of TG were 
6.90/0 and 4.6% at 1.0 and 2.2 rnrnom. CVs of HDL-C were 3.8% at 1.0 and 
4.0 mmoW, and 0fHDL3-C 3.7% and 5.4% with an "abnormal" and a "normal" 
sample (ACSABNASY lot No. 025103 and ACSNORASY Lot No. 020103 
from CIBA-Coming). Those of the apo A-I and apo B measurements were 
<6% at all concentrations. 
Over the study period, the laboratoty participated in the United Kingdom 
Randox Commercial EQA programme and the Royal College of Pathologists of 
Australia AQAP scheme. Accuracy (in terms ofbias) ofthe TC and TG assays 
were always within 土 5o/o. For apo A-I and apo B assays, Beckman's standard 
(Lot M307062) was calibrated against internationally accepted reference 
materials (SPl-01 for apo A-I, SP3-07 for apo B). 
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4. ETHICAL CONSIDERATIONS 
(1) General Ethical Considerations 
There are a wide variety of guidelines for the conduct of medical research 
which range from international agreements to those in operation within 
institutions and departments. The studies performed as part ofthis thesis were 
conducted in accordance with the code of ethics described in the Declaration of � 
！；! 
Helsinki originally drawn up in 1964 and last amended in 1989 (World 
Medical Association Declaration of Helsinki, 1992). It states in part that "It is 
. '：'! 
the mission of the medical doctor to safeguard the health of the people. His or 
her knowledge and conscience are dedicated to the fulfillment ofthis mission. 
The purpose of biomedical research involving human subjects must be to 
improve diagnostic, therapeutic and prophylactic procedures and the 
understanding of the aetiology and pathogenesis of disease." 
The studies conducted in this thesis were undertaken to demonstrate an effect 
ofhormone replacement therapy which had been not previously been proven. 
Although the prescription of HRT is now a commonly accepted therapeutic 
intervention in postmenopausal women, the ability to show an additional 
benefit would further explain the cardioprotective action of HRT and would 
add to the existing evidence for the prophylactic effect ofthis treatment. 
^ accordance with the basic principles of the Declaration of Helsinki，the 
research conformed to generally accepted scientific principles with a thorough 
knowledge of the scientific literature having been obtained before the 
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commencement of the studies. The design of the experimental procedure was 
approved by a specially appointed independent committee (the Ethics 
Committee ofthe Faculty of Medicine, the Chinese University of Hong Kong) 
and the studies were conducted by scientifically qualified persons. 
The importance of the objectives were considered to be in proportion to the 
inherent risks which will be described below. Every precaution was taken to 
“ • � , 
respect the privacy of the subjects and to minimize the impact of the study on (丨丨 
,•' 
the subjects' physical and mental integrity and on the personality of the 
subjects. The hazards of the investigations were thought to be minimal, and 
the accuracy of the reporting of the results was preserved. 
The subjects were adequately informed of the aims, methods, anticipated 
benefits and potential hazards of the study and the discomfort it would entail. 
They were told that they were free to abstain from participation in the study or 
to withdraw their consent or participation at any time. Freely given verbal 
consent was obtained in all cases. 
(2) Ethical Considerations Specific to These Studies 
The ethical issues in the study on the short term effects of oral oestrogen 
differed from those of the other studies in that a placebo was used. 
Considering the strength of evidence for the benefits of prescribing HRT，it 
was necessary to decide whether the prescription of a placebo was likely to 
have any detrimental effects on the subjects who were recruited into this study. 
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hi terms of symptoms, it was a theoretical advantage to perform such a study in 
a Chinese rather than in a Caucasian population, as Chinese women suffer less 
from acute menopausal symptoms (Haines et al, 1994). This suggested that the 
prescription of a placebo would in most cases not cause distressing symptoms 
and that the integrity ofthe double blind placebo controlled nature ofthe study 
could be effectively preserved. 
' 、 
The risk of prescribing a placebo for a period of 6 months was thought to be ;；] 
.•‘ 
small. It was not considered to be of sufficient duration to cause medium term 
symptoms, nor was it thought to be long enough to cause significant bone loss. 丨 
The cardiovascular risk of prescribing a placebo rather than oestrogen for 6 
months cannot be accurately assessed，but since the risk of CAD is reduced in 
both cuirent and previous users of HRT, all of the women involved in this 
study were offered a continuation of oestrogen treatment when the study 
finished. 
The decision to prescribe oestrogen alone rather than oestrogen and a 
progestogen to women without a uterus was in accordance with currently 
accepted practice and this did not have an ethical implication. 
In all studies, there was one area in which the subjects were potentially 
disadvantaged compared with women attending the clinic who were not 
participating in the research. It was necessary for those recruited into the 
studies to fast before blood sampling, and for the convenience ofthe handling 
ofthe samples, they were asked to attend on specific momings for the sampling 
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to be performed. Ifthis was difficult because ofwork or other commitments, an 
alternative day was offered to encourage continued participation in the studies. 
Nearly all of the women attending the clinic had been internally referred and 
had therefore already received some counselling regarding the risks and 
benefits of HRT. As most women were asymptomatic，the anticipated benefits 
of the treatment were the reduction in risk of osteoporosis and cardiovascular 
..、丨 
disease. Apart from the inconvenience of taking the treatment, the � 
；' 
'； 
disadvantages included the possible short term side effects of nausea and breast 
tenderness, and the long term risk of breast carcinoma. The use of HRT in the , 
short term has not been shown to be associated with any adverse effects in 
previously healthy women, and current understanding is that there is no 
measurable increase in the risk of breast cancer with less than 5 years of 
treatment (McPherson, 1995). Women attending the clinic therefore have an 
expectation of receiving treatment and were mostly keen to participate in the ): 
‘ ' t 
studies. 
There was less of an ethical problem in the studies which were open 
longitudinal in design. In each of these, the subjects received the same 
treatment as would have been prescribed if they were not participating in 
research. For the majority ofwomen who have had a hysterectomy, the choice 
of oral or percutaneous treatment can be made solely on personal preference, 
and in this population there were few women who specifically requested one 
treatment rather than the other. 
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hi accordance with the Declaration ofHelsinki, it was therefore considered that 
these studies combined medical research with professional care, at the same 
time acquiring new knowledge of potential therapeutic and prophylactic value 









STUDY I - THE SHORT TERM EFFECTS OF ORAL OESTROGEN 
INTRODUCTION � 
fl / 
The reduction in the incidence of CAD recorded in current and previous users 
ofhormone replacement therapy has been discussed in detail in the Chapter 2. 
The action of oestrogen in improving the basic lipid profile of postmenopausal 
women is one explanation for the cardioprotective effect of this treatment, but 
most studies have been conducted among Caucasian populations in which the 
incidence of CAD is higher than in the Chinese. There are fewer data 
concerning the effects of HRT on the basic lipid profile of postmenopausal 
• H 
Chinese women, and there have been no studies which have examined the 
influence ofHRT on concentrations ofLp(a) in this population. The ability to 
demonstrate a reduction in concentrations in response to HRT would suggest 
that this is another mechanism by which oestrogen lowers the risk of 
cardiovascular disease. Assuming that the distribution of concentrations of 
Lp(a) in Chinese women is similar to that ofCaucasians, then the results ofthis 
study could be expected to apply equally to Caucasian women. 
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The primary aim of this study was to examine the short term effect of oral 
oestrogen on concentrations of Lp(a) in postmenopausal Chinese women. The 
response of the other atherogenic lipids and lipoproteins was also assessed for 
comparison with other populations. The relationship between the metabolism 
of Lp(a) and that of LDL-C has already been discussed, and in this study the 
correlation between changes in Lp(a) and LDL-C concentrations was examined 
•、 
to further investigate whether their metabolic pathways are shared. ；) 
/ 
The population in Hong Kong has retained many cultural practices which 
originated in mainland China，but its lifestyle is becoming increasingly 
influenced by western societies in which the incidence of lipid abnormalities 
and cardiovascular disease is considerably higher. The combination of an 
ageing population and a greater prevalence of lipid abnormalities in the Hong 
Kong population suggests that the prevention of cardiovascular disease will be 
of increasing importance in future years. 
-n< 
METHODS 
Previous studies investigating the effects of oestrogen on the basic lipid profile 
have shown beneficial changes within months of the commencement of 
treatment (Farish et al, 1990). The examination of the short term effects of 
orally administered 17p-oestradiol on concentrations of Lp(a) and other 
atherogenic lipids and lipoproteins was conducted using a prospective, 
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randomized, double-blind placebo controlled crossover design with 6 month 
treatment periods. 
This study design was used as the problem of lipid abnormalities can be 
likened to a chronic disease process where a treatment intervention can be 
expected to produce a response within a reasonably short period oftime. It was 
unlikely that individual Lp(a) concentrations would change in response to 
•^. 
placebo, as concentrations are independent of age except for the menopause, :丨 
；•• 
and there was no evidence from other studies in which controls were used to 
suggest that the response of Lp(a) to the menopause occurs rapidly. 丨 
The calculation of sample size has been discussed in Chapter 4. It was 
considered that the placebo controlled crossover design would result in a high 
rate of dropouts, and for this reason more cases than the minimum requirement 
were recruited. 
Before commencing this study, a pharmaceutical company which was 
distributing an oral oestrogen preparation in Hong Kong agreed to provide the 
placebo preparation. The provision of active and placebo packs of oral 17p_ 
oestradiol identical to those already marketed (Estrofem, Novo Nordisk, 
Bagsvaerd, Denmark) was requested and was agreed to. Each pack holds 28 
tablets inside a plastic disk designed for ease of dispensing. The active tablet 
contains 2 mg of 17p-oestradiol and is prescribed on a daily basis. For the 
purposes of this study, 100 boxes of drugs were supplied, each of which 
contained one pack with a 6 month supply of active tablets and a second pack 
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with a 6 month supply of placebo. Neither the investigators nor the patients 
were aware of the order in which the oestrogen and placebo were prescribed. 
A 6 month supply was handed to the patients when they entered the study, and 
a second package was provided 6 months later so that there would be no 
possibility that the active and placebo packs would be taken out of order. 









I 1 » 
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Compliance in the study was assessed by questioning the subjects at the end of 
each 6 month period and by determining the number of unused tablets. A 
retrospective assessment of compliance was also made after the study had been 
completed by examining the measurements of oestradiol in each group and 
comparing these with the code for randomization. 
Concentrations of gonadotropins and oestradiol and measurements of lipid and 
*,, 
lipoprotein concentrations apart from Lp(a) were available soon after each 丨 
/ • 
episode ofblood sampling, and were recorded in a separate database so that the 
results were not brought to the attention of the investigators during the study. 
All results were made available to the patients at the completion ofthe study. 
Statistical analysis 
Before proceeding with the analysis of the effect of oestrogen treatment, the 
normality of the distribution of each of the baseline lipid and lipoprotein 
variables was examined using the one-sample Kolmogorov-Smimov test. As 
expected, a normal distribution was found for all variables except for Lp(a) and 
TG. As the logarithm of these measurements was found to have a normal 
distribution, Lp(a) and TG were analyzed after logarithmic transformation. 
Median values and ranges of Lp(a) have also been included in the tables to 
simplify the comparison between the results of this and other studies. The 
logarithmic transformation of the variables without a normal distribution 
enabled parametric methods ofstatistical analysis to be used. 
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The distribution of the physical characteristics and the comparison between 
baseline concentrations of lipids and lipoproteins in each of the study groups 
was analyzed using the two samples t-test. The comparison between the 
changes in the values of lipids and lipoproteins within each group after 6 
months oftreatment was made using the paired samples t-test. 
The outcome of the crossover study and the effect of time and period were 
»., 
analyzed using the method ofHills and Armitage (1979). In a crossover study, 1 
it is necessary to consider whether the variables may change as a result of the 
time taken to complete the study (time effect) or the order in which the 
treatment is given (period effect). The analysis is performed by calculating for 
each subject the difference and average of the observations in the two periods, 
and averaging these for each group. 
The degree of association between the different lipoproteins and the 
relationship between baseline concentrations of Lp(a) and the change in Lp(a) 
concentrations with treatment were examined by calculating the correlation 
coefficient using the standard Pearson product-moment correlation method. 
RESULTS 
Ofthe 100 women enrolled in the study, 91 completed their treatment, leaving 
46 in Group 1 (oestrogen;^placebo) and 45 in Group 2 (placebo/oestrogen). Of 
the 9 women who withdrew from the study, one suffered muscle twitching and 
shoulder pain after the first 4 months of treatment and the code for her 
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randomization was broken. She was found to have been taking placebo, and 
the symptoms resolved within a few weeks. Five of the subjects took their 
drugs on an irregular basis and at follow-up had not used all of the packets 
which had been allotted to them. One other subject overstayed a visit to 
mainland China and ran out of drugs, and the remaining two subjects failed to 
return in time for blood sampling. All were excluded from the study. 
'、 
Whilst there were some women who complained of symptoms suggestive of 丨 
oestrogen deficiency over the 12 month period, this was infrequent and the 
investigators remained unaware of the order of randomization until the study 
had been completed. 
(1) Characteristics of the study population. 
There were no significant differences in the mean age, weight, height nor body 
mass index between the two groups. There were also no differences in the 
mean age at the menopause nor in the time interval between the menopause and 
entry in the study. Forty of the study population had undergone surgery for 
uterine fibroids，22 for endometriosis and 7 for benign ovarian cysts. The 
remainder of the operations had been performed for a variety of other benign 
conditions. A summary ofthe characteristics ofthe study population is shown 
in Table 17. 
163 
Table 17. Characteristics of the study population on the short term effects 
of oral oestrogen. 
GROUP 1 GROUP 2 
n=46 n=45 p 
Mean 士 SD Mean 土 SD 
Age (years) 43.8±4.5 43.4士5.4 0.680 
Weight (kg) 56.1 土 8.5 57.3 士 9.3 0.547 
Height (cm) 154.5±4.9 155.6土5.8 0.792 -
I f 
Body Mass Index 23.4±3.2 23.7土3.3 0.669 
(kgW) 
Age at menopause 43.1士4.6 42.5 ± 4.9 0.561 
(years) 
Years since 0.6±1.2 0.8土 1.8 0.425 
menopause 
(2) The distribution ofconcentrations ofLp(a) 
t' 
The distribution of values of Lp(a) was positively skewed to the right with 
degrees of skewness and kurtosis of 1.85 and 2.88 in Group 1 and 1.69 and 
2.79 in Group 2. Detectable concentrations of Lp(a) were present in all 
subjects, with a minimum value of 0.8 mg/dl and a maximum of 108.5 mg/dl. 
Twenty four subjects (27.3%) (3 missing values) had concentrations above 30 
mg/dl, the cut offlevel above which the risk ofCAD is significantly increased. 
A summary of the distribution of Lp(a) concentrations in the total study 
population is presented in Figure 6. 
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Figure 2. Distribution of concentrations ofLp(a) before the 
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3) Comparison of baseline concentrations of variables between the two 
groups. 
For convenience of presentation, the comparison of baseline concentrations of 
Lp(a), gonadotropins and oestradiol will be presented separately from that of 
the basic lipid profile. Also for convenience, the changes in Lp(a), 
gonadotropins and oestradiol during the study period will be presented 
separately from the changes in the basic lipid profile. � 
!• 
冬 
(i) Comparison between baseline concentrations of Lp(a), gonadotropins 
and oestradiol 
Before the commencement of treatment, there were no significant differences 
in the mean concentrations of Lp(a), gonadotropins nor oestradiol between the 
two groups. A comparison between the baseline concentrations of Lp(a), 
gonadotropins and oestradiol is shown in Table 18. 
rt. 
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Table 18. Comparison between baseline values of Lp(a), 
gonadotropins and oestradiol in Groups 1 and 2 of the crossover study. 
Group Baseline p 
Mean (SD) (Group 1 vs 2) 
Lp(a),mg/dl 1 10.78 [2.2-108.5] 0.928 
Median [Range] 2 12.74 [0.8- 98.1] 
Lp(a) LN 1 2.55± 1.04 0.981 � 
2 2.56 土 1.08 I' 
FSH, IU/1 1 85.9±31.0 0.478 
2 80.8±36.5 
f 
LH, IU;1 1 28.7士 11.8 0.241 
2 25.9±10.8 
E2, pmol/1 1 92.5土9.4 0.195 
2 95.4土11.3 
!• 
Mean values of FSH and LH were in the menopausal range in each group 
(Range: FSH > 18 KJ/1 and LH > 12.6 RJ/l). The mean values of E2 were 
slightly above the minimum detectable level of 90 pmoVl but were appropriate 
for the menopausal state (< 361 pmoVl). 
(ii) Comparison between baseline concentrations of other lipids and 
lipoproteins 
A comparison between the baseline concentrations of the other lipids and 
lipoproteins in each ofthe groups is presented in Table 19. 
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Table 19. Comparison between baseline values of the components of 
the basic lipid profile in Groups 1 and 2 ofthe crossover study. 
Group Baseline p 
Mean (SD) (Group 1 vs 2) 
TC, mmol/1 1 5.14士0.90 0.884 
2 5.21±0.90 
fl.*i 
LDL-C, mmol/I 1 2.94±0.91 0.354 i 
2 3.12土0.89 
apo B, mg/dl 1 121.5±29.8 0.702 
2 126.6土28.8 
HDL-C, mmol/1 1 1.55 士 0.37 0.806 
2 1.54±0.31 
HDL2-C, mmol/1 1 0.48 土 0.27 0.556 
2 0.51±0.24 , 
m 
HDL3-C, mmol/1 1 0.99 土 0.23 0.208 
2 0.94土0.16 
apoA-I,mg/dl 1 165.9±24.1 0.702 
2 163.9士21.3 
TGLN, mmol/I 1 0.05土0.74 0.878 
2 0.02 土 0.62 
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There were no significant differences between the two groups in the baseline 
concentrations ofthe components ofthe basic lipid profile. The distribution of 
concentrations of TG were skewed to the right with degrees of skewness and 
kurtosis of 0.97 and 0.85 in Group 1 and 1.12 and 1.08 in Group 2. The 
minimum value ofTG was 0.06 mmol/1 and the maximum 8.92 mmoVl. 
Forty six subjects (51.1%) (1 missing value) had concentrations of TC which 
«*>, 
were either borderline or high according to the NCEP 1993 guidelines for 
treatment of abnormalities of the lipid profile. Twenty nine subjects (34.1%) 
(6 missing values) had concentrations of LDL-C which were either borderline 
or high. The level of HDL-C was below the recommended minimum of 0.9 
mmoVl in one subject (1.1%) (1 missing case). 
(4) Comparison ofthe response to treatment during the first 6 months of 
the study. 
I 
Apart from the crossover analysis of data performed at the completion of the 
study, a separate analysis was also made after the first 6 months so that a 
comparison could be made with the results ofthe other studies on the effects of 
oestrogen on Lp(a). 
(i) Comparison between Lp(a), gonadotropin and E2 concentrations in 
Groups 1 and 2 after 6 months of treatment. 
An analysis of the effect of treatment on Lp(a), gonadotropin and oestradiol 
concentrations at the end ofthe first 6 months is presented in Table 20. 
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Table 20. Comparison between Lp(a), gonadotropin and E2 concentrations 
in Groups 1 and 2 after 6 months of treatment in the crossover study. 
Group Baseline 6 months pi p^  
Mean (SD) Mean (SD) 
Lp(a),mg/dl 1 10.78 [2.2-108.5] 6.44 [0.1-97.6] 
Median 2 12.74 [0.8-98.1] 10.75 [1.6-104.4] 
[Range] 
**w 
Lp(a) LN 1 2.55土 1.04 1.98±1.28 <0.001 <0.001 
2 2.56± 1.08 2.49± 1.03 0.351 
FSH, IU/1 1 85.9±31.0 36.1 土27.4 <0.001 <0.001 
2 80.8±36.5 71.2土30.8 <0.01 
LH, IU/1 1 28.7土 11.8 22.5士16.7 <0.01 <0.01 
2 25.9± 10.8 29.0±19.1 0.229 
E2, pmol/l 1 92.5±9.4 522.7±301.1 <0.001 <0.001 
2 95.4±11.3 119.7土114.3 0.175 
pi refers to changes within groups 
p2 refers to changes between groups 
Changes in the study variables were analyzed within each group as well as 
between groups. Within Group 1 (oestradiol), there was a significant 40.3% 
reduction in the median Lp(a) concentration from 10.78 mg/dl to 6.44 mg/dl 
(mean LN 2.55 to 1.98) (p<0.001). Within Group 2 (placebo), there was a 
15.6% reduction in the median concentration of Lp(a) from 12.74 mg/dl to 
10.75 mg/dl (mean LN 2.56 to 2.49) which was not statistically significant. 
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There were also significant reductions in the mean concentrations of FSH 
(p<0.001) and LH (p<0.01) and a significant increase in the mean level of 
oestradiol (p<0.001) in Group 1 and a significant decrease in the mean level of 
FSH (p<0.01) within Group 2 (placebo). 
When comparing the changes between the groups, there was a significant 
reduction in the mean concentration ofLp(a) in Group 1 compared with Group 
"'4S 
2 (p<0.001) and there was also a strong correlation between the baseline value 
of Lp(a) and the magnitude of the reduction in Lp(a) in Group 1 (r=0.34, 
p=0.001). There were also significant reductions in the concentrations of 
gonadotropins and a significant increase in the level 0fE2 in Group 1 compared 
with Group 2 during this period. 
(ii) Comparison between concentrations of the components of the basic 
lipid profile in Groups 1 and 2 after 6 months of treatment. 
Table 21 shows the changes in the basic lipids and lipoproteins in Groups 1 
and 2 after 6 months oftreatment. 
171 
Table 21. A comparison between concentrations of basic lipids and 
lipoproteins in Groups 1 and 2 after 6 months of treatment in the crossover 
study. 
Group Baseline 6 months pi p^  
Mean (SD) Mean (SD) 
TC, 1 5.14±0.90 5.21士1.23 0.511 0.17 
mmol/1 2 5.21±0.90 5.50土0.87 <0.05 
'i«*— 
LDL-C, 1 2.94土0.91 2.73±0.94 0.182 <0.01 
mmol/1 2 3.12±0.89 3.45±0.84 <0.05 
apoB， 1 12L5±29.8 116.0±33.6 0.105 0.369 
mg/dl 2 126.6±28.8 124.8土31.9 0.623 
HDL-C, 1 1.55士0.37 1.80土0.43 <0.01 <0.01 
mmol/1 2 1.54±0.31 1.54±0.32 0.803 
HDL2-C, 1 0.48士0.27 0.62±0.30 <0.001 <0.001 
mmol/1 2 0.51土0.24 0.50土0.27 0.542 
HDL3-C, 1 0.99±0.23 0.99±0.22 0.822 0.580 
mmol/1 2 0.94±0.16 0.98±0.24 0.224 
apo A-I, 1 165.9±24.1 189.9土29.1 <0.001 <0.001 
mg/dI， 2 163.9±21.3 161.9± 18.5 0.356 
TQLN 1 0.05土0.74 0.13 土0.81 0.409 <0.001 
mmol/l， 2 0.02 土 0.62 -0.09 士 0.60 0.080 
pi refers to changes within groups 
p2 refers to changes between groups 
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During the first 6 months of the trial there were significant increases in the 
concentrations of HDL-C, HDL2-C and apo A-I within Group 1 (p<0.01, 
<0.001 and <0.001 respectively). Within Group 2, there were significant 
increases in the concentrations ofTC and LDL-C (p<0.05 for each variable). 
When comparing the two groups, there was a significant reduction in the mean 
concentration of LDL-C and increases in the mean values of HDL-C, HDL2-C, 
"*s 
apo A-I and TG in Group 1 compared with Group 2 (p<0.01, <0.001，<0.001， 
and <0.001 respectively). 
(5) Analysis of data at the completion of the crossover study. 
The following data describe the changes in variables with oestradiol and 
placebo which were found over the total duration ofthe study period. 
(i) Crossover analysis of changes in Lp(a), gonadotropin and E2 
concentrations between Groups 1 and 2 at the completion ofthe study. 
it*_ 
A summary of the crossover analysis of the effect of oestrogen on Lp(a), 
gonadotropins and E2 concentrations over 12 months is presented in Table 22. 
A comparison of changes in values during the last 6 month period was not 
provided as these would have been affected by the treatment ofthe preceding 6 
months, and would have had little meaning. 
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Table 22. Final crossover analysis showing the changes in Lp(a), 




No. Mean p 
change (± SD) (Treatment vs placebo) 
Lp(a) LN 85 -0.45±0.67 <0.001 -
FSH, IU/I 85 -41.7±28.0 <0.001 
LH, IU/1 86 -11.3±20.2 <0.001 
E2, pmol/1 86 424.3 ±300.5 <0.001 
Analysis of the data after 12 months showed a reduction in the median 
concentration of Lp(a) of 9.6% with oestrogen compared with placebo 
(p<0.001). This represented the total effect of oestrogen when both study 
groups were combined and the data analysed according to the method of Hills 
and Armitage (1979). The reduction in Lp(a) occurred in association with a 
significant increase in the level of oestradiol and a significant reduction in FSH 
and LH in the treated group. In the second 6 month period when those in 
Group 1 received placebo, the initial reduction in Lp(a) which had occurred 
during oestrogen treatment was reversed. There was an increase in the median 
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Lp(a) concentration during this time from 6.44 to 8.57 mg/dl, a value which did 
not significantly differ from the baseline measurement (p=0.34). 
(ii) Final crossover analysis showing the changes in the basic lipid 
profile over the complete 12 month study period. 
A summary of the crossover analysis of changes in the basic lipid profile 
、 
between Groups 1 and 2 at the completion of the study is presented in Table 
23. 
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Table 23. Final crossover analysis showing the changes in the basic 
lipid profile over the complete 12 month study period. 
CROSSOVER ANALYSIS 
TREATMENT EFFECT 
No. Mean change (士 SD) p 
TC (mmol/1) 86 -0.25士0.82 <0.01 
*、 
LDL-C (mmol/1) 81 -0.58±0.69 <0.001 
HDL-C (mmol/1) 86 0.17±0.27 <0.001 
HDL2-C (mmol/I) 85 0.12 土 0.23 <0.001 
HDL3-C (mmol/1) 85 0.01 土0.19 0.50 
Apo A-1 (mg/dl) 85 23.27 土 26.72 <0.001 
Apo B (mg/dl) 85 -8.74±21.26 <0.001 
TG(LN) 86 0.2±0.5 <0.001 
(mmol/1) 
p = Treatment vs placebo 
Oestrogen treatment resulted in reductions of 3.7% for TC, 14.9% for LDL-C 
and 4.8% for apo B compared with placebo (p<0.01, p<0.001, p<0.001 
respectively). In addition, HDL-C increased by 12.6%, HDL2-C by 40.6% and 
apo A-I by 15.0% (p <0.001 for all variables). Concentrations ofTG increased 
by 6.6% with oestrogen (p<0.001), but there was no significant change in the 
concentration 0fHDL3-C. 
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There were no significant time nor period effects for any of the variables 
measured in the study, indicating that neither the order in which the oestrogen 
and placebo were administered nor the time taken to complete the study had an 
effect on the final results. 
(6) Analysis of the relationship between concentrations Lp(a) and other 
lipids and lipoproteins during the crossover study. � 
i 
• I 
Changes in the concentrations of Lp(a) were compared with those in the basic 
lipid profile to provide indirect evidence for a shared metabolic pathway. The 
relationship between the concentrations of Lp(a) and the other lipids and 
lipoproteins at the commencement ofthe study and at the end of each period of 
the crossover are presented in Table 24. 
i i i i 
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Table 24. The correlation between Lp(a) and the other lipoproteins 
during the crossover study. 
TEVIE Lp(a) p* Lp(a) p* Lp(a) p* 
BASELEVE 6 MTHS 12 MTHS 
0 0.338 0.001 0.248 0.01 0.286 0.004 
TC 6 0.265 0.007 0.317 0.001 0.287 0.004 
12 0.184 0.046 0.100 0.18 0.219 0.02 
•、 
0 0.310 0.003 0.265 0.009 0.365 0.001 
LDL-C 6 0.237 0.02 0.361 0.001 0.185 0.048 
12 0.069 0.27 -0.001 0.49 0.256 0.01 
i i 
0 0.276 0.005 0.215 0.02 0.233 0.02 | 
apo B 6 0.308 0.002 0.287 0.004 0.285 0.004 
12 0.168 0.06 0.082 0.23 -0.090 0.20 
I 
i ( 
0 -0.028 0.40 -0.036 0.37 0.112 0.15 
HDL-C 6 -0.130 0.12 -0.112 0.15 0.028 0.40 
12 -0.034 0.38 0.008 0.36 0.077 0.24 
0 -0.140 0.10 -0.069 0.26 0.046 0.34 
HDL2-C 6 -0.162 0.07 -0.157 0.07 0.048 0.33 
12 -0.107 0.17 -0.016 0.44 -0.010 0.46 
0 0.090 0.20 0.014 0.45 0.080 0.23 
HDL3-C 6 0.002 0.49 -0.019 0.43 0.003 0.49 
12 0.034 0.38 -0.038 0.36 0.110 0.16 
0 -0 072 0.25 -0.060 0.29 0.016 0.44 
apo A-I 6 -0.135 0.10 -0.248 0.01 0.051 0.32 
12 -0.071 0.26 -0.013 0.45 -0.090 0.20 
0 0 014 0.45 -0.091 0.21 -0.116 0.15 
TG 6 0 017 0.16 -0.066 0.27 0.034 0.38 
12 0.027 0.40 -0.040 0.36 -0.162 0.07 
*2 -sided p-value. Significant values in bold type. 
178 
f 
There was a significant positive correlation between the concentrations of 
Lp(a) and TC as well as LDL-C both before and during the study. In addition, 
there was a positive correlation between the concentrations of Lp(a) and apo B 
before treatment and at the end of the first period. There was no correlation 
between concentrations of Lp(a) and those lipoproteins which are structurally 
unrelated to Lp(a). 
"'n 
DISCUSSION 
The women who entered this study had undergone surgery for benign 
conditions which are commonly encountered in this age group. The mean 
interval between surgery and entry into the study in the two groups was 6 and 8 
months respectively, which resulted in the study population having a mean age 
between 43 and 44 years. There was no reason to suspect that the results ofthis 
study of younger postmenopausal women would not apply to an older age 
group. Age itself does not affect concentrations of Lp(a), but concentrations 
increase after the menopause regardless of age. There are no data to determine 
whether a response to oestrogen treatment is more likely with a longer rather 
than a shorter duration of oestrogen deficiency. If this study group had been 
older, a higher incidence of abnormalities in the basic lipid profile would have 
been expected. However these women were healthy and had not been 
menopausal for long. As a result of the exclusion criteria any bias in the 
selection of subjects would have been more likely to have reduced than to have 
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increased the chance ofdemonstrating a beneficial effect of oestrogen, as fewer 
subjects would have been expected to have abnormal lipid profiles. 
Having completed the study, it did not appear as if any unintentional bias had 
been introduced in the process of randomization. After the code for 
randomization was broken, no significant differences were found in either the 
baseline concentrations of Lp(a) or in the concentrations of the other lipid and 
•S i 
lipoproteins between the two groups. Lp(a) concentrations showed a skewed 
distribution to the right similar to that observed in Caucasians and in the few 
! 1 
previous studies in Chinese populations. The range of values was also similar, | 
i 
and the proportion of women with Lp(a) concentrations greater than 30 mg/dl 
(27.3% overall) approached that previously described in an older group of 
I 
Hong Kong Chinese women (30.7%) (Woo and Lam, 1990; Woo and Lam, 
1991) and in a slightly younger group of black African females (35%) (Bovet 
et al, 1991). However the frequency of elevated concentrations was much 
,•» 
higher than the 6.1% reported in Caucasians by Schriewer et al (1984), but 
when that study was conducted the assay for Lp(a) may have been less reliable. 
These differences in Lp(a) concentrations are inconsistent with the incidence of 
CAD observed in the respective populations, and this may be due to the small 
sample sizes, selection bias (premenopausal or postmenopausal women) or the 
use ofdifferent assays in some ofthese studies. It could, however, be possible 
that other factors (such as a less atherogenic basic lipid profile) could be 
protective against elevated Lp(a) concentrations in those populations where the 
incidence ofCAD is lower. This would explain why cardiovascular disease is 
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less of a problem in Chinese populations despite the presence of a similar or 
higher proportion having raised Lp(a) concentrations. HDL-C is important in 
reverse cholesterol transport, but it is not known whether it affects the uptake 
ofLp(a). 
Baseline concentrations of gonadotropins were within the menopausal range in 
each of the groups. The mean value of oestradiol was between 90 and 100 
•'、 
pmoVl，which is well within the menopause reference range of < 361 pmoVl. 
. I 
Apart from a biochemical confirmation of menopausal status, operative records 
and pathology reports were available in all but three of the cases and these 
confirmed that bilateral oophorectomy had been performed. 
The baseline distributions of the components of the basic lipid profile were 
I 
similar to those found in previous studies of Chinese subjects in Hong Kong, 
Taiwan and Singapore. However mean concentrations of TC and LDL-C 
tended to be higher and HDL-C lower than in mainland China. There were, 
• i 
however, a higher than expected number of subjects with elevated 
concentrations of TC according to the NCEP guidelines (51.1%). This figure 
was more than double that of a mixed Chinese population surveyed recently in 
the United States (Pinnelas et al, 1992)，and was also higher than in two other 
Hong Kong studies where only slightly more than 20% of similarly aged 
women had abnormally high concentrations of TC (Cho and Donnan, 1988; 
Fong et al, 1994). The proportion of subjects with raised concentrations of 
LDL-C was also high (34.1%), but there were very few with concentrations of 
HDL-C below a critical value of0.9 mmol/1 (1.1%). Although the sample size 181 
was not large enough to represent the Hong Kong population, the number of 
women with abnormal values should not be ignored. Previous studies have 
been conducted mainly in premenopausal women, and the population in the 
current study had only become menopausal shortly before the commencement 
oftreatment. It is questionable whether the effect ofthe menopause during this 
short interval could have accounted for the high number of lipid abnormalities, 
' V 
and further studies will help to confirm this trend towards a higher prevalence 
of lipid abnormalities in Hong Kong. | 
During the first 6 months of the study period, there were significant and 
j| 
predictable reductions in mean gonadotropin concentrations as well as an | 
i| 
increase in the mean level of oestradiol in those receiving oestrogen (Group 1). | 1^  |. 
. J 
These were expected findings and confirmed the clinical impression that j 
^ 
1 
compliance with treatment had been maintained. There were five women who 
’丨 
had one or more packets of tablets remaining at the completion of one of the I 
,J 
study periods, and they were excluded from data analysis, bi the placebo 
group (Group 2), there was a smaller but still significant reduction in the mean 
concentration ofFSH, but no significant change in concentrations of either LH 
or oestradiol. There is no obvious explanation for this decrease in FSH, but it 
remained within the menopausal range, and as concentrations of lipids and 
lipoproteins correlate with concentrations of oestradiol, this decrease did not 
appear to be important. 
During the first 6 months there was also a significant reduction in the mean 
concentration ofLp(a) with oestrogen compared with placebo. The magnitude 
182 
；： 
ofthis reduction was ofthe order of 40.3% within the oestrogen treated group, 
which exceeded the 16% reported by Muesing et al (1991) over a period of 4 
months, and was also higher than the 31.7% decrease described by Lobo et al 
(1992) in another study of6 months duration. Although there was a decrease in 
the median concentration ofLp(a) during this period, there were no significant 
changes in the concentrations of TC, LDL-C, apo B nor TG within the 
oestrogen treated group. There were, however, significant increases in the 
concentrations of HDL-C, HDL2-C and apo A-I. The rates of change of the j 
i 
I 
various lipids and lipoproteins after the menopause in untreated women are not j 
known, but in this study there was some variation in their response to | 
！ 
exogenous oestrogen. The HDL-C related lipoproteins showed a more marked 
(； 
response than the LDL-C related group. | 
I 1 
When comparing the changes in the lipid profile between the two groups i 
i < 
during the first 6 months, there were significant reductions in Lp(a) and LDL-C j 
I 
and increases in HDL-C，HDL2-C, apo A-I and TG with oestrogen compared 
with placebo. These anticipated changes in the basic lipid profile supported a 
genuine effect ofoestrogen on Lp(a). 
The fmal analysis of data from the crossover study revealed a significant 9.6% 
reduction in the concentration ofLp(a) with oestrogen compared with placebo. 
This was considerably lower than the 40.6% reduction found during the first 6 
months in Group 1，but it was a more accurate representation of the effect of 
oral oestrogen, as this value was derived from the analysis of the data from 
both of the study groups over the complete study period. As expected, there 
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were also significant reductions in concentrations ofTC, LDL-C and apo B and 
increases in HDL-C, HDL2-C and apo A-I with oestrogen treatment. A 
significant effect of oestrogen on TC had not been found during the first 6 
months, but the power of the study was sufficient to demonstrate a significant 
difference in the crossover analysis. This was accompanied by an expected rise 
in the concentrations of TG in those treated with oestrogen. As was the case 
s, 
during the first 6 months, in the final data analysis the HDL-C related | 
lipoproteins also showed a comparatively greater response to oestrogen than 1； 
I 
. I： 
the LDL-C related group. The differences in concentrations of gonadotropins i 
1 
and oestradiol between the two groups were maintained throughout the study ； 
period, which again confirmed the impression gained at the follow-up visits 
i 
( 
that a high level of compliance had been maintained. The results of crossover 
analysis provided convincing evidence of the ability of oral oestrogen to reduce 
concentrations of Lp(a), and it was noteworthy that reductions were greatest in 
those with the highest baseline concentrations. This implies that those most at 
risk of developing CAD because ofraised Lp(a) concentrations should receive 
the greatest benefit from treatment. 
Whilst the metabolic pathway of Lp(a) remains incompletely understood, the 
liver appears to be important in both synthesis and catabolism, and given the 
structural resemblance between Lp(a) and LDL-C, oral oestrogens should have 
a similar effect on Lp(a) as LDL-C. Throughout the study, there was a good 
correlation between concentrations ofLp(a) and those of TC, LDL-C and apo 
B. This was not the case for lipids and lipoproteins structurally dissimilar to 184 
Lp(a), and these findings supported the theory that Lp(a) and LDL-C do in fact 
share a common metabolic pathway. 
In summary，concentrations of Lp(a) and other atherogenic lipids and 
lipoproteins were similar in this group of postmenopausal Chinese women as in 
Caucasians, and there was a significant reduction in Lp(a) concentrations as 
well as an improvement in the basic lipid profile in response to oestrogen 
、 
treatment. In each of the study groups the duration of treatment was 6 months, 
and in the following chapter the response to sustained treatment with oral j 














STUDY II - THE SUSTAINED EFFECTS OF ORAL OESTROGEN 
INTRODUCTION -. 
At the time this study was performed, there had been no reports describing the j 
I 
response of Lp(a) to more than 6 months of treatment with oestrogen. The j 
. j 
longer term effects of oestrogen are important because the influence of some j 
li 
drugs is known to diminish with time in a process known as chronic tolerance. |； 
^ 
Tolerance is a state of decreased responsiveness to the pharmacological effect | 
^ 
f 
of a drug resulting from a prior exposure to that drug or to a related drug | 
i 
(Goldstein et al, 1974). The body has a number of mechanisms by which 
•V 
tolerance can develop, although the pathways are often incompletely 
understood. As an example, tolerance to barbiturates and other drugs which 
are metabolized by the liver may develop as a result ofincreased activity ofthe 
enzyme which metabolizes the drug. This usually takes place within hepatic 
microsomes, and the increase is associated with heightened activity in the 
endoplasmic reticulum (Remmer, 1967). Although tolerance is not a 
recognized feature of oestrogen administration, this area has not been 
thoroughly investigated, and there are few data to confirm whether the short 
186 
term effects of oestrogen on the lipid profile are maintained with prolonged 
use. The results of cross-sectional studies suggest that with continuous 
oestrogen administration the effects on the basic lipid profile are maintained 
(Nabulsi et al, 1993), but Lp(a) metabolism differs from that of the other 
lipoproteins, even though Lp(a) appears to share a metabolic pathway with 
LDL-C. There have also been few prolonged prospective studies on the effects 
of hormone replacement therapy on the basic lipid profile. Rijpkema et al | 
(1990) reviewed the results of all studies on oestrogeny'progestogen j 
replacement therapy published between 1984 and 1990. There were 43 such j 
I 
studies, and in only 6 of these was the period of observation greater than one j 
year. The study ofWolfe and Huff (1989) was the longest (4 years), but only 5 | 
i, 
I. 
women completed the study. j 
M 
t 
The recently completed PEPI Trial (The Writing Group for the PEPI Trial, | 
i' ( 
i\ 
1995) examined the effect of unopposed oestrogen and 3 different 
• j 
oestrogen/progestogen combinations over a period of 3 years and provided the 
strongest evidence to date for the sustained effect of HRT. Of note in this 
study was the observation that concentrations of HDL-C increased during the 
first 6 to 12 months oftreatment and then gradually declined, but they did not 
retum to baseline values in any of the treatment groups. Concentrations of 
LDL-C also reached their lowest point within 6 to 12 months and did not 
change significantly thereafter and a similar pattern was observed for TC and 
TG. 
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In the crossover study described in the preceding chapter, there was a 
significant reduction in concentrations of Lp(a) with oestrogen administration, 
but in each group the duration of treatment was only 6 months. There were 
anticipated changes in the basic lipid profile, but as most women who use HRT 
do so for a period of years rather than months, the effects of prolonged 
treatment are potentially more important. There are a number of reasons why 
few long term studies on the lipid effects of HRT have been conducted. One of j 
these is that such studies are reliant on compliance with treatment, and the 
I 
longer the study runs, the greater the likelihood of withdrawals from the study j 
• j 
protocol. Unless the number of cases recruited is well above that required by | 
!l 
. 丨! 
the sample size calculation, this can eventually leave a study population which [ 
I 
I; 
is too small for reliable statistical analysis. Poor compliance is a well | 
/ f 
recognized problem in HRT users. Ryan et al (1992) found that 40% of a | 
ii 
group of women receiving HRT because of low bone mineral density had | 
•) 
stopped taking their treatment 8 months after commencing it，and Cano (1995) 
found that 51% of 331 women using HRT interrupted their therapy mainly in 
the first year, and 9% never had their prescriptions filled. Therefore, to conduct 
a trial of this type introduces the risk of losing a large proportion of the study 
group. 
There are also ethical problems to consider, especially if a placebo is used. If a 
placebo is taken for longer than 6 months, postmenopausal women are exposed 
to a potentially higher chance of developing osteoporosis and they may also 
increase their cardiovascular risk. Another factor to be considered is the 
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impatience of some investigators to achieve significant results. They may be 
under pressure to release their study findings as soon as a significant change 
can be demonstrated, and this may occur well within the planned study period. 
This study was an extension of the crossover study on the short term effects of 
oral oestrogen. The aim of the study was to examine the sustained effects of 
oestrogen on Lp(a) and other atherogenic lipids and lipoproteins in 
•s 
postmenopausal Chinese women. 
METHODS 
I 
. . II 
This study was conducted among a subgroup of women who had participated |; 
i 
in the crossover study on the short term effects of oral oestrogen on lipids and 
t： 
1 
lipoproteins. Those who agreed to continue were treated with the same oral i； 
'i; 
oestrogen as had been used previously. The study was of an open longitudinal , 
design, which overcame the problem ofusing a placebo or a control group for j 
more than 6 months. All were asked to take oral oestrogen for an additional 12 
months, but this created a problem because their participation in the crossover 
study meant that some women had been using oestrogen and others placebo in 
the 6 months before this study commenced. Although there had been no 
differences between the 2 groups at the start ofthe crossover study, they now 
differed with respect to their prior treatment. If a "washout" period had been 
used to make the groups comparable, the effect of prolonged treatment would 
have been lost. It would have been preferable to have used a separate study 
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group to investigate the sustained effects of oral oestrogen, but in practice 
sufficient numbers would have been difficult to achieve, and it was thought 
that the results would be valid if the two groups from the crossover study were 
analyzed separately. 
The structure of this study is shown in Figure 7. The "Start", “6/12”，and 
“12/12” refers to the start, 6 month and 12 month intervals during the crossover 
study. The current study began at "12/12" and continued until "24/12". In the 
6 months preceding this study, those from Group 1 had been taking placebo | 





Figure 7. The structure of the study on the sustained effects of oral ^ 
oestrogen. 
I f. ； 
1 
Group 1 \ 
j 
，l 
E2 Placebo 艮 
1- ^ ； 
I L I ‘ 
Start 6/12 12/12 24/12 
Group 2 
Placebo E2 ^2 • 
I I ^ ‘ 
Start 6/12 12/12 24/12 
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The baseline concentrations of lipids and lipoproteins in this study were those 
which had been measured in each group at the completion of the crossover 
study. Follow-up continued at 6 monthly intervals as was the normal clinic 
practice, and the same measurements of Lp(a) and the basic lipids and 
lipoproteins were repeated at the end of 12 months oftreatment. 
Statistical analysis | 
The response to the additional 12 months of oestrogen treatment was examined | 
f 
using the paired samples t-test. As in the crossover study, logarithmic j 
. I 
transformation was used for the measurements of Lp(a) and TG. In view of the | 
i: I； 
dissimilarity between the 2 groups described above, an analysis ofthe response j 
i： 






At the completion of the crossover study, 54 women agreed to continue 
treatment with oestrogen for a further 12 months, which included 28 who had 
been in Group 1 and 26 from Group 2. All subjects completed this additional 
period oftreatment and had blood sampling performed. A comparison between 
the concentrations of Lp(a) and other lipoproteins at the completion of the 
crossover study and at the end of a further 12 month period oftreatment with 
oestrogen is shown in Table 25. 
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Table 25. Effect of sustained administration of oestrogen on Lp(a) and 
other lipids and lipoproteins. 
VALUE AT END~~VALUE AFTER 
CROSSOVER 12 MONTHS 
Group Mean 土 SD Mean 土 SD p 
Lp(a) (mg/dl) 1 8.57 (2.5-99.8) 5.77 (0.8-75.4) 
(Median/range) 2 7.75 (1.1-57.4) 7.07 (0.7-48.8) 
Lp(a) LN 1 2.15土0.93 1.93 ±1.07 <0.001 i 
2 2.05 ±1.11 1.98土1.10 0.628 
TC,mmol/I 1 5.36±0.94 5.06±0.75 0.057 | 
2 5.25 土0.93 5.25 土0.70 0.749 j 
I { 
LDL-C,mmolA 1 3.33±0.72 2.71 士0.79 <0.001 




apo B, mg/dl 1 115.9±28.7 117.7±32.4 0.724 ！； 
2 111.4土20.9 122.4±29.3 <0.01 [ 
'i. r i 
ii f 
HDL-C, mmol/l 1 1.57±0.34 1.66±0.28 0.088 | 
2 1.63土0.31 1.65±0.27 0.514 
HDL2-C, mmol/l 1 0.59±0.27 0.73 ±0.30 <0.001 
2 0.61土0.27 0.66±0.28 0.227 
HDL3-C, mmol/l 1 0.97 士 0.20 0.93 士 0.13 0.303 
2 0.97士0.24 0.99±0.16 0.664 
apeA_I,mg/dl 1 171.6士32.8 200.7士24.5 <0.001 
2 189.5土23.6 200.7i25.2 <0.05 
TG(LN) 1 -0.12 + 0.51 0.27±0.59 <0.001 
2 0.27±0.64 0.36士0.64 0.272 
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The median concentration of Lp(a) for those in Group 1 who completed the 
additional 12 months oftreatment decreased from 8.57 mgAil [Range 2.5-99.4] 
to 5.77 mg/dl [Range 0.8-75.4], (p<0.001). In Group 2，the median 
concentration decreased from 7.75 mg/dl [Range 1.1-57.4] to 7.07 mg/dl 
[Range 0.7-48.8]，but the difference was not significant (p=0.628). 
There was also a significant reduction in Group 1 in the mean concentration of 
LDL-C (p<0.001) and increases in apo A-I, HDL2-C and TG (p<0.001, <0.001 | 
t 
. jl 
and <0.001 respectively). Li Group 2, there were significant increases in apo | 








The response to the continuation of oestrogen which was given for an 1 
i' j 
additional 12 months after the completion ofthe crossover study is particularly 
_ ^ 
important because most women continue with treatment over periods of years 
rather than months. A recent study by Marsh et al (1994) on the use of 
combined HRT found that after an initial reduction in Lp(a) concentrations in 
the first 6 months of treatment, concentrations rose during the second 6 
months. Whether this could have been due to tolerance or some other reason 
was not discussed. 
In this study there was a further significant reduction in Lp(a) concentrations of 
32.7% in those women who had been taking placebo in the 6 months preceding 
this study. For those already taking oestrogen, there was a further reduction in 
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the median concentration of Lp(a) of 8.8%, but this decrease was not 
significant. 
The responses in the basic lipid profile were also more marked in those who 
had been taking placebo in the 6 months before this study commenced. In this 
group the response to oestrogen was similar to that which had been observed 
during the crossover study, and over 12 months there were significant 
reductions in Lp(a) and LDL-C, a lowering of TC of borderline significance 
and significant increases in apo A-I, HDL2-C and TG. For those who had been | 
taking oestrogen before the start of the study, the changes were less marked. | 
There were reductions in the concentrations ofLp(a) and LDL-C and increases 
；丨 i| 
in HDL-C, HDL2-C and TG, but these changes were not statistically | 
|丨 
'i 
significant. There was a significant increase in the level of apo A-I, but this j 
!,i 
f ‘i 
was opposed by an increase in apo B. These results suggest that the effects of 1 
j； 
oestrogen on lipids and lipoproteins are greatest during the initial phase of 
S 
treatment, but as in the PEPI Trial, the changes are maintained with prolonged 
therapy. 
Further studies of an even longer duration would be of interest，as would 
measurements of lipids and lipoproteins in previous users of HRT after the 
discontinuation oftheir treatment. Previous users are known to have a reduced 
incidence of CAD, but whether this relates to a lipid effect or to some other 
mechanism is unknown. The long term consequences of HRT administration 
are of great importance to postmenopausal women, and the results of studies in 
which the observation periods have been longer will carry more weight. These 
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data show that the short term effects of HRT on Lp(a) and other atherogenic 













STUDY III - THE EFFECTS OF COMBINED CYCLICAL HORMONE 
REPLACEMENT THERAPY 
INTRODUCTION | 
. . . ! 
Theoretical concerns have been raised about the potential nullifying action of i 
progestogens on the favourable lipid effects exerted by oestrogen. This may ； 
1  
have resulted from a failure to recognize the differences between the actions of j 
ri 
|> 
steroids used in oral contraceptives and those used for hormone replacement. : 
1¾ f 
The oral contraceptives usually contain progestogens which are more j 
l ^, 
androgenic and these have been shown to have adverse effects on lipids and , 
r' [ 
1： 
lipoproteins. Notelovitz et al (1989) found that both norethindrone and § 
levonorgestrol increased concentrations of TC, LDL-C and TG and lowered 
concentrations of HDL-C and HDL2-C when combined with ethinyl oestradiol 
in triphasic preparations. On the other hand, low dose natural progestogens 
combined with oestrogen in HRT regimens may benefit the lipid profile (Bolaji 
et al, 1993). In general，the C-19 progestogens are more androgenic than the 
C-21 group, but some of the newer progestogens have little or no effect on 




The effect of progestogens on Lp(a) is less predictable than on the basic lipid 
profile. Reductions in concentrations of Lp(a) have been observed with 
oestrogens but also when the more androgenic progestogens have been 
prescribed (Farish et al, 1991). The mechanism of action in each case remains 
unclear, but if both oestrogens and progestogens are able to reduce 
concentrations of Lp(a) when used separately, then in theory they could act 
synergistically if prescribed in combination. | 
Apart from the lipid effects, there are other disadvantages in using combined jj 
I; 
I 
treatment with oestrogen and a progestogen rather than unopposed oestrogen. j 
• . j 
Whilst some combined preparations are now available which provide the | 
: i (•• 
oestrogen and the progestogen in a single tablet or other means of delivery, ^ 
[ 
these drugs are usually administered separately, and this is likely to reduce j 
‘1 i' 
»1 
compliance. In addition, if the regimen is not fully understood, there may be 1 
‘I 
an increase in the incidence of unscheduled vaginal bleeding. Progestogens i； i: ^ 
may also cause a variety of additional side effects including tiredness, 
depression, decreased libido, oedema and breast tenderness (Lauritzen, 1990). 
However combined treatment should be prescribed for all women who have not 
had a hysterectomy to prevent hyperplastic changes in the endometrium 
resulting from oestrogen administration. 
Women who use a continuous combined rather than a combined cyclical HRT 
regimen receive the same drugs each day, and there are unlikely to be any 
fluctuations in the lipid response to treatment. With combined cyclical 
treatment, however, the progestogen is given for only 12 days each month, and 
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the timing of blood sampling may affect the lipid measurements. If the 
progestogen opposes the lipid effects of oestrogen, then this may be easier to 
demonstrate during the combined phase oftreatment than when the patients are 
only taking oestrogen, and few studies have taken this into account. 
The objectives ofthis study were to investigate the effects of combined cyclical 
hormone replacement therapy on Lp(a) and other lipids and lipoproteins and to 







In a combined cyclical HRT regimen, oestrogen is usually prescribed for all or 
丨！ 
most days of each month, and the progestogen is given for the minimum time 
I-i 
thought to be effective in preventing endometrial hyperplasia. In such a 丨 
'li 
•i 
regimen there should be predictable withdrawal bleeding after the progestogen !, 
•r 
is discontinued. The endometrial effects of prescribing the progestogen on a 1^ 
less frequent basis have been studied (Kemp et al，1989)，but these regimens 
have not been widely accepted. The decision to examine a combined cyclical 
regimen rather than a continuous combined or other form of delivery was made 
because our clinic population consisted mainly of women who had recently 
become menopausal. These women are unsuited to continuous combined 
treatment as they would have a high incidence ofunscheduled bleeding. Under 
ideal circumstances, the effects of both types of therapy would have been 
examined, as both are in common use. 
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An open longitudinal study design was chosen for a number of reasons. 
Firstly, the oestrogen and the progestogen preparations were supplied by 
different manufacturers, and an agreement from both companies to provide 
placebo tablets was not possible. In addition, a double-blind study would have 
been difficult to perform with this drug combination. The patients would have 
been likely to have experienced regular withdrawal bleeding when taking the 
active treatment but to become amenorrhoeic on placebo, and this would have | i 
I 
！ 
exposed the double-blind nature of the study. In addition, a control group was | 
1 
I 
not included because of the ethical implications of withholding treatment for | 
12 months. Trabecular bone loss may occur at a rate of up to 8% per year in | 
postmenopausal women, and is most rapid soon after the menopause ！ 
i' 1 
(Llewellyn-Jones, 1991). As has been discussed previously, to have withheld | 丨: 
[i 
treatment for this long would have exposed the subjects to a greater risk of j 
developing osteoporosis and it may also have increased the risk of CAD. 丨 
i 
However the lack of a control group was not thought to have seriously 
weakened the study as a significant change in Lp(a) concentrations in untreated 
postmenopausal women over this period was thought to be unlikely. The 
absence of a group treated with placebo meant that this study was unlikely to 
suffer from methodological difficulties. It was anticipated that there would be 
some withdrawals due to irregular bleeding, but otherwise side effects were not 
expected to be a serious problem. 
A 12 month study was chosen as it was thought this duration was sufficient to 
demonstrate the lipid effects of the treatment without having a high number of 
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1 
dropouts due to lack of compliance. The calculation of sample size has been 
discussed in Chapter 4. Fewer dropouts were expected in this study than in the 
more complicated crossover study, but recruitment was not overly difficult, and 
the number of subjects included exceeded the minimum which was required. 
All of the subjects had undergone a spontaneous menopause and had clinical 
and biochemical evidence of an established menopause. The treatment 
I 
regimen consisted of the uninterrupted daily administration of 2 mg oral 17p-
oestradiol (Estrofem, Novo Nordisk，Bagsvaerd, Denmark) as well as 5 mg 
medroxyprogesterone acetate (MPA) (Provera, Upjohn Company, MI, USA) | 
i 
for the first 12 days of each calendar month. The subjects were instructed to ； 
use the westem rather than the Chinese calendar and to expect withdrawal 
bleeding towards the end of the progestogen treatment. A total of 49 women 
j 
were invited to participate in this study, and 42 ofthese agreed. Blood samples | 
:i 
for the measurement of the same lipids and lipoproteins as described in the 
H •» 
previous studies were taken before the commencement of treatment and 
repeated 6 and 12 months later. 
The logistics of the study prevented a randomization of cases to blood 
sampling at specific times during the treatment cycle, so a retrospective 
analysis was made to determine whether the timing ofblood sampling affected 
the lipid measurements. As all of the women were taking the progestogen for 
the first 12 days of each calendar month, it was possible to retrospectively 
determine in which phase of treatment the samples had been taken. A 
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comparison was then made of the mean values according to the timing of 
sampling. 
Statistical analysis 
The analysis of the distribution of each of the baseline lipids and lipoproteins 
was made using the one-sample Kolmogorov-Smimov test. The distribution of 
values was normal except for Lp(a) and TG, and a logarithmic transformation ； 
ofthese variables was performed. 
The response to combined cyclical treatment was examined using the paired 
I 
samples t-test. The comparison between the effect of sampling in the oestrogen 





The relationship between baseline concentrations of Lp(a) and the change in i 
‘ ,1 
Lp(a) concentrations with treatment was examined by calculating the 
'i 
correlation coefficient using the standard Pearson product-moment correlation 
method. 
RESULTS 
Ofthe 42 women who consented to participate in this study, all completed the 
full 12 months of treatment. Three of the subjects were excluded from the 
study as they failed to attend for the final blood sampling and could not be 
traced. The mean age ofthe subjects was 41.8 (± 8.9) years, their weight 55.9 
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(士 9.1) kg, their height 156.1 (士 5.3) cm and body mass index 23.4 (士 3.8) 
kgAn2 The mean age of their menopause was 39.5 (± 9.8) years and the 
duration from the time of the last menstrual period until recruitment into the 
study was 2.6 (士 5.5) years. The distribution of baseline concentrations of 








Figure 8. Distribution ofconcentrations ofLp(a) before the 
commencement ofthe study on combined cyclical HRT. 
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The median baseline value of Lp(a) was 9.45 mg/dl (range 1.47-95.62, 
skewness 2.11, kurtosis 4.57). Seven of the 42 women (16.7%) who 
commenced the study had a baseline value of Lp(a) exceeding 30 mg/dl. The 
baseline values ofLp(a) and the other lipids and lipoproteins and their response 





Table 26. Baseline values of lipids and lipoproteins and the response to 
treatment with cyclic combined HRT. 
Baseline 6 months 12 months p 
Mean (SD) Mean (SD) Mean (SD) (0-12 months) 
Lp(a) (mg/dl) 9.45 7.70^ 7.14 
Median (Range) (1.47-95.62) (1.12-72.59) (0.63-69.23) 
Lp(a) LN 2.43 (1.04) 2.16(1.16)^ 2.15(1.24) <0.001 
Apo A-I 162.6 (21.0) 172.4 (24.1/ 173.3 (27.0) <0.01 
(mg/dI) 
ApoB 116.1 (31.1) 114.7(31.4) 111.6(31.5) <0.05 
(mg/dl) 
TC 5.16(0.84) 4.99 (0.82) 4.90 (0.84) 0.05 
(mmolyl) 
HDL-C 1.65 (0.43) 1.60(0.36) 1.63 (0.43) 0.793 
(mmol/l) 
HDL2-C 0.59(0.36) 0.65 (0.30) 0.62(0.34) 0.111 
(mmol/l) 
HDL3-C 0.97 (0.17) 0.93 (0.21) 0.97 (0.21) 0.730 
(mmol/l) 
LDL-C 3.02 (0.77) 2.78 (0.72) 2.74 (0.78) <0.05 
(mmol/l) 
TG (mmol/l) 0.88 1.02 0.90 0.235 
Median (Range) (0.27-4.07) (0.30-6.00) (0.86-5.38) 
TG (log N) -0.09 (0.56) 0.07 (0.69) -0.03 (0.61) 0.286 
FSH (ro/l) 68.1 (25.6) 29.9 (18.3)*' 25.7 (17.6) <0.001 
LH (ni/l) 22.3 (9.3) 16.3 (11.3/ 16.3(12.¾ 0.076 
E2 (pmol/l) 110.9(63.1) 576.3 (300.6)b 522.3 (245.1) <0.001 
a p<0.05;b p<0.01 
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After the first 6 months of treatment there was a significant reduction in the 
median concentration ofLp(a) from 9.45 (range 1.47 - 95.62) mgMl to 7.70 
(range 1.12-72.59) mg/dl, Q)<0.01, 0-6 months). There was also a significant 
increase in the mean concentration of apo A-I from 162.6 (士 21.0) mg/dl to 
172.4 (± 24.1) mg/dl, (p<0.05), but there were no significant changes in the 
other lipids and lipoproteins. There was a significant increase in the mean 
concentration of oestradiol from 110.9 (± 63.1) pmoU to 576.3 (士 300.6) 
prnom (p<0.01) and significant reductions in FSH from 68.1 (± 25.5) RJ/1 to 
29.9 (士 18.3) nJ/1 Op<0.01) and in LH from 22.3 (土 9.3) RJ/1 to 16.3 (士 11.1) 
KJ/1 (p<0.05). 
At the end of 12 months, the median concentration of Lp(a) had decreased to 
7.14 (0.63-69.23) mg/dl (p<0.001, 0-12 months). There was a significant 
positive correlation between the baseline values of Lp(a) and the magnitude of 
the reduction in Lp(a) concentrations (r=0.474, p<0.01). There was a 
significant reduction in the mean concentration of LDL-C over the 12 month 
period from 3.02 (土 0.77) mmoW to 2.74 (土 0.78) mmol/1 (p<0.05) and a 
reduction in apo B from 116.1 (士 31.1) mg/dl to 111.6 (士 31.5) mg/dl; p<0.05). 
There was also a decrease in TC of borderline significance. Apo A-I 
concentrations increased further to 173.3 (士 27.0) mgAil (p<0.01), but there 
were no other significant changes in the HDL-C related lipoproteins over 12 




were similar to those at 6 months (p<0.001, 0.076 and <0.001 respectively; 0-
12 months). 
The second part of the study examined the effect of the timing of sampling on 
the measurements of lipids and lipoproteins. When blood sampling took place 
after 6 months oftreatment, 17 women were using unopposed oestrogen and 20 
women were on combined treatment. At the time of blood sampling after 12 
months of treatment, 11 women were using unopposed oestrogen and 27 were 
on combined treatment. A comparison between measurements made during the 
unopposed oestrogen and the combined phase of treatment with oestrogen and 
progesterone is presented in Table 27. 
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Table 27. The comparison between the measurements of lipids and 
lipoproteins made during the unopposed oestrogen and the combined phases 
of treatment. 
Baseline 6 months 12 months 
Mean (SD) Mean (SD) p Mean (SD) p 
Lp(a) (mg/dl) 
Median 9.45 EP 7.66(1.12-55.93) 0.784 8.05 (0.63-69.23) 0.506 
(Range) (1.47-95.62) E 7.70(1.19-72.59) 6.02(0.98-63.91) 
Apo A-I 62.6 (21.0) EP 163.2 (26.5) 0.112 176.0 (23.8) 0.540 
(mg/dl) E 176.8 (22.1) 170.5 (30.6) 
ApoB 116.1(31.1) EP 127.3 (32.8) 0.912 118.4 (33.6) 0.185 
(mg/dl) E 108.6 (29.5) 104.5 (28.5) 
TC 5.16(0.84) EP 5.06 (0.92) 0.752 5.11 (0.78) 0.151 
(mmol/1) E 4.97 (0.79) 4.69 (0.88) 
HDL-C 1.65 (0.43) EP 1.47 (0.38) 0.124 1.55 (0.46) 0.242 
(mmol/1) E 1.67(0.34) 1.72 (0.38) 
HDL2-C 0.59 (0.36) EP 0.54 (0.27) 0.145 0.59 (0.40) 0.231 
(mmol/1) E 0.69(0.30) 0.65 (0.26) 
HDL3-C 0.97(0.17) EP 0.87 (0.22) 0.219 1.00(0.20) 0.391 
(mmoI/l) E 0.96 (0.20) 0.94 (0.21) 
LDL-C 3.02(0.77) EP 2.89 (0.79) 0.268 2.92 (0.82) 0.163 
(mmol/1) E 2.73 (0.70) 2.54 (0.71) 
TG 0.88 (0.27-4.07) EP 1.36 (0.49-6.00) 0.430 1.08 (0.47-4.41) 0.136 
(mmol/1) E 0.80 (0.30-5.63) 0.76 (0.44-2.17) 
Median (Range) 
EP = Sampling during Oestrogen + Progestogen treatment 
E = Sampling during Oestrogen treatment alone 
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There were no significant differences between the mean concentrations of any 
of the variables according to the timing of blood sampling at either 6 or 12 
months. There was, however，a trend towards higher mean concentrations of 
TC, LDL-C, apo B and TG and lower HDL-C and HDL2-C concentrations 
during the combined phase of treatment. There was little difference between 
the median values of Lp(a) at the 6 month sampling, but at 12 months the level 
was higher during combined treatment than with unopposed oestrogen. 
DISCUSSION 
The administration of oestrogens to postmenopausal women influences the 
atherogenic lipids and lipoproteins in a direction which favours a reduction in 
the atherosclerotic process, and both current and previous users of oestrogen 
have a lower incidence of CAD than do those who have never used oestrogen 
(Stampfer et al, 1991� . The 19-nortestosterone group of progestogens have 
been found to oppose oestrogen induced increases in HDL-C and reductions in 
LDL-C concentrations in a dose related manner (Hirvonen et al，1987). Whilst 
the 17-hydroxyprogesterone derivatives are considered to have a less 
pronounced action than the 19-nortestosterone group, MPA in a dose of 10 mg 
has still been shown to diminish oestrogen induced lowering of HDL-C 
(Ottosson et al，1985). For both types ofprogestogens, the antagonistic effect 
on HDL-C appears to be greater if continuous combined rather than combined 
cyclical regimens are used (Prough et al, 1987). 
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The effect of progestogens on concentrations of Lp(a) appears to differ from 
that on the other lipoproteins. Despite the potential adverse effects on the basic 
lipid profile, a study in which the 19-nortestosterone derivative norethisterone 
acetate was used showed that there was a significant reduction in Lp(a) 
concentrations over an 8 week treatment period (Farish et al，1991). The 
anabolic steroids stanozolol and danazol have also been reported to reduce 
concentrations of Lp(a) (Albers et al，1984; Crook et al，1992)，although it 
should be noted that the first of these studies examined premenopausal 
subjects, and in the second the mean age ofthe patients was 73 years. 
In this study the mean age ofthe subjects was lower than in the crossover study 
and reflected a referral bias towards women whose menopause had occurred at 
a younger age. As with the crossover study, the inclusion of younger women 
was, if anything, more likely to have increased the difficulty in demonstrating 
significant changes in the lipid pattern. The median values ofLp(a) and TG and 
the mean values of the other lipids and lipoproteins were similar to those 
described in Caucasians (Soma et al, 1993) and the baseline measurements of 
Lp(a) showed the same skewed distribution which was present in the crossover 
study. 
Although there are few data concerning the normal range of lipid values in 
Hong Kong Chinese women, the baseline values in this study were similar to 
those which have previously been described. There were 4/39 women (10.3%) 
in this study with mean concentrations of TC above 6.2 mmoW，which 
compares with 5% of females aged 20-39 years and 20.5% aged 40-59 years 
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found in a survey conducted in the same area of Hong Kong some years ago 
(Cho and Donnan, 1988). The number of women with elevated concentrations 
of TC was, however, lower than in the crossover study in which the sample 
size was greater. 
hi response to combined cyclical treatment, there were significant reductions in 
the median concentrations of Lp(a) at both the 6 and the 12 month time 
intervals. During the first 6 months，the median level decreased by 18.5%, and 
at the end of 12 months, there was a reduction of 24.5%. As was the case with 
unopposed oestrogen, the greatest reductions were found in those with the 
highest baseline concentrations of Lp(a). The decrease in the median Lp(a) 
concentration was similar in magnitude to the 17.5% found by Van der Mooren 
(1992) in a study using micronized 17p-oestradiol and dydrogesterone 10 mg 
daily for 14 days each month and also that ofKim et al (1994) who described a 
20% reduction using conjugated equine oestrogens 0.625 mg daily for 25 days 
each month and MPA either 5 or 10 mg for 10 days each month. 
Over 12 months there was also a significant reduction in the concentration of 
LDL-C of 9.2% and a decrease in concentrations of apo B (4%) and TC (5.0%) 
which were of borderline significance. There was a significant increase in the 
mean level of apo A-I (6.6%), but there were no changes in any of the lipids 
and lipoproteins in a direction which would favour atherogenesis. Unlike the 
results with unopposed oestrogen, concentrations of TG were unaffected. The 
percentage changes in the concentrations of the basic lipids and lipoproteins 
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during combined treatment were not as great as those ofLp (a), as was the case 
during the first 6 months of the crossover study. However the changes 
observed were in a direction which favoured a reduction in CAD risk, which is 
opposite to that which would be expected in untreated postmenopausal women. 
The HDL-C related lipoproteins were less responsive to treatment than those of 
the LDL-C group, which is consistent with the results of previous studies 
where MPA has been used in a similar dose (Weinstein, 1987; Sherwin and 
Gelfand, 1989). This observation differed from that ofthe studies on the short 
term and sustained effects of unopposed oestrogen where the HDL-C 
lipoproteins were more responsive than the LDL-C group. Presumably the 
addition of a progestogen changed the relative responses of the LDL-C and 
HDL-C groups of lipoproteins which occurred with unopposed oestrogen. The 
concentrations of oestradiol at 6 and at 12 months, the bleeding pattems 
observed during treatment and the amount of drugs remaining at the end of 
each 6 month treatment period all suggested that compliance with the drug 
regimen had been maintained. There were 3 dropouts during the study, but 
none ofthese were due to the anticipated problem ofirregular vaginal bleeding. 
Studies on the lipid profile of premenopausal women have revealed 
contradictory findings with respect to the effect of endogenous steroids on lipid 
measurements. Whilst in some studies concentrations of HDL-C have been 
observed to increase at midcycle and to remain elevated in the luteal phase 
(Azogui et al, 1992; Lyons Wall et al, 1991), others have found no change at 
all in HDL-C concentrations (De Leon et al, 1992). There have also been 
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studies in which none ofthe lipids or lipoproteins have changed with the phase 
of the menstrual cycle (Lebech et al, 1990; Owens et al, 1993). It is also 
unclear whether the timing of blood sampling in patients receiving cyclical 
progestogens in HRT regimens affects the results of lipid measurements, and in 
most studies this factor has been ignored. 
Li this study there were no significant differences in lipid or lipoprotein 
concentrations whether the assays were performed during the administration of 
unopposed oestrogen or when the subjects were receiving oestrogen as well as 
the progestogen. However there was a tendency for almost all of the variables 
to move in direction towards a more atherogenic pattem when sampling was 
performed during combined treatment. The consistency of these results 
suggests that in a larger study, ifthe timing ofblood sampling is more precisely 
controlled, a significant difference could be demonstrated. There is sufficient 
evidence from this study to suggest that the lipid profile may be adversely 
affected by the addition of a progestogen, and that the phase of treatment 
should be taken into consideration in future studies o fa similar nature. 
As far as Lp(a) was concerned, the administration of oestrogen and a cyclical 
progestogen produced a progressive and significant lowering of concentrations 
throughout the study period. Whilst the beneficial effect of combined HRT on 
the basic lipid pattem is well recognized，these data confirm that this treatment 
is also effective in reducing concentrations of Lp(a). These results provide 




STUDY IV - THE EFFECTS OF PERCUTANEOUS OESTROGEN 
INTRODUCTION 
Although oestrogens are most frequently prescribed orally, they are also 
available as percutaneous, subcutaneous, transdermal and vaginal preparations. 
These methods avoid the hepatic "first pass", and each of them can be used for 
hormone replacement therapy. In theory, non-oral treatment may be preferable 
for patients with a history of thrombosis or embolism，hypertension, 
carbohydrate intolerance and other conditions where hepatic metabolism could 
exacerbate the disorder. In practice, the vaginal route is usually reserved for the 
treatment of genital tract symptoms such as atrophic vaginitis, but the other 
methods are used as an alternative to oral therapy. Under some circumstances, 
for example in cases of hypercholesterolaemia, the oral route may be 
preferable, but in most cases the method of administration of oestrogen can be 
made according to patient preference. 
There has only been one study in which the effect of a non-oral method of 
delivery of oestrogen on concentrations of Lp(a) has been investigated. 
Although other pathways appear to be involved, the liver is thought to be the 
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primary site of Lp(a) metabolism, and as percutaneous oestrogen bypasses the 
liver，the effect of this treatment on Lp(a) may differ from that of oral 
administration. Oral oestrogen has repeatedly been shown to reduce 
concentrations ofTC and LDL-C and to increase those ofHDL-C, but non-oral 
treatments have been found to have inconsistent effects on the components of 
the basic lipid profile. 
The aim of this study was to examine the effect of percutaneous oestrogen on 
concentrations ofLp(a) and other atherogenic lipids and lipoproteins. 
METHODS 
This study examined the influence of a percutaneous oestrogen gel on 
postmenopausal Chinese women who had undergone a total abdominal 
hysterectomy and bilateral salpingo-oophorectomy for benign gynaecological 
conditions. The inclusion and exclusion criteria were the same as for the 
crossover study on the effects of oral oestrogen. A total of 35 women were 
suitable for inclusion in this study and agreed to use the treatment and have the 
necessary investigations. 
An open longitudinal study design was chosen for similar reasons to those 
described in the study on combined cyclical HRT. Whilst it would have been 
preferable to have compared the effect of the gel with that of a placebo, the 
manufacturer was unable to provide a placebo preparation, and it could not be 
produced locally. When considering the use of a control group, there would 
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have been an ethical problem if treatment had been withheld for longer than 6 
months. Li addition, Lp(a) concentrations would be expected to remain stable 
over 12 months i fno treatment was prescribed, and for these reasons a control 
group was not included. A 12 month study period was chosen to match the 
duration of treatment in the other studies and to allow comparisons to be made 
with the results of other studies. The calculation of the sample size was 
described in Chapter 4. Recruitment in this study was more difficult than in 
the others as the patients were in some cases reluctant to try the percutaneous 
method of treatment. It was，however, possible to obtain sufficient cases to 
meet the requirement ofthe sample size calculation. 
The treatment consisted of the daily percutaneous administration of 1.5 mg 
i7p-0estradi0l (Oestrogel, BI Excelsior, Paris, France) in 2.5 g of gel, which 
provides similar circulating concentrations to that of 2 mg oral 17p-oestradiol. 
The subjects were shown how to place the required amount of gel onto a 
plastic spatula which is supplied with each 80 g tube. The explanation of the 
use ofthe gel was provided in some detail, as failure to apply the gel properly 
can result in incomplete absorption. If a residuum is left on the skin this can 
stick to clothing and lead to a reduction in compliance. The gel is spread out 
over a large surface area of the body excluding the vulva and breasts, and each 
tube lasts approximately one month. It was expected that there may be some 
withdrawals from the study because of difficulty with the application of the 
gel, but dropouts were not expected for other reasons. 
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Blood samples for the same lipid and lipoprotein measurements as in the other 
studies were taken before the commencement of treatment and repeated 6 and 
12 months later. 
Statistical analysis 
The analysis of the distribution of each of the baseline lipid values was made 
using the one-sample Kohnogorov-Smimov test. The distribution of values 
was normal except for Lp(a) and TG, and a logarithmic transformation of these 
variables was performed. 
The response to treatment with percutaneous oestrogen was examined using the 
paired samples t-test. 
The relationship between baseline concentrations of Lp(a) and the change in 
Lp(a) concentrations with treatment was examined by calculating the 
correlation coefficient using the standard Pearson product-moment correlation 
method. 
RESULTS 
Of35 women entered into the study, 31 completed 12 months of treatment and 
were included in the final analysis of data. Of those excluded from the study, 
one had high baseline oestradiol measurements despite the presence of 




follow-up and could not be contacted, a third complained of skin irritation after 
using the gel and the other preferred oral treatment. 
The mean age ofthe subjects was 42.7 years (土 4.1), and the mean time from 
surgical menopause to the commencement of treatment was 0.8 years (士 1.4). 
Their mean weight at entry was 60.8 kg (土 7.1), their height 155.3 cm (± 5.2) 
and body mass index 25.0 (± 3.5) kg/m^. Li 12 cases the primary indication for 
surgery had been uterine fibroids, in 6 cases endometriosis, in 4 cases benign 
ovarian cysts and in the remainder the diagnosis was adenomyosis. 
The distribution ofbaseline Lp(a) measurements is shown in Figure 9. 
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Figure 9. Distribution of concentrations ofLp(a) before the 
commencement of the study on the percutaneous gel. 
14 T ^ 
ssss^ws^i^S' 
^S^^SSS5S^^55^$5k 
^ ^ M 
{ ^ M r J ^ ^ 8 S ^ * y ^ ? 
W ^ ^ m m ^ 00^^^^ 
_ 麵 _ l%__ i^^ WS^J^**2^||!"^ ^ 變 麵 
_ _ 
f^tvvX^S^X*Kv' 
1, _ _錄！务纖纖 
I / • 8 5 ¾ ¾ ^ ¾ ! ¾ ¾ ¾ ¾ 
mMmi ggS®JSSP»5» ^ ¾ 努絲鏃玄纖 ¾^<^ <¾¾¾¾ 
K ^ ： ： 
9vc^^^*v^***v*w 
ViSSf*JS^K^tSSA*A ^ * 
纖飄戀 
10 - - ^ ^ B 
^\伪 
g^ :«j»K^SjS f^'^jj ¾^¾:%%¾^  ^ ¾ 
0m^^m 
^ ^ K 
I 卜 _ I _ 
: k J 
1-10 10-20 20-30 30^0 40-50 50-60 60-70 
Lp(a) (_dl) 
219 
！ 1 j 
Values of Lp(a) showed a skewed distribution to the right, with a median 
baseline concentration of 7.87 mg/dl (Range 1.89-62.51, kurtosis 2.09, 
skewness 1.66). Five of the 31 subjects (16.1%) had baseline Lp(a) values 
which were above a clinical threshold value for coronary artery disease risk of 
30 mg/dl. A summary of the changes in lipids and lipoproteins with 
percutaneous oestrogen is presented in Table 28. 
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Table 28. A summary of the changes in lipids and lipoproteins in women 
receiving percutaneous oestrogen. 
Baseline 6 months 12 months p 
Mean (SD) Mean (SD) Mean (SD) (0-12 mths) 
Lp(a) 7.87(1.89-62.51) 6.16 (1.33-44.38)' 9.38 (1.61-58.10)' 0.545 
(mg/dl) 
Median (Range) 
Apo A-I 154.3 (17.1) 149.2 (16.9^ 154.5 (19.4)^ 0.948 
(mg/dl) 
ApoB 140.9 (33.9) 134.2(27.8^ 136.7 (27.1) 0.244 
(mg/dl) 
TC 5.67 (0.88) 5.53 (0.95) 5.73 (0.85) 0.250 
(mmol/1) 
HDL-C 1.45 (0.32) 1.28 (0.27)' 1.43 (0.30)^ 0.839 
(mmol/1) 
HDL2-C 0.34(0.19) 0.33 (0.20) 0.39 (0.24) 0.236 
(mmol/1) 
HDL3-C 1.04 (0.19) 0.93 (0.15)b 0.97(0.19) 0.117 
(mmol/1) 
LDL-C 3.55 (0.88) 3.44 (0.80) 3.56 (0.80) 0.565 
(mmol/l) 
TG 0.38 (0.70) 0.40(0.67) 0.32(0.70) 0.436 
(log N) 
FSH 69.8 (26.5) 42.1 (23.7)^ 45.8 (23.2) <0.001 
(IU/1) 
LH 29.0(17.1) 24.7 (15.9) 33.9(18.9) 0.076 
(IU/1) 
E2 118.9 (59.5) 381.4 (384.8)^ 391.6 (256.7) <0.001 
(pmol/l) 
a p < 0.01 VS baseline value; ^ p < 0.05 vs baseline value; 'p<0.01 vs 6 month value; 
d p<0.05 vs 6 month value 
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The median value of Lp(a) decreased from 7.87 mg/dl to 6.16 mg/dl (Range 
1.33-44.38) during the first 6 months of treatment (p<0.01) and then increased 
to 9.38 mg/dl (Range 1.61-58.1) at the completion ofthe study. There was no 
significant difference between the median value of Lp(a) at the baseline 
examination and after the completion oftreatment (p=0.545, 0-12 months). The 
reduction in Lp(a) concentrations observed during the first 6 months of 
treatment was greatest in those subjects whose baseline Lp(a) concentrations 
had been the highest (Pearson correlation coefficient r=0.799, p<0.001). 
The mean concentrations of oestradiol were 118.9 (土 59.5) pmoH at the 
commencement ofthe study, 381.4 (士 384.8) pmoVl at 6 months (p<0.01) and 
391.6 (土 256.7) pmol/1 at 12 months (p<0.001, 0-12 months). The 
corresponding values ofFSH were 69.8 (土 26.5) RJ/1, 42.1 (士 23.7) KJ/1 and 
45.8 (士 23.2) m/ l (p<0.001, 0-12 months) and for LH 29.0 (±17.1) IU/1, 24.7 
(士 15.9) IU/1 and 33.9 (18.9) RJ/1 (p= 0.076，0-12 months). There was a 
significant decrease in the level of FSH during the first 6 months of treatment 
(p<0.05), however both FSH and LH values remained in the menopausal range 
throughout the study. 
Mean concentrations of apo A-I, apo B, HDL-C and HDL3-C decreased 
significantly during the first 6 months of treatment (^<0.05 for all variables). 
There were, however, no significant differences between the baseline and 12 




The administration of oral HRT opposes most ofthe changes in the basic lipid 
profile which occur after the menopause (Walsh et al，1991), but not all ofthe 
effects of oral therapy are beneficial. Oral oestrogens also cause a rise in 
concentrations of TG and they have also been associated with adverse effects 
on carbohydrate tolerance, clotting factors and on concentrations of renin 
substrate. These negative aspects of therapy stimulated the development of 
other forms of delivery of oestrogen which avoided the hepatic "first-pass" 
whilst maintaining stable circulating concentrations of oestradiol (Marty et al, 
1980). 
Percutaneously administered oestrogen is one such method of delivery, and 
although it is as effective as oral treatment in controlling menopausal 
symptoms and in preventing bone loss (Riis et al, 1987; Dupont et al, 1991), it 
has been found to have variable effects on the basic lipid profile. De Lignieres 
et al (1986) found that an 8 week course of treatment produced a significant 
reduction in TG but no changes in concentrations of TC, HDL-C nor LDL-C. 
However in a subsequent study conducted over a period of 6 weeks, no 
significant differences in lipid concentrations were observed (Basdevant et al, 
1991). Moorjani et al (1991) examined the effect of percutaneous oestrogen 
after 24 weeks and found an increase in HDL-C but no changes in either TC, 
LDL-C or TG, and Jensen et al (1987) found that percutaneous oestrogen 
significantly reduced TC and LDL-C concentrations but had no effect on HDL-
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C or TG. In the only study in which treatment was continued for 12 months, 
no changes in any lipids or lipoproteins were demonstrated (Palacios et al， 
1994). 
There have also been contradictory findings from studies conducted on another 
form of non-oral oestrogen, the transdermal patch. Chetkowski et al (1986) 
found no significant change from the baseline in measurements of TC, HDL-C, 
LDL-C or TG after the short term administration of transdermal oestrogen, 
however Stanczyk et al (1988) described a significant increase in HDL-C after 
24 weeks but no change in either TC, LDL-C or TG. These findings were 
supported by Tufekci et al (1993) in another study of 9 months duration. The 
reasons for these contradictory findings are unclear, but they were not dose 
related. 
The distribution of baseline values of Lp(a) in this group of relatively young 
Chinese women showed a similarly skewed pattem to that which has been 
observed in other populations and in the other studies in this thesis. The 
median values resembled those previously reported in Chinese subjects ofboth 
sexes (Gaw et al, 1994), and the number of subjects with values ofLp(a) above 
30 mg/dl (16.1%) was similar to that of a comparable group of Caucasian 
females from Sweden (11%) (Dahlen, 1990). 
There were no significant differences between the baseline values ofLp(a) and 
those at the end ofthe 12 month period ofpercutaneous treatment. There was a 
significant 21.7% decrease in the median concentration ofLp(a) during the first 





baseline concentrations. In the second 6 months, however, values of Lp(a) 
increased, and at the end of the study the median concentration was actually 
higher than at the beginning. 
There were variable changes in the measurements of the basic lipid profile 
during the first 6 months，and these were in some cases difficult to explain. 
The significant reduction in apo B can be considered favourable in terms ofthe 
relationship between lipoproteins and CAD risk, as can the trend towards 
decreased values of both TC and LDL-C. These changes are similar to those 
found with oral treatment, but the reductions which were observed in HDL-C, 
apo A-I and HDL3-C resemble those which would be expected in untreated 
women. 
In the second 6 months, all of the initial changes in the basic lipids and 
lipoproteins were reversed, and as with Lp(a), there were no significant 
differences between baseline values and those at the end of the treatment 
period. There are a number ofpossible explanations for the fact that lipid and 
lipoprotein concentrations were significantly lowered during the first 6 months 
oftreatment but then returned to near baseline concentrations after 12 months. 
The most likely of these explanations is that the avoidance of hepatic 
metabolism by the percutaneous gel prevented a sufficient amount of oestradiol 
from reaching the liver, which is the primary organ involved in lipid and 
lipoprotein metabolism. As the percutaneous gel passes directly into the 
circulation, it would not be expected to be as effective as oestrogen given 
orally. However, in the first 6 months of treatment, there were significant 
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reductions in the concentration of Lp(a) and most of the other lipids and 
lipoproteins, and it may be that whilst the direct application of the gel allowed 
some oestradiol to reach the liver, this amount was relatively small, and 
subsequent enzyme induction may have nullified the response to this dose so 
that the effect of treatment with the gel was not maintained. Tolerance may 
also develop with oral oestrogen but may be overcome as a result of the larger 
dose which passes through the liver. Another possible explanation could have 
been that the inconvenience of percutaneous treatment resulted in reduced 
compliance during the second 6 month treatment period, and that this reduced 
the effectiveness of treatment. This does not appear to have been the case， 
however, as oestradiol concentrations were maintained within the therapeutic 
range throughout the study period. 
These explanations are speculative, however, and the results obtained in this 
study require confirmation before it can be certain that percutaneous treatment 
has an initial but non-sustainable effect on these lipids and lipoproteins. 
There was no significant change in the mean level of TG throughout the study, 
and this reinforced the suggestion that the gel may be preferable to oral 
treatment for individuals with hypertriglyceridaemia. It can be assumed that 
the amount of oestrogen which reaches the liver is not enough to affect TG 
metabolism. 
This is the first study to have investigated the influence of percutaneous 
oestrogen on concentrations of Lp(a) in postmenopausal women. Lobo et al 




a longitudinal study of 16 women over 6 months, and although concentrations 
decreased by 10.6%, this was not statistically significant. 
The results ofthis study suggest that the percutaneous route may be effective in 
the short term in lowering concentrations of Lp(a), but that this effect is not 
maintained with a longer course oftreatment. Studies involving larger numbers 
are indicated to further investigate the lipid effects of this treatment and to 
determine whether the percutaneous method may provide cardioprotection 
through some other mechanism. 
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CHAPTER 8 
SUMMARY AND CONCLUSIONS 
The studies which contributed to this thesis were conducted during a time of 
emerging interest in the properties of the Lp(a) lipoprotein. Using a 
computerized literature search as the source, 63 publications on Lp(a) were 
listed in the 15 months from July 1989 until September 1990. This number 
increased more than four times to 259 in the 14 months from February 1993 
until March of 1994. Most of the earlier studies were concerned with the 
pathophysiology of Lp(a) and in particular its role as a risk factor for CAD. 
There were few studies which had investigated the effect of hormone 
replacement therapy on Lp(a) concentrations in postmenopausal women, and 
these had frequently been small in size and had used a variety of HRT 
combinations. As has been discussed, some of these studies reported 
reductions in concentrations of Lp(a) in response to oestrogen which were not 
statistically significant and in others there were methodological problems 
which brought the validity of the results into question. These included the 
failure to justify the sample sizes of the study populations, a disregard for the 
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skewed distribution of Lp(a) values in the statistical analysis and the use of 
unreliable assays for Lp(a) measurements. 
Women who consider using HRT should be as fiilly informed as possible about 
the advantages as well as the disadvantages of the treatment. Grady et al 
(1992) addressed this balance in a meta-analysis of the published English 
language literature from 1970 onwards. This review examined the effect of 
HRT on endometrial and breast cancer, coronary heart disease, osteoporosis 
and stroke. They found no apparent increase in the risk of endometrial cancer 
with combined HRT, but with unopposed oestrogen the RR was 8.22 (95% CI 
6.25-10.81) i f the duration of treatment was more than 8 years. For CAD, the 
RR in "ever-users" compared with "never-users" was 0.65 (95% CI 0.59-0.71), 
for hip fracture 0.75 (95% CI 0.68-0.84) and for stroke 0.96 (95% CI 0.82-
1.13). The RR of breast cancer among "ever-users" of oestrogen was 1.01 
(95% CI 0.97-1.05)，but the results ofmore recent studies suggest that this may 
be an underestimate of the risk in those who use HRT for 5 years or longer 
(Colditz et al, 1995). 
The overall conclusion was in favour of the use of HRT, although the authors 
admitted that their study was incomplete as the effects of this treatment on 
quality of life had not been examined. Negative aspects which were not 
considered included the necessity for daily treatment, other side effects such as 
vaginal bleeding and the need for regular follow-up. These factors could be 
offset by such benefits as the prevention of kyphosis, the preservation of 
urinary and sexual function and an improved sense of well-being, but the 
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relative importance of these factors was not considered, nor have they been 
fully assessed in other studies. 
When considering the use of HRT, an informed decision must be made about 
the riskA)enefit ratio. The low rates of acceptance of these drugs suggests that 
in many cases the risk and inconvenience of treatment may be considered to 
outweigh the potential advantages. The rate of acceptance of HRT may be 
influenced by the counselling which the patient receives from her medical 
practitioner or from other sources. In the United States, it has been estimated 
that less than 40% of postmenopausal women who are prescribed HRT 
continue to use it for longer than 12 months. In more than 70% of cases the 
treatment is used irregularly (Rowles, 1990; Ravnikar, 1992). A survey 
conducted in the United Kingdom found that 80% of doctors agreed that HRT 
was effective in reducing the risk of osteoporosis, but almost 50% thought that 
this treatment increased rather than reduced CAD risk (Bryce and Lilford， 
1990). It is therefore important that medical practitioners as well as their 
patients are as fully informed as possible about the benefits as well as the side 
effects ofthis treatment. 
Xhe results of the studies described in this thesis confirmed earlier reports 
which suggested that the administration of HRT reduced concentrations of 
Lp(a) in postmenopausal women. There were, however, some differences 
between the studies which have been described in these chapters and those 
which were referred to earlier. Apart from using Chinese rather than 
Caucasian subjects, these studies also investigated women who had become 
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menopausal at a younger age than would have normally been expected. This 
resulted from a bias in the referral pattem to the outpatient clinic, but since an 
early menopause is a risk factor for coronary artery disease, the age factor 
should not detract from the principal fmdings. As far as the duration of the 
studies was concerned, it was fortunate that the open longitudinal studies were 
conducted over a period longer than 6 months or else the reversal of the effect 
of the percutaneous gel would not have been detected. Li addition, if the 
follow-up study on the use of oral oestrogen had been omitted, it would not 
have been possible to determine whether the effect of oral oestrogen observed 
within 6 months in the crossover study would have been maintained with 
prolonged treatment. 
The patient characteristics were similar in each ofthe studies. There was little 
difference in the baseline concentrations of lipids and lipoproteins, but 
concentrations ofTC and LDL-C were higher and HDL-C lower in the gel than 
in the other studies, and this may have been due to an irregular distribution 
within the smaller sample group of the gel study. The age of the subjects and 
the duration of the menopause were also similar in each of the study 
populations. Pre-treatment values of TC, LDL-C, HDL-C and TG closely 
resembled those of Caucasian women, but the lipid profile tended to be more 
atherogenic than in most mainland Chinese populations. Although the baseline 
distribution of values does not necessarily represent all of Hong Kong, a 
comparison between these results and those of earlier studies suggests that the 
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lipid profile in this territory is gradually worsening, and now lies close to that 
ofthe developed countries. 
Baseline concentrations of the Lp(a) lipoprotein were also similar in each of 
these studies and matched that of Caucasians. As demonstrated in Chapter 3， 
there have only been 4 studies which have listed Lp(a) distributions in other 
Chinese subjects, and the values found in Hong Kong Chinese women were 
comparable with these. Li all of the studies the response of the components of 
the basic lipid profile matched that of Lp(a), with reductions in Lp(a) usually 
being observed when TC and LDL-C concentrations decreased and HDL-C and 
associated lipoproteins increased. The fact that there were predictable changes 
in the basic lipid profile in response to treatment added credibility to the 
conclusion that the administration of oral HRT reduced concentrations of 
Lp(a). 
Not all of the lipids and lipoproteins were affected by these treatments. 
Concentrations of HDL3-C remained basically unaltered by any of the 
treatment regimens, but there is considerably less evidence that HDL3-C is a 
risk factor for CAD than there is for the other lipoproteins. This result was 
consistent with that of previous studies, as was the observation that 
concentrations of TG increased with each of the oral treatment regimens. In 
theory, this should increase rather than reduce CAD risk, but in practice this 
may not be true. The increase in TG concentrations is now thought to arise 
mainly from the production of a large, light form of VLDL-C which is not 
catabolized to other atherogenic lipoproteins, and this would explain why TG 
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may play a lesser role (Walsh et al, 1991). This contradicts the earlier studies 
of Gordon et al (1977), Heyden et al (1980) and Miller Bass et al (1993) who 
found that TG independently predicted CAD in women, and the role ofTG as a 
risk factor in women deserves fiirther attention. 
Jn these studies no attempt was made to control for diet, exercise or any other 
external influences on the basic lipid profile. Considering the sizes of the 
sample groups, it was not surprising that there were some small quantitative 
differences between the changes in lipids and lipoproteins in these studies 
compared with others. Although similar drugs and dosages were used, it was 
often difficult to make direct comparisons with other studies, as frequently the 
duration of treatment had not been as long and differences in mean rather than 
logarithmically transformed values had been presented. 
Ofall ofthe studies described in this thesis, the crossover study had the largest 
number of subjects and the most reliable design. This study confirmed that 
oral oestrogen significantly reduced concentrations of Lp(a) compared with 
placebo. There were also anticipated changes in the components of the basic 
lipid profile, and the correlation between the reductions in Lp(a) and the LDL-
C related lipoproteins suggested that they shared a common metabolic 
pathway. The follow-up study outlined in Chapter 6 showed that the initial 
response to oral oestrogen in the crossover study was maintained with 
prolonged treatment. A number of other studies have now been published on 
the effect of combined cyclical HRT, but that presented in Chapter 7 used a 
longer period of observation than many of these, and like the others in this 
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thesis confirmed that the response to HRT appeared to be similar in Chinese 
women. Overall，the percentage reductions in Lp(a) have been found to be 
greater with combined treatment than with unopposed oestrogen, which 
suggests that there may be a synergistic effect on Lp(a) if oestrogen and a 
progestogen are given in combination. The possibility that the addition of a 
progestogen may enhance the beneficial effect of oestrogen on Lp(a) has been 
suggested by the results of a number of studies where the reduction in Lp(a) 
concentrations with combined treatment has been found to be greater than in 
other studies where unopposed oestrogen was used (Van der Mooren et al, 
1992; Kim et al, 1994). The results of the studies in this thesis could not be 
directly compared because of differences in methodology, and although it 
would be difficult to perform, a randomized crossover study comparing 
unopposed oestrogen, continuous combined treatment and combined cyclical 
HRT would provide a better idea of the relative effect of each of these 
regimens on Lp(a). The results of the study on combined cyclical HRT also 
suggests that the timing of blood sampling may be important when measuring 
lipids and lipoproteins during combined treatment. 
The study on the percutaneous gel provided different results from those in 
which oral treatment had been used. After a significant response to the first 6 
months oftreatment, the reduction in Lp(a) concentrations was not maintained. 
The other lipid variables responded in a similar way during the first half ofthe 
treatment period but concentrations also returned to near baseline by the end of 




effective than oral treatment, and this is most probably related to the avoidance 
ofhepatic metabolism of oestrogen. However this was the first study in which 
the response ofLp(a) to this method oftreatment had been measured, and these 
results require verification. 
There are a number of areas of research concerning Lp(a) and the menopause 
which have yet to be explored. Perhaps the most confusing aspect of the 
relationship between the sex hormones and Lp(a) is that reductions in Lp(a) 
concentrations have been demonstrated with oestrogens, progestogens and also 
with androgens. This contradicts the findings ofmost studies on the basic lipid 
profile which have found that androgens, and to a lesser extent progestogens, 
oppose the actions of oestrogen. Until the metabolism of Lp(a) is better 
understood, the association between treatment with any ofthe sex steroids and 
a reduction in Lp(a) concentrations is likely to remain unexplained. A better 
understanding of Lp(a) metabolism will also help to explain the difference in 
response between oral and percutaneous oestrogen. 
The pre-treatment values of lipids and lipoproteins differed from those of 
earlier Hong Kong studies and suggested that a more atherogenic lipid pattern 
may be developing. Large cross-sectional studies of the Hong Kong Chinese 
population are indicated and intervention would seem necessary to prevent an 
increase in the incidence of CAD which has been observed in other countries 
where the lipid profile has changed in a similar manner. 
The data derived from these studies showed that oral oestrogens given alone or 
in combination with a progestogen lowered concentrations of Lp(a) in 
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postmenopausal Chinese women. Whilst there is no direct evidence to prove 
that a reduction in the concentrations of Lp(a) alone lowers the risk of CAD in 
men or in women, epidemiological data provides firm evidence to suggest that 
individuals with elevated concentrations are at increased risk. Since oestrogen 
treatment also improves the other atherogenic lipids and lipoproteins, it will be 
difficult to determine how much of the cardioprotective action of oestrogen is 
due to its effect on Lp(a). 
The percentage changes in Lp(a) with the different treatment regimens have 
akeady been described. In all ofthe studies the reductions in concentrations of 
Lp(a) were statistically significant, although the effect was not maintained with 
percutaneous oestrogen. Although percentage changes have often been quoted 
in studies on Lp(a), this may be misleading because of the skewed distribution 
ofvalues. Ifthe baseline concentration ofLp(a) is below a critical level, then a 
ftuther reduction is unlikely to affect CAD risk. In these studies, however, the 
subjects who were at greatest risk experienced the most benefit from the 
treatment. This was confirmed by determining the number of cases in each 
study group where treatment reduced concentrations of Lp(a) below a value 
associated with increased CAD risk. Dahlen et al (1986) proposed a widely 
accepted threshold value of Lp(a) of 30 mg/dl, and this level was supported by 
the study of Armstrong et al (1986). The determination of a threshold value 
was made from case control studies and is at present the best estimate 
available. When this level was applied to each of the study populations, a 
consistent pattern was observed. In the crossover study, 24/91 (27.3%) women 
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were in the "at risk" category, and there was an overall reduction in Lp(a) 
concentrations in 19/20 of these "at risk" cases (95%). bi addition, 9 women 
with pre-treatment values above this cutoff had their concentrations reduced 
below the threshold value with oestrogen treatment (37.5%). In the study on 
combined cyclical treatment, 7/42 (16.7%) had pre-treatment values above the 
cutoff, and concentrations decreased in all women in response to treatment, bi 
4/7 cases (57.1%), concentrations fell below the critical value after treatment. 
There were too few cases to apply this in a meaningful way to the gel study, 
but using these criteria it is apparent that those women particularly at risk of 
CAD from high concentrations ofLp(a) received the maximum benefit. Whilst 
much work is required to more accurately defme the risks associated with the 
use ofHRT, these results provide additional information on the positive effects 
oftreatment. 
In summary, the results of these studies supported the hypothesis that the 
administration of hormone replacement therapy reduces concentrations of 
Lp(a) and improves the basic lipid profile ofpostmenopausal Chinese women. 
Significant reductions in Lp(a) concentrations were recorded with unopposed 
oral oestrogen as well as with cyclical combined HRT. Those women with the 
highest baseline concentrations had the greatest response, and there was also a 
beneficial effect on the basic lipid profile. Significant reductions in 
concentrations of Lp(a) were also found with percutaneous oestrogen 
treatment, but unlike the oral method of administration, the effect was not 
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maintained. The basic lipids and lipoproteins responded to percutaneous 
oestrogen in a similar manner to Lp(a). 
Previously there have been few therapeutic options for women with raised 
concentrations of Lp(a). Diet and exercise have proven to be ineffective, and 
the only drug which has consistently been shown to reduce concentrations of 
Lp(a) is nicotinic acid，which does not have any effect on menopausal 
symptoms, nor does it prevent osteoporosis or have other cardioprotective 
actions. 
These results of these studies have important implications. Firstly, they 
provide indirect evidence for another mechanism by which this treatment can 
prevent atherosclerosis and reduce CAD risk in postmenopausal women. In 
addition, they show that Chinese women have a lipid response to HRT which is 
similar to that of Caucasian women. These studies have contributed to current 
knowledge on the effects of hormone replacement therapy in postmenopausal 
Chinese women, and have a clinical application to the Hong Kong population 
where the prevention ofCAD is becoming an increasing problem. 
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